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AD Alzheimer’s disease  
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Cr Creatine 
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HCO3
- Bicarbonate 
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HE Hepatic encephalopathy 
 
 
6
HETE Hydroxy eicosatetraenoic acid 
HPLC High performance liquid chromatography 
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IL Interleukin 
IM Intramuscular 
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IP Intraperitoneal 
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LFTs Liver function tests  
Ln Lanthanum nitrate (ionic tracer) 
LOLA L-ornithine, L-aspartate 
LPS Lipopolysaccharide (bacterial) 
MAP Mean arterial pressure  
MAPK Mitogen-activated protein kinase 
MARS Molecular adsorbents recirculating system 
MDA Malondialdehyde 
mRNA Messenger ribonucleic acid 
MHE Minimal hepatic encephalopathy 
MRI Magnetic resonance imaging 
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MV Microvessel 
Myo-Ins Myo-inositol 
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NAA N-acetyl-aspartate 
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NCT Number connection test 
NH3 Ammonia 
NH4
+  Ammonium  
NMDA  N-methyl-D-aspartate 
nNOS Neuronal NO synthase 
NO Nitric oxide 
Nox Nitrate/nitrite ratio 
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NT Nitrotyrosine 
OLT Orthotopic liver transplantation 
OP L-ornithine, Phenylacetate 
PAG Phosphate-activated glutaminase 
PCS Portacaval shunt 
PCT Proximal collecting tubule 
PDH Pyruvate dehydrogenase 
PET Positron emission tomography 
PG Prostaglandins 
PHES Psychometric HE score 
RAAS Renin-aldosterone-angiotensin system 
RBF Renal blood flow 
SBP Spontaneous bacterial peritonitis 
SEM Standard error of mean 
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SIRS Systemic inflammatory response syndrome 
SMT Standard medical therapy 
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SPECT  Single photon emission computed tomography 
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TIPS Transjugular intrahepatic portosystemic shunts  
TLR Toll-like receptor 
TNF-a Tumour necrosis factor-alpha 
VEP Visual evoked potential 
WCC White cell count 
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Abstract 
 
 
 
Current evidence indicates synergy between hyperammonaemia and inflammation 
in the brain with liver failure. Utilising animal and laboratory experiments, this 
thesis explored a number of concise questions focused on progression to brain 
oedema and coma with hepatic encephalopathy (HE).  
STUDY 1: It is unclear whether the background cirrhotic state or 
hyperammonaemia predisposes to superimposed inflammation. Question 1: Does 
lipopolysaccharide (LPS)-induced systemic inflammation worsen brain oedema in 
cirrhotic bile duct-ligated rats? and is this associated with blood-brain barrier 
disruption? altered brain ammonia and/or inflammatory pathways? Answer 1: LPS-
induced pre-coma/coma and exacerbated cytotoxic oedema, indicating synergy 
between hyperammonaemia and inflammation associated with brain protein 
nitrosation.  
STUDY 2: New ammonia-lowering therapies targeting multiple organs are 
necessary. Question 2: Does combining L-ornithine and phenylacetate (OP), 
synergistically improve ammonia reduction? Answer 2: L-ornithine and 
phenylbutyrate synergistically lead to sustained ammonia-lowering and limited 
oedema; L-ornithine detoxifying ammonia by providing a substrate for glutamine 
synthesis and phenylacetate renally excreting the glutamine as 
phenylacetylglutamine.  
STUDY 3: Despite apparent synergism, therapies for HE target either 
hyperammonemia or inflammation, not both. Question 3: Can a reduction in 
ammonia in cirrhotic rats prevent LPS-induced worsening of brain oedema and 
progression to pre-coma/coma? Does targeting hyperammonaemia and 
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inflammation together provide therapeutic synergy? Answer 3: Ammonia primes 
the brain to the deleterious effect of LPS, with the ammonia-lowering effect of OP 
preventing LPS-induced coma and brain edema.  
STUDY 4: Aquaporin-4 (AQP4), a bi-directional astrocyte water channel, is thought 
to provoke brain oedema in neuropathic disorders. Question 4: Is AQP4 causally 
involved in the brain oedema associated with models of liver failure? Answer 4: 
AQP4 has no causal role in the brain edema associated with hyperammonemia or 
inflammation, with or without acute liver dysfunction. However in cirrhosis, AQP4 
upregulation, with contemporaneous p38MAPK activation is possibly a compensatory 
response to inhibit edema formation. 
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Research questions 
 
 
 
CHAPTER 2: Mechanistic study 
Role of ammonia & inflammation in hepatic encephalopathy 
1. Do systemic changes in ammonia and inflammation act synergistically to effect 
the progression and complications associated with hepatic encephalopathy (HE) 
as indicated by the depth of coma or cerebral oedema?  
2. With progression of HE, is there an anatomical or functional alteration of the 
blood brain barrier? 
3. Does the bacterial lipopolysaccharide (LPS) challenged bile duct-ligation (BDL) 
rat model represent clinical of acute-on-chronic liver failure (ACLF)?  
4. On a background of hyperammonaemia and systemic inflammation, are the 
cerebral effects associated with HE due to alterations in brain ammonia and 
amino acid metabolism, and/or cerebral inflammatory responses?  
 
 
CHAPTER 3: Interventional study 
Targeting ammonia & amino acid metabolism 
1. Can the novel therapeutic agent L-ornithine, Phenylacetate (OP), by targeting 
inter-organ ammonia & amino acid metabolism, ameliorate the 
hyperammonaemia and development of advanced HE in rats with cirrhosis? 
2. What are the interorgan pathophysiological mechanisms involved?  
3. Can any ammonia-lowering effect of OP last throughout a prolonged period of 
administration?  
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4. By lowering ammonia, can OP lead to a reduction in brain water? 
 
CHAPTER 4: Interventional study 
Targeting ammonia & inflammatory pathways 
1. Can a reduction in ammonia in rats with cirrhosis prevent LPS induced 
worsening of brain oedema and progression to pre-coma and coma stages? 
2. Does targeting hyperammonaemia and inflammation together provide 
therapeutic synergy in the treatment HE? 
 
 
CHAPTER 5: Mechanistic study 
Role of Aquaporin 4 in liver failure 
1. Are spatial and/or temporal changes in aquaporin-4 (AQP4) involved in the 
development of   pathogenic brain oedema in liver failure?  
2. LPS augments cerebral oedema in HE; Does this involve alteration in AQP4 
expression as suggested in other disease states?  
3. Does any effect of AQP4 expression on such brain oedema involve changes in 
MAPK expression? 
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Chapter 1.1 
 
Hepatic Encephalopathy: 
 
Defining the Syndrome 
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Introduction 
Hepatic encephalopathy (HE) is a neuropsychiatric syndrome that may develop with 
liver insufficiency. Acute liver failure (ALF) is defined by the presence of HE, which 
may progress from confusion to coma, and at its most advanced is associated with 
intracranial hypertension and possible death from brain herniation.(1) In 
cirrhosis,(2, 3) HE usually occurs insidiously with wide ranging neuropsychiatric 
disturbances (e.g. psychomotor dysfunction, impaired memory, decreased reaction 
time, diminished attention, sensory abnormalities and poor concentration). Patients 
with cirrhosis can deteriorate and may develop cerebral changes indistinct from 
ALF, termed acute-on-chronic liver failure (ACLF). Ammonia, inflammation and 
modulation of cerebral blood flow (CBF) autoregulation are central to the 
development of HE, and with the predisposing factors which trigger acute liver 
injury, have become important therapeutic targets in the management of HE.  
This chapter discusses the nomenclature, staging, diagnosis and investigation of 
this complex neuropsychiatric syndrome. It also introduces the fundamental factors 
involved on its pathogenesis, which will be expanded on in later chapters. 
 
Nomenclature 
The wide range of neuropsychiatric presentations (especially when subclinical) has 
made comparative interpretation of studies into HE problematic.(4, 5) This led to 
the development of consensus terminology by the ‘World Congress of 
Gastroenterology’ in 2002 to classify the cause of liver disorder:(6)  
• Type A: ALF 
• Type B: portal-systemic bypass without intrinsic hepatocellular disease  
• Type C: cirrhosis and portal hypertension with portal-systemic shunts  
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However, this classification should be revised to incorporate the widespread 
acceptance of the new clinical entity: 
• Acute-on-chronic liver failure (ACLF): acute liver injury on the background of 
a chronic liver disease phenotype, which is clinically indistinct from ALF.(7) 
 
However HE can also be described by the varied clinical course of encephalopathy:  
• Acute encephalopathy: with the time to encephalopathy defining ALF: 
1. Hyper-acute: 7 days between onset of jaundice and encephalopathy 
2. Acute: 8–28 days 
3. Sub-acute: 5–12 weeks 
• Recurrent encephalopathy: episodic mental alterations in cirrhotic patients 
even in the absence of a recognised precipitating factor.  
• Persistent encephalopathy: unresolved neurological deficit, which may 
persist despite complete reversal of the liver injury (e.g. successful orthoptic 
liver transplantation) or removal of precipitant. 
• Minimal or subclinical encephalopathy: despite absence of overt 
encephalopathy, mild cognitive abnormalities remain, detected only by 
psychometric or neurophysiologic tests. This is present in 60-80% of 
patients with established liver disease. 
 
Clinical staging 
Although the ‘West Haven criteria’ (Table 1) is a specific staging classification of 
altered mental state in liver injury,(8) the ‘Glasgow coma scale’(9) as a robust 
assessment of consciousness in structural and metabolic brain disorders is also an 
applicable staging system. 
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DIAGNOSIS 
 
History & Examination: The need for a detailed history and examination are 
fundamental to the diagnosis of HE given a broad spectrum of differential diagnosis 
(e.g. vascular, metabolic, intracranial and other neuropsychiatric disorders, (Table 
2). To establish a diagnosis of HE it is necessary for there to be a history or clinical 
evidence of liver disease with or without the presence of a precipitating factor(s), 
which also include transjugular intrahepatic portosystemic shunts (TIPS) for 
intractable ascites or variceal bleeding, (Table 3). With early diagnosis there is an 
increasing reliance on laboratory and imaging modalities to establish a diagnosis of 
HE. Findings suggestive of the presence of a precipitating factor must not be 
missed. For example, spontaneous bacterial peritonitis (SBP) usually presents with 
signs of peritoneal irritation, pain, nausea, vomiting and changes in gastrointestinal 
motility (diarrhoea or ileus), but these symptoms and signs may be absent and only 
detected if a diagnostic paracentesis is routinely performed on acutely unwell and 
hospitalised patients with ascites.  
  
INVESTIGATIONS 
 
Laboratory tests: Routine biochemical tests with a full hepatitis screen are 
necessary to establish the specific cause of liver failure as this may impact on 
treatment options. The diagnosis of precipitating factors like infection (e.g. cultures) 
and electrolyte imbalance is critical. Laboratory diagnosis of SBP is confirmed by the 
presence of ascitic fluid polymorphonuclear count (>250cm3) or positive ascitic fluid 
culture, usually monomicrobial (e.g. Escherichia coli or other gram-negative 
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bacteria). The use of a dipstick test for leukocyte esterase (present in biological 
fluids) provides a more rapid diagnosis.  
 
Arterial ammonia: There is evidence to suggest that blood ammonia (especially 
arterial), correlates with severity of HE in ALF (see later). In cirrhosis, any 
correlation is somewhat unclear, where levels may be normal in stable disease, 
persistently elevated (e.g. portosystemic shunting) without clinical impact, or in the 
very high levels where it may or may not be associated with pre-coma or coma.  
 
Imaging: Diagnostic ultrasound (U/S) and computer-assisted tomography (CT) are 
the predominant imaging modalities, to establish the extent and possible cause of 
liver injury. In regard to HE (in the non-ventilated patient), head CT remains a 
useful imaging modality, principally to exclude other differential causes of 
neurobehavioral change. But research into the pathophysiology of HE has required 
the use of other brain imaging techniques:(10) 
• Magnetic resonance imaging (MRI): has detected increased manganese 
deposition in the basal ganglia, with deposition only associated with portal-
systemic shunting and chronic liver dysfunction (not ALF).(11) 
• Single photon emission computed tomography (SPECT): has shown that in 
cirrhosis changes to the basal ganglia are related to regional alterations of 
cerebral blood flow (CBF) in the cortex and subcortical regions.  
• Positron emission tomography (PET) studies: has shown that in cirrhosis, 1) 
blood brain barrier permeability and cerebral ammonia metabolism is 
increased and 2) regional ammonia supply and energy utilisation (using the 
glucose tracer- fluorodesoxyglucose), correlates to regional blood flow. 
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Electroencephalogram (EEG): This is a useful tool in the diagnosis of HE due to 
characteristic background slow-wave development of between 4-6Hz, triphasic 
waves (TW) which consist of a high-voltage positive wave followed by a smaller 
negative deflection (usually bilaterally synchronous and maximal frontally)(12) and 
occasionally epiliptiform, Table 1. However, slow-waves and TW’s are not 
pathognomonic as other forms of encephalopathy (e.g. metabolic or toxic) may lead 
to similar EEG findings. However, in the context of other representative findings 
may help establish a diagnosis of HE as distinct from a number of otherwise 
similarly presenting pathologies. Such changes may even persist following liver 
transplantation.(13) Care with interpreting such findings should be taken as in liver 
injury patients also have confounding effects of e.g. malnutrition, hyponatraemia, 
thiamine deficiency (Wernicke’s encephalopathy) and other nutritional and 
electrolyte anomalies can equally cause a number of indistinct EEG findings like 
diffuse slowing of brain waves. 
 
Evoked potentials: Evoked potentials are objective and quantitative methods of 
evaluating the function of peripheral and central nervous systems (PNS and CNS) 
and may assess auditory, somatosensory or visual evoked potentials, with the latter 
the most common. HE may be associated with prolonged latency of visual evoked 
potentials (VEPs)(14) (e.g. N2, P2 and N3), which are assigned according to where 
the positive (P) or negative (N) waves occur (e.g. the second negative wave, N2) 
and reduced wave amplitudes (P100 and P300). However, correlation with depth or 
chronicity HE, though more closely associated with sub-clinical presentation, is 
debated and inferior to psychometric tests,(15-17) limiting its uses to research. 
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Neuropsychological tests: the use of neuropsychometric battery tests have been 
limited to research of minimal HE. Although results from most studies have not 
been easy to compare due to the array of different tests, the common finding in 
cirrhotic patients is impaired psychomotor speed, visual perception and attention, 
while verbal ability is unimpaired. Most studies advocate using the ‘number 
connection test’ (NCT), ‘digit symbol test’ (DST) and/or the ‘block design test’ (BDT) 
for the diagnosis of minimal HE. However, a standardised test battery, the 
‘psychometric HE score’ (PHES) is frequently used(5) and considered the ‘gold 
standard’ in the diagnosis of minimal HE as it covers the spectrum of cognitive 
changes, has normative age-corrected data and is inexpensive.(6) This uses the line 
drawing test (LDT), the serial dotting test (SDT), the DST and the NCT (A and B), to 
examine motor speed and accuracy, visual perception, visuospatial orientation, 
visual construction, concentration, attention and to a lesser extent memory. Also, a 
good performance of all tests will also assess attention. 
 
Critical flicker frequency (CCF): CCF measures the ability of the central nervous 
system to detect flickering light. An intrafoveal light stimulus with defined pulses 
(wavelength of 650 nm), initially generates red light as a high-frequency pulse (60 
Hz) giving the patient the impression of a steady light. This is gradually reduced 
until the patient has the impression that the steady light had changed to a flicker, 
registered by pressing a hand-held switch. These changes are directly influenced by 
cortical activity and thus correlate to possible brain damage. CCF detects a wide 
range of neuropsychological abnormalities including visual signal processing (e.g. 
with retinal gliopathy) to cognitive functions like arousal and attention, but cannot 
detect motor abnormalities. Over the last 40 years has been utilised to establish 
responses to certain psychotropic drugs and more recently lend itself to the 
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diagnose a number of neurological disorders such as Multiple sclerosis and 
Alzheimer’s disease. CCF is beneficial as a test for minimal HE compared to other 
measures as it is not influenced by age, gender, cultural or educational factors. CFF 
has also proven a useful test for the diagnosis of minimal HE, with Kircheis and 
colleagues reporting a 55% sensitivity and 100% specificity using a <39 Hz 
threshold cut-off,(18) though Sharma et al. report a diagnostic accuracy of 
83%(19) and Romero-Gomez et al. 79%(20) when compared to other 
neuropsychometric tests like computer-based, evoked potentials, NCT and PHES. 
Furthermore, a CFF <38 Hz predicts the risk of developing overt HE, correlating 
with Child-Pugh score, though not survival.(20) 
 
PATHOGENESIS OF HE 
 
Current paradigm 
Though many factors have been implicated in the pathogenesis of HE, it is the 
interplay between ammonia, inflammatory responses and auto-regulation of 
cerebral haemodynamics (the ‘multiple-hit’ hypotheses) that appears most 
important and will be elucidated in greater depth in later chapters.  
 
Ammonia: Arterial ammonia level (at admission) is an independent predictor of 
outcome(21) and a plasma ammonia level >150umol/L is associated with brain 
herniation,(22) with recent studies suggesting a linear correlation between arterial 
ammonia level and HE grade.(21, 23) Post mortem brain tissue from patients with 
hepatic coma and animal models of liver failure,(24) suggest that ammonia may be 
related to the development HE by propagating astrocyte swelling and cerebral 
oedema. In liver failure, progressive ammonia uptake in astrocytes, increases levels 
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of the osmolyte glutamine (catalysed by glutamine synthetase) with accumulation 
of water due the osmotic imbalance.(2) To better understand the role of ammonia 
in HE, one needs to understand interorgan ammonia & amino acid metabolism 
which will be discussed in chapter 1.2.  
 
Inflammation/infection: Infection is detected in 80% of patients with acute liver 
injury(25) and its presence at admission is a predictor for worsening HE.(26) 
Development of sepsis may trigger decompensation of cirrhosis with progression to 
renal failure, encephalopathy, and gastrointestinal bleeding, with reduced survival. 
However, the associated proinflammatory cytokine release(27) is as important as 
the microbial pathogen itself. The term ‘systemic inflammatory response syndrome’ 
(SIRS) refers to the clinical manifestation of inflammation and describes a 
dysregulated host inflammatory response whether triggered by infection or not. 
Aseptic inflammation is just as implicit to the natural history of acute liver injury 
(e.g. drug induced ALF), and SIRS (in the absence of infection) is as significant to 
progression of encephalopathy as is SIRS triggered by infection.(28) However, it is 
plausible that in such studies worsening SIRS and encephalopathy are related to 
undetected infection, therefore establishing the presence of infection is paramount. 
Of particular concern in these patients is SBP that is diagnosed in 8-30% of 
hospitalised cirrhotic patients presenting with ascites and usually occurs in the 
absence of a primary focus of intra-abdominal infection. It arises by haematogenous 
spread of translocated intestinal flora via mesenteric lymph nodes. Predisposing 
factors are; – overgrowth of jejunal gram-negative aerobic bacilli and reduced 
intestinal barrier function and blood flow. In a patient with acute liver injury and 
uncontrolled intracranial hypertension, who underwent an emergency hepatectomy 
for critical hepatic necrosis (as a bridge to successful orthotopic liver transplant 
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(OLT), removal of necrotic hepatic tissue resulted in a sharp and sustained 
reduction in the circulating proinflammatory cytokine concentration and stabilisation 
of both systemic and cerebral haemodynamics independent of arterial 
ammonia.(29) This alludes to a relationship between systemically derived 
proinflammatory cytokines and cerebral blood flow modulation in the pathogenesis 
of intracranial hypertension in patients with acute liver injury.   
 
Cerebral blood flow modulation: In ALF, cerebral hyperaemia often develops, 
especially in those with malignant intracranial hypertension.(30) Even with medical 
treatment, malignant hypertension precedes death which can only be treated by 
orthotopic liver transplantation (OLT).(30) With the 2-3x increased blood-brain 
barrier permeability and cerebral metabolic rate for ammonia with HE,(31) elevated 
cerebral blood volume, besides increasing intracranial pressure, may serve to 
promote osmotic movement of water across the blood brain barrier predisposing to 
cerebral herniation. 
 
Other pathogenic factors 
There are a number of notable factors that are associated with progression of HE. 
However, their role appears to be intertwined with their interaction with the effect 
of ammonia on astrocytes. Such secondary factors, which modulate the role of the 
three principal pathogenic factors of HE – ammonia, inflammation and disrupted 
cerebral haemodynamic autoregulation, and worth a mention, are electrolyte 
imbalance and alterations in receptor concentrations.  
 
Electrolyte imbalance: Anecdotal evidence from patients with ACLF, suggests that 
hyponatraemia is implicit to the progression to cerebral oedema.(32) A recent study 
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using 1H-magnetic resonance spectroscopy (MRS), suggests that patients with 
hyponatraemia have significantly lower levels of the organic osmolyte myo-
inositol(33) which would normally compensate for the rising intracellular glutamine 
seen with acute liver injury; other intracellular osmolytes are important (e.g. 
Taurine). Hypokalaemia increases renal ammonia production,(34) and if co-exists 
with metabolic alkalosis can potentially increase brain ammonia uptake by 
promoting formation of ammonia (NH3+) which crosses the blood-brain barrier, 
from ammonium (NH4+), a charged particle which doesn’t. However, as discussed 
later (chapter 1.4), metabolic acidosis triggers increased renal ammonia production 
and relative increase in excretion. 
 
Neurotransmitters/receptors: Metabolic and degenerative brain diseases 
characteristically demonstrate disorders of specific neurotransmission pathways. HE 
is no exception, with notable effects on glutamine, monamine, serotonin (5-HT), 
opiate, catecholamine pathways and γ-Aminobutyric acid (GABA), the chief 
inhibitory neurotransmitter in the central nervous system. GABAergic 
neurotransmission is one of the most investigated pathways over the last two 
decades, with reported "increased GABAergic tone" in HE.(35) This is suggested by 
a number of important observations. Firstly allosteric agonists of the GABA-A 
receptor complex (GRC) show similar visual evoked response potentials to rabbits 
with galactosamine-induced fulminant hepatic failure (FHF). Also, the activity of 
Purkinje neurons are more depressed by GRC modulator compounds in FHF rabbits 
compared to controls.(36) Also in patients with HE, Flumazenil - a highly selective 
benzodiazepine antagonist at the GRC, ameliorates neurobehavioural symptoms and 
EEG activity, suggesting its beneficial effect is not due to antagonist action on 
blood-borne endogenous benzodiazepines (see chapter 4). Proposed 
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pathophysiological mechanisms for this increased GABAergic tone includes 
increased brain GABA (due to increased uptake through altered barrier 
permeability), alteration in GRC integrity and/or increased endogenous GRC 
modulators such as benzodiazepines and neurosteroids (potent GRC agonists). 
However recent studies suggest that only increased endogenous brain agonists are 
likely to be important; with no significant alterations of either GABA content,(37, 
38) or GRC integrity. GABA activates the postsynaptic GRC, a ligand-gated chloride 
channel, which then allows chloride to enter and inhibit the postsynaptic neuron. 
Barbiturates, benzodiazepines and neurosteroids (e.g. tetrahydoprogesterone (THP) 
also known as allopregnanolone and tetrahydrodeoxycorticosterone (THDOC)) all 
bind at the GRC; neurosteroids enhancing chloride uptake and positively influencing 
GABA and benzodiazepine agonist GRC binding.(39) It appears however, that only 
neurosteroids concentrations(40) and not benzodiazepine levels are increased in HE 
and therefore important to its pathogenesis. However, although such 
neurotransmitter pathways show promise, the interaction with other key pathogenic 
factors of HE like ammonia and electrolyte imbalance are likely significant, making it 
hard to elucidate the true role of specific neurotransmitters in this condition. 
Therefore as yet there are few therapeutic interventions that target the relevant 
neurotransmitters, which have proven to be of benefit outside of laboratory and 
animal experimentation, and though further study is needed, the role of 
neurosteroids was not investigated in this thesis. 
 
Nutritional factors: Patients with cirrhosis (especially if alcohol-induced), usually 
have a poor nutritional reserve due to anorexia, poor diet, malabsorption, and 
altered metabolic state. Furthermore, hospitalised patients are often hypermetabolic 
and hypercatabolic, worsened by complications such as gastrointestinal bleeding, 
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continued anorexia and fasting for tests. Given concerns of nitrogen loading with 
high calorie intake, clinicians previously advised dietary protein restriction in liver 
failure to prevent a rise in blood ammonia levels. However, this has the potential to 
lead to a worsening negative nitrogen balance, which aside from limiting energy 
production will reduce muscle mass that may alter the potential of skeletal muscle 
glutamine synthetase to buffer ammonia. Recently, the ‘European Society for 
Parenteral and Enteral Nutrition’ consensus review(41, 42) recommended a 
normal/higher supply of dietary proteins to achieve nitrogen balance, which can be 
tolerated without risk of HE. However, infrequently in certain cases where the 
patient has persistently high circulating ammonia and intracranial hypertension and 
oedema despite other interventions, short-term low protein feeds (e.g. short-term 
glucose infusions) are occasionally used to provide calories (energy), without 
nitrogenous compounds. In advanced cirrhosis, there is also evidence of an increase 
in aromatic amino acids and reduction in branched-chain amino acids (BCAAs) 
resulting in effects on neurotransmitter synthesis, associated with HE; providing a 
rational for preferentially supplementing dietary BCAAs.(43, 44) 
 
In conclusion, despite a number of different causal factors in the development of 
HE, the role of ammonia and precipitating factors in disease progression continues 
to be key to its pathogenesis and influence current ‘best treatment’, which will be 
outlined in chapter 1.4. There is also a need for better designed and powered 
randomised control studies, if not metanalysis, assessing the therapeutic benefit of 
interventions targeting HE. 
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Table 1: Western Haven criteria 
 
            
 
 
Table adapted from that originally published by Conn HO. Trail-making and number-connection tests in the assessment of mental state in portal systemic 
encephalopathy. Am J Dig Dis 1977;22:541-550. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stage Consciousness Intellect and Behaviour Neurological Findings EEG findings
0 Normal Normal Normal examination; impaired
psychomotor testing
Normal, slowing (4-6Hz)
1 
Mild lack of awareness, 
personality change, day/night 
reversal
Shortened attention span; impaired 
addition or subtraction
Mild asterixis or tremor,
mild incoordination Slowing
2 Lethargic, inappropriate 
behaviour
Disoriented Obvious asterixis; slurred speech,
abnormal reflexes
Slowing, triphasic
3 Asleep, somnolent but rousable Gross disorientation; bizarre 
behaviour; loss of meaningful 
communication
Muscular rigidity and clonus;
hyperreflexia, abnormal reflexes
Slowing, triphasic
4 
Coma Coma Decerebrate posturing Very slow (2-3Hz), delta
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Table 2: Differential diagnosis 
 
            
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Metabolic Toxic CNS
Glycaemic control - hyper Alcohol - intoxification Encephalitis
- hypo - withdrawal Meningitis 
Calcaemic control - hyper Drugs    - prescribed Abscess 
- hypo - illicit Trauma
Hypokalaemia Carbon monoxide narcosis Tumour
Hypoxia Bleed 
Uraemia Infarction
 42 
 
Table 3: HE precipitants 
 
Precipitating Factors In Hepatic Encephalopathy
Increased nitrogen 
• Constipation
• Gastrointestinal bleeding
• Azotaemia/uraemia
• Excessive dietary protein
Electrolyte imbalance
• Hypokalaemia 
• Hypoglycaemia
• Hypothyroidism
• Hypoxia
• Hypotension
• Dehydration
• Metabolic alkalosis/acidosis
Drugs
• Narcotics sedatives
• Tranquilizers
• Sedatives
Miscellaneous 
• Infection (e.g. subacute bacterial peritonitis) 
• Surgery
• Anaemia 
• Progressive liver disease 
• Superimposed liver disease (e.g. hepatoma)
• Vascular occlusion
• TIPS and surgical shunt insertion 
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Chapter 1.2  
 
Hepatic Encephalopathy: 
 
Interorgan Ammonia and Amino Acid 
Metabolism in HE 
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Introduction 
The impact of liver disease on neuropsychological function, termed hepatic 
encephalopathy (HE), is incumbent on the accumulation of ammonia.(45) With liver 
failure, aside from urea cycle disruption and portal-systemic shunting, ammonia 
homeostasis is dependent on differential changes within a number of key organs, 
amino acids (glutamine metabolism(46)) and enzymes. However, aside from liver 
transplantation, recent meta-analysis suggest that current clinical strategies which 
primarily target lowering ammonia, fail to make a clinical impact on HE.(47, 48) The 
shortfall in donor organs for transplantation dictates a need for new therapeutic 
interventions to correct hyperammonaemia. This chapter highlights interorgan 
ammonia and amino acid metabolism pertinent to liver disease and 
hyperammonemic states and future concepts based on this understanding which 
may lead to more targeted therapy.  
 
CELLULAR AMMONIA AND AMINO ACID METABOLISM  
 
Dietary intake and production: Nitrogen is necessary for cellular structure and 
energy. Humans assimilate reduced nitrogenous compounds as dietary protein, free 
amino acids, and the gas- ammonia, derived from the splitting of urea (and possibly 
amino acids) by ‘urease’-producing intestinal bacteria; with their relative importance 
in intestinal ammonia metabolism to be discussed later.  
 
Chemical properties: In the body ammonia (NH3) is co-existent with its charged 
form ammonium (NH4
+), with the time to equilibrium of- ‘NH3 + H
+ 
 NH4’ 
(milliseconds), dependent on pH.(49) At a physiological pH, 98% of ammonia exists 
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as NH4
+, but as NH3 is the main form transported across biological membranes, in 
this review we refer to NH3/NH4
+ as simply, ‘ammonia’.  
 
Plasma transport: Ammonia is hydrophilic and easily transported in plasma unlike 
albumin-bound hydrophobic toxins (e.g. bilirubin, bile and fatty acids) that 
accumulate in liver failure. In health, ammonia transport is tightly regulated to 
maintain low plasma concentrations (normal range 10-40 µmol/L). In several 
organs (e.g. intestinal or kidney) ammonialevels are the mmol/L range. 
 
Transmembrane movement: Ammonia’s moderate lipid solubility should limit 
membrane permeability, but as most membranes are very thin, ammonia 
permeability is good; though with highly lipid based membranes it maybe 
impermeable. Charge is also important, with metabolic alkalosis increasing the 
conversion of NH4
+ to NH3, serving to improve ammonia membrane permeability. 
However, within the cell negatively charged mitochondria show a very poor 
permeability to NH3 despite a high pH, but do display a high permeability to 
NH4
+.(50) Transmembrane ammonia transport involves a number of constitutive ion 
channels (discussed later), influenced by certain transporters (e.g. Aquaporins). 
Aquaporins (AQP) are bi-directional water channels that may increase the 
permeability of the cell to ammonia (e.g. AQP3, AQP7, AQP8 and AQP9).(51-53) 
Ammonia’s membrane movement is pH-dependent and driven by the NH3 
gradient(54) which like the osmotic gradient is bidirectional. Given there wide 
distribution and variable permeability properties it is possible that differential AQP 
expression may play a role in cellular and whole body ammonia homeostasis, 
independent of their effect on water transport. Recently, the erythroid ‘Rhesus 
family’ transmembrane proteins,(55-57) were found on epithelial cells of the 
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intestinal, kidney and liver,(58) influencing ammonia transport in these organs. 
However, their precise role in whole body ammonia metabolism remains unclear. 
 
INTERORGAN AMMONIA AND AMINO ACID METABOLISM 
 
Relationship between ammonia, glutamine and glutamate 
Whole body ammonia metabolism is dependent on the localisation, activity and 
differential concentrations of certain key enzymes common to all organs.(59) 
Glutamine Synthetase (GS) converts ammonia and glutamate to glutamine 
[Glutamate + adenosine tri-phosphate (ATP) + NH3 → Glutamine + adenosine di-
phosphate (ADP) + phosphate] expending 1 ATP for every molecule of ammonia 
consumed. Phosphate-activated glutaminase (PAG) carries out the reciprocal 
reaction - glutamine to glutamate and ammonia. Glutamine is a non-essential 
amino acid (five-carbon chain and two nitrogen residues), abundant in protein and 
constitutes 50% of the whole body free amino acid pool.(60) Glutamine and 
glutamate are therefore central to organ and whole body nitrogen balance by 
serving as both nitrogen donor and acceptor; with glutamine both a sink for excess 
ammonia (GS), or its source (PAG).(61) It is the location, expression and activity of 
these key enzymes that impact on the ammonia and amino acid metabolic flux of 
different organs in both health and disease which influences circulating ammonia 
levels. 
 
Interorgan ammonia metabolism 
There are multiple organs involved in whole body ammonia and amino acid 
metabolism: 
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Intestines: Feeding increases intestinal ammonia generation, with dietary protein 
yielding differential ammoniagenic potential(62) (meats > dairy(63) > vegetable 
protein(64)), possibly influenced by carbohydrate.(65) In addition to dietary protein 
and intestinal bacterial ammonia production, studies on post-absorptive healthy 
animals show that 50% of intestinal ammonia is from amino acids derived from its 
blood supply (Figure 1).(61, 66, 67) This is mainly from circulating glutamine (the 
enterocytes main energy source) taken up and converted by phosphate-activated 
glutaminase (PAG), to ammonia and glutamate (subsequently transamidated to 
alanine(68, 69)), before its release into the mesenteric vein. In both humans and 
rats by measuring enzyme activities in mucosal biopsies from different intestinal 
sites, about 80% of intestinal PAG is found in the small bowel and 20% in the large 
bowel,(70, 71) to a greater extent equating to their relative activities. This is 
further suggested by the correlation between PAG activity and MHE. Therefore, due 
to high relative abundance of PAG, the intestines are a major glutamine-consuming 
and ammonia-producing organ,(68, 69) as suggested by substantial intestinal 
ammonia production in germ free rats, or hyperammonaemia in germ-free 
hepatectomised rats.(72) Such observations also serve to highlight that intestinal 
bacterial ammonia production is not the predominant contributor to systemic 
ammonia as historically thought. Differences in arterial-venous ammonia from 
gastrointestinal (GI) malignancy patients undergoing elective abdominal surgery 
supports animal data, with glutamine extraction (24% Jejunum, 9% Ileum and 8% 
colon), associated with jejunal and ileal ammonia release.(73) The colon provides the 
remaining intestinal ammonia (which in dogs is derived from 9% glutamine, 42% 
arterial urea and 49% from luminal bacterial breakdown products, glucose, short-
chain fatty acids and ketones).(66) Therefore in the post-absorptive state, around 
50% of intestinal ammonia arises directly from dietary nitrogen and 50% from 
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circulating amino acids; with equal contribution from the small bowel (with its 
predominant circulating amino acid conversion) and large bowel (with its predominant 
bacterial amino acid and urea breakdown). Although as discussed later, the small 
bowel may become increasingly important with progressive liver injury.(74) 
 
Liver: A typical diet contains ~100grams protein/day (25% glutamate–producing 
amino acids - glutamine, ornithine, proline, histidine, arginine and glutamate); the 
bulk metabolised by the liver. Excessive dietary nitrogen must be either excreted, 
or converted to a non-toxic form. This is achieved in the compartmentalised 
periportal and perivenous hepatocytes of the liver acinus. Firstly these nitrogenous 
compounds (mainly as glutamine of ammonia) need to get into the hepatocytes. 
Ammonia is readily diffusible and assisted by a number of transporters (see earlier). 
Glutamine movement is aided by the transport protein ‘sodium-coupled neutral 
amino acid transporter’ (SNAT3)(75) (found in liver, kidney, muscle and 
astrocytes), which is important for both glutamine uptake in periportal cells and 
glutamine release by perivenous cells; due to bi-directional properties related to its 
ability to counter-transport H+.(75, 76) 
Periportal hepatocytes: contain the ‘hepatic urea cycle’ (Figure 2) that culminates in 
the conversion of ammonia (produced by oxidative deamination) to urea, the major 
end-product of nitrogen metabolism. One mole of urea removes 2 moles of waste 
nitrogen but requires 4 moles of ATP (2 ATP per ammonia); 15 mgs of total soluble 
ammonia, given production of 1 gram of urea [2 NH3 + CO2 + 4ATP ---> urea 
[(NH2)2CO] + H2O + 4ADP]. The ‘urea cycle’ is not the only route for ammonia 
detoxification, as bicarbonate (HCO3
-), rather than CO2 may be involved; impacting 
in pH metabolism (see later). Periportal hepatocytes are highly abundant and a 
prominent site for not only urea cycle enzymes (e.g. carbamoyl-phosphate 
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synthetase (CPT), the 1st step and rate limiting enzyme of the cycle), but also PAG 
and alanine-/aspartate aminotransferases (ALT/AST). Liver PAG has a low-affinity 
and high capacity for its product (ammonia),(46) which is also activated by NH3 
(but not NH4
+). PAG is also critical to urea cycle, by providing intramitochondrial 
glutamate for N-acetylglutamate synthesis, activating CPT. Therefore, the bigger 
the supply of intestinal ammonia (and glutamine), the bigger its turnover to 
urea.(77, 78) Alanine is another important source for urea via periportal ALT and 
AST. Collectively, urea synthesis derives from - 33% portal ammonia, 6-13% portal 
glutamine, 20% mitochondrial glutamine and 33-40% others (e.g. portal and 
hepatic alanine, and hepatic ammonia and glutamine via various enzymes).(79)  
Perivenous hepatocytes: These cells surrounding terminal venules, make-up only 
7% of hepatocytes and via hugely abundant GS (high affinity, but low capacity for 
ammonia(46)) convert ammonia to glutamine.(80) Therefore, if any ammonia 
escapes periportal hepatocytes, it can be scavenged and detoxified by perivenous 
hepatocytes. GS and PAG act in concert to accommodate rapid changes in systemic 
ammonia levels from one of glutamine uptake to glutamine release.(81-83) Hepatic 
glutamine metabolism, in concert with urea synthesis, is therefore very important in 
systemic ammonia detoxification due to the unique regulatory properties of hepatic 
glutaminase, acinar compartmentalisation (‘zonation’) of urea and glutamine 
synthesis, and ‘intracellular glutamine cycling’(78) between periportal and 
perivenous hepatocytes. Metabolic zonation, the spatial organization of various 
metabolic pathways and functions, forms the basis for the efficient adaptation of 
liver metabolism to the different nutritional requirements of the whole organism in 
different metabolic states. As such, in the post-absorptive state with a normal 
healthy liver, hyperammonaemia should never occur due to the capacity of the 
hepatic urea cycle and intercellular glutamine cycling (Figure 3).  
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A further ability of the urea cycle is pH homeostasis. Portal ammonium ions can also 
be converted into urea, with the simultaneous involvement of bicarbonate (HCO3
-) 
rather than CO2 [NH3 + HCO3
-  urea]. This is a significant pathway at time of 
metabolic acidosis helping to maintain pH homeostasis, as unlike glutamine 
synthesis, urea synthesis removes bicarbonate; this leads to a change from urea 
synthesis to glutamine synthesis during acidosis, to conserve bicarbonate.(78, 84)  
The Kreb’s cycle is the primary metabolic pathway for cellular energy production, 
converting carbohydrates, fats and proteins to energy, with CO2 and water as 
waste. The urea cycle is closely linked to the Kreb’s cycle deriving one of its 
nitrogens through transamination of oxalacetate to form asparate and returns 
fumarate to that cycle. This allows amino acids formed by the urea cycle to be used 
as a source of fuel in the Kreb’s cycle; which is important as energy is expended 
through the urea cycle (~20% of the energy derived from metabolism of 
gluconeogenic amino acids). Ammonia is quickly combined with α-ketoglutarate to 
form glutamate (glutamate dehydrogenase (GDH)) and glutamine (GS). The NH2 
groups can then be moved on to other recycled carbon skeletons to form new amino 
acids by transamination and transamidation by vitamin-B6-dependent ALT/AST 
(e.g. keto acids, pyruvate and oxaloacetate). Relative substrate levels largely 
determine the reaction direction of transaminases (as the equilibrium constant 
approaches 1). The only amino acids that are not formed during this process are the 
diet-dependent essential amino acids - threonine and lysine. As GDH is NADPH-
dependent, cellular energy status critically regulates hepatic ammonia and amino 
acid metabolism. In low energy states proteogenesis is limited, promoting the 
reverse instead with glutamate converted to ammonia and oxidizable cycle 
intermediates for energy production.  
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Changes in pH also directly influence the hepatic enzymes, with acidosis also 
reducing the rate of glutamate metabolism by affecting mitochondrial PAG and GDH 
flux,(85) while as mentioned earlier, stimulating glutamine synthesis and recycling. 
Therefore acidosis directly effects ureagenesis by effecting PAG-dependent 
glutamate metabolism via its influence on nitrogen provision for carbamyl 
phosphate and N-acetylglutamate synthesis;(85) with alkalosis having the converse 
effect.  
 
Kidney: Urinary ammonia excretion involves tightly regulated mechanisms such as 
tubular urine flow, apical/basolateral ion exchangers (e.g. Na+-K+-NH4
+-ATPase) 
and ammonia counter-current system. In the post-absorptive state, glutamine is 
the main substrate for renal ammoniagenesis,(86) but unlike other organs kidney-
PAG is strongly inhibited by glutamate (its product), not ammonia. Ammonia 
synthesised by proximal tubular cells is excreted into tubular fluid and quickly 
reabsorbed by the medullary thick ascending limb (MTAL) (Figure 4). There it 
accumulates in the interstitium before excreted as NH4
+ (due to the effect of urinary 
acidification) in the medullary collecting ducts. 
In the post-absorptive state of humans, urinary ammonia excretion reflects the 
renal excretion rate(86) and match ammonia circulatory release.(86, 87) In post-
absorptive animals (e.g. dogs,(88) pigs(89) and rats(90)) 70% of renal ammonia is 
released into the circulation (renal vein) with only 30% excreted in urine. Owing to 
compensatory GS and glutaminase activity with changing arterial ammonia delivery, 
the kidney can become a net producer or excretor of ammonia,(91) as evident by 
an increase in ammonia renal excretion with elevated plasma ammonia in healthy 
volunteers administered ammonium chloride.(86) Yet under certain conditions (e.g. 
changes in acid-base balance) this can shift to net ammonia production. 
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Acid-base balance: In response to acute metabolic acidosis, within the kidney 
proximal tubular cells take up glutamine and due to increased PAG activity form 
ammonia and glutamate.(85) Glutamate is then either released into the renal vein, 
transamidated to form alanine (hepatic energy source), or converted to α-
ketoglutarate and ammonia (by GDH).(92) Alpha-ketoglutarate can then be 
metabolised to either lactate and glucose (for release into the renal vein),(93) or 
pyruvate for oxidization to CO2 in the TCA cycle. Such decarboxylation of α-
ketoglutarate causes net circulating bicarbonate synthesis, to compensate for the 
acidosis.(94) By conserving circulatory bases to compensate for acidosis, more 
ammonia can be excreted (≤70% of total renal ammonia production), at the 
expense of urea to conserve acid-base balance, reversing normal conditions while 
maintaining nitrogen excretion at a constant.(88, 95) The reverse may occur with 
alkalosis.  
Hormonal control also has a role, with Angiotensin ΙΙ dose dependently increasing 
renal ammoniagenesis by directly increasing MTAL absorption via its effect on Na+-
K+-NH4
*-CL-. Via such ammonia ion-exchangers, renal ammonia transport is also 
differentially sensitive to certain diuretic therapies (e.g. Frusemide).  
 
Muscle: Although the GS activity of skeletal muscle is significantly greater than of 
competing glutaminase activity,(96) GS activity in skeletal muscle is still low;(97) 
but by virtue of muscles mass it can impact greatly on interorgan ammonia 
metabolism. In healthy volunteers, one study suggested an estimated 50% arterial 
13N-ammonia extraction from skeletal thigh muscle.(31) However, other studies 
demonstrate a zero arterial-venous difference across forearm and leg suggesting an 
absence of muscle ammonia uptake.(97-100) which is a more robust measure of 
organ metabolism as extraction does not truly reflect a net metabolic 
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consumption/production as this is dependent on organ flow. Skeletal muscle 
ammonia production also provides an additional route for nitrogen (and carbon) 
transport from muscle to liver, with muscle pyruvate transaminated to alanine and 
then transported to the liver for conversion to ammonia (by ALT). Once in the liver, 
alanine (with α-ketoglutarate) is converted to pyruvate and glutamate (also by 
ALT). The generated liver pyruvate can be incorporated into the Kreb’s cycle by 
pyruvate dehydrogenase (PDH), oxidatively decarboxylated to acetyl coA and thus 
used as a substrate for gluconeogenesis which can be recycled back to muscle. The 
glutamate produced by this reaction also allows for the formation of ammonia (and 
glutamine) by liver PAG and later urea; with α-ketoglutarate recycled from 
glutamine dehydrogenase (GDH). This ‘glucose-alanine cycle’ (Figure 5) allows 
skeletal muscle to eliminate nitrogen while replenishing its energy supply. Under 
conditions of fasting, the glucose-alanine cycle was originally thought to maintain 
glucose homoeostasis when exogenous supplies of energy were limited.(101) But 
given concerns over the relative significance of carbon homeostasis between 
glucose, lactate and alanine in the muscle,(102, 103) recent evidence suggests that 
it is more important in maintaining nitrogen transport,(104) with alanine a major 
source of urea.(105)  
 
Brain: Ammonia is important for the regulation of glial cell metabolism (a signaling 
function). In health, ammonia readily traverses the blood brain barrier, with positive 
arterial-venous differences suggesting net brain ammonia uptake; with the rate of 
arterial ammonia clearance directly correlating to arterial concentration. Though 
some studies suggest little/no net ammonia uptake,(99, 106) arterial extraction 
(13N-ammonia) maybe as high as 47% within gray matter (astrocytes).(31) 
Astrocytes (20% of brain cells) contain 80% of brain GS, whereas neurons contain 
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20% (and nearly all brain Glutaminase).(107, 108) Astrocyte GS preferentially 
takes up ammonia and glutamate to form glutamine, which can then be transferred 
to neurons for deamination to re-form glutamate and GABA (important 
neurotransmitters). Furthermore glutamate can be converted to alpha-ketoglutarate 
and lactate and transported to neurons as a source of energy, though changes in 
intracellular pH and K+ effect the regulation of these glial-neuronal metabolic 
processes.(85) Therefore in health, the brain is a significant organ for ammonia 
utilisation and detoxification; comparable to skeletal muscle.(31) However, amino 
acids involved in neurotransmission must be limited to reduce neurotoxicity. In glial 
cells, glutamate uptake is dependent on excitatory amino acid transporter (EAAT-2) 
and glutamate transporter (GLT-1) and in neurons on excitatory amino acid carrier 
(EAAC) and EAAT-3. If extracellular glutamate accumulates (usually kept within 
micromolar range) it may lead to toxic N-methyl-D-aspartate (NMDA) receptor 
activation and neuronal death. Intracellular glutamate (at milimolar levels), is 
actively taken up (without ATP) against an electrical gradient by co-transport of ions 
moving down their electrochemical gradients (3 Na+ and one H+ enter, while one K+ 
is transported out of the cell), as glutamate is slightly negatively charged as is the 
inside of the cell.  
 
Lung: Lung parenchyma also possess PAG and GS,(59) but although there is the 
potential to play a role in whole body ammonia metabolism, recent evidence from 
interorgan ammonia and amino acid trafficking in pigs,(109) suggest that in health 
the lung has little net effect. 
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Heart: As the heart is muscle it has a significant amount of GS(83) and also 
contains PAG(96) and therefore a possible role in ammonia metabolism, but 
evidence is limited. 
 
AMMONIA IN DISEASE 
 
Evidence of a role for ammonia in liver disease                                    
The importance of ammonia with liver disease was first identified by Nencki & 
Pavlov (1896) who demonstrated that hyperammonaemia induced neurobehavioral 
change in portacaval shunted (PCS) dogs.(110) This hepatic encephalopathy (HE), 
encompasses a spectrum of mental disturbances that range from sub-clinical to 
coma and death.(6) Since, innumerable studies provide the consensus view that 
ammonia is central to the pathogenesis of HE. In liver failure, the presence of HE 
defines temporal classification of liver failure. Arterial levels best prognosticate 
circulating ammonia, correlating to HE severity;(23) though venous sampling is 
adequate. In acute liver failure (ALF), arterial ammonia levels of >150umol/L 
predict a poor outcome(22) and correlate with increased ICP and cerebral 
oedema.(21, 22, 111) This is likely to be related to increased brain delivery and 
uptake of ammonia associated with hyperammonaemia highlighting the importance 
of interorgan ammonia metabolism.  
 
Inherited enzyme deficiencies 
In addition to liver failure, as there is no alternative pathway for urea synthesis, 
inherited disorders of the hepatic urea cycle may cause profound accumulation of 
toxic by-products (e.g. CPT), with hyperammonaemia, mental retardation and even 
death, though this will not be further discussed in this review.  
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Liver failure: altered interorgan ammonia metabolism (Figure 6) 
Animal models of liver failure show a widespread disturbance in ammonia and 
glutamine metabolism,(109, 112) supporting similar, though limited data (owing to 
complexity) from clinical studies.(113-117) But caution is necessary in correlating 
findings from animal models (with variable extent, type and duration of injury) to 
human physiology and disease. Furthermore, most studies utilise arterial-venous 
differences across organs. Yet, this fails to reflect the rate of ammonia 
production/consumption, referred to as flux, which is dependent on organ flow. 
However, organ flux measurements are necessary to enable quantification of 
metabolism and comparison of individual organs.  
 
Intestines: Cirrhosis is associated with a four-fold increase in intestinal PAG 
activity in the small bowel,(74) pointing to an increase in the relative importance of 
small bowel ammoniagenesis (derived from circulating amino acids) with liver 
injury.(74) In stable patients with cirrhosis and a transjugular intrahepatic 
portosystemic shunt (TIPS), there is net intestinal ammonia production (though 
limited) which directly correlates with glutamine uptake.(118) In patients with 
cirrhosis and a TIPS, made hyperammonemic by either a simulated bleed (amino 
acid solution mimicking haemoglobin) or acute variceal GI bleeding, there was no 
sign of increased net intestinal ammonia production, no efflux from the splanchnic 
circulation or muscle uptake, but instead a significant increase in renal production 
(6-fold).(115) In PCS rats, intestinal ammonia production and stiochiometric 
glutamine consumption was no different to the post-absorptive state.(119) In pigs, 
ALF did not provoke net intestinal ammonia production.(109) In PCS rats, induction 
of ALF with hepatic artery ligation (HAL) caused an early and slight increase in 
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ammonia production and glutamine consumption, though at 4hrs ammonia 
remained elevated despite a fall in glutamine consumption.(119) A loss of 
stiochiometric ammonia production to glutamine consumption suggests that with 
liver failure the intestines contribution to the hyperammonemic state is mainly due 
to portacaval shunting and not to changes in the intestines ability to metabolise 
ammonia and amino acids.(109) This is possibly due to the saturation of PAG, with 
rising arterial glutamine (8-fold) reflecting reduced consumption (or muscle 
release), as arterial ammonia eventually plateaus;(120, 121) as with earlier in vitro 
data.(68)  
Hyperammonaemia due to the ammoniagenic blood protein meal of a bleed, is 
possibly related to an absence of the branched-chain amino acid - isoleucine.(122-
126) In patients with cirrhosis given a simulated bleed, administration of 
intravenous isoleucine improved hepatic and muscle protein synthesis (e.g. net 
phenylalanine incorporation) without any significant effect on the kidneys or 
intestines.(117) Isoleucine may also be cerebroprotective against HE, bypassing 
ammonia’s inhibition of the TCA cycle (alpha-ketoglutarate dehydrogenase) through 
provision of acetylCoA and succinylCoA. However, in the absence of bleeding, 
administration of intravenous isoleucine to correct HE in ALF rats was shown to 
have no effect on coma stage, cerebral oedema, brain lactate or plasma ammonia 
level.(127) 
 
Liver: Hepatocyte injury limits ammonia detoxification by reducing periportal urea 
and perivenous glutamine synthesis,(82, 128) but there is usually enough ammonia 
detoxifying capacity to remove it all from the portal vein and hepatic artery until 
advanced liver failure.(22) With portal-systemic shunting ammonia detoxification 
can be further compromised as it may account for 50% of portal flow,(129, 130) 
 
 
 
 
58
and as much as 93% in TIPS patients.(129, 130) In response to the rising ammonia 
of liver failure, despite compensatory increases in periportal glutaminase activity 
(≤6-fold) and ammonia fed into the 1st step of the urea cycle (CPT),(82) failure to 
compensate increases the amount of ammonia passed through to the terminal 
venules.(84) As perivenous GS capacity also becomes swamped and fails to 
scavenge ammonia, it leaches into the hepatic vein with post-absorptive levels of 
40-60µM in cirrhosis, 70-90µM in acute-on-chronic liver failure (ACLF) and 200-
240µM in ALF; correlating with arterial ammonia concentrations.(22) The lower 
levels with stable cirrhosis (minimal ammonia flux across the hepato-splanchnic 
area), suggests that the liver is still able to remove the majority of ammonia from 
the portal vein and hepatic artery until quite late on. Even with advanced disease 
demonstrable ammonia removal may be somewhat masked by even significant 
portal-systemic shunting.(22) 
 
Muscle: Skeletal muscle ammonia uptake is correlated to arterial levels at various 
stages of ALF(99, 100) and cirrhosis.(97, 98) On a background of 
hyperammonaemia, specific organs (muscle and brain), due to their predominant 
GS activity, try to compensate by switching to net ammonia consumption. In ALF 
patients with advanced HE, skeletal muscle consumes ammonia 
(100nmol/100g/min) and glutamate with the stiochiometric release of 
glutamine.(113) However, with the catabolic state that is ALF, such increased 
glutamine release may impart reflect muscle catabolism and resultant amino acid 
production (10-fold(113)), rather than ammonia conversion from increased GS 
expression and activity(131, 132)). In cirrhotic patients with hyperammonaemia 
who underwent TIPS for gastrointestinal bleeding, skeletal muscle was also the 
main site of ammonia removal.(115, 133) But, hyperammonaemia does not usually 
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occur in stable cirrhotics with normal muscle mass,(99) only in those with 
significant muscle wasting,(97-100, 106) due to reduced ammonia extraction;(97) 
this highlights the need to maintain adequate muscle mass. Skeletal muscle mass 
therefore, provides an alternative therapeutic target for ammonia 
detoxification(134) as supplying ornithine (providing 2 glutamate) can theoretically 
buffer the hyperammonemic state of liver failure by GS converting ammonia and 
glutamate, with glutamine efflux.(132)  
Early clinical studies reported increased circulating glutamate with liver failure,(135-
137) but recent evidence tends to confirm the converse – a circulating glutamate 
deficiency;(113, 116, 138) due to a reduction in hepatic synthesis and/or 
conversion of stores to glutamine. However, in ALF (PCS + HAL) devascularised 
pigs, despite an initially raised arterial glutamine at 2 hours, levels eventually fell 
(8-fold), possibly due to a fall in glutamate provision.(109) In contrast to clinical 
studies, in the ALF devascularised pig model there was no net skeletal muscle 
ammonia uptake 6 hours post ALF, despite initially increased at 2 hours.(109) 
Absent muscle ammonia uptake was also reported in PCS rats with acute liver 
ischaemia with no net glutamine efflux despite increased muscle glutamine 
levels.(120) Contrasting results between animal experiments and clinical studies 
may only reflect differences in species physiology and/or type and extent of liver 
injury. Also, skeletal muscle ammonia uptake and glutamine release does not 
necessarily lead to net whole body ammonia detoxification as muscle-derived 
glutamine can be taken up by the splanchnic region or kidneys and converted to 
ammonia for release into the circulation. 
 
Kidney: As discussed earlier in this chapter, Glutamine is the main substrate for 
renal ammoniagenesis. In the PCT, glutamine is converted to ammonia and 
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glutamate by PAG, with GDH further converting glutamate to ammonia. Ammonia 
(NH3) is excreted into tubular fluid by non-ionic diffusion (pH gradient) and 
ammonium (NH4
+) via ionic diffusion (electrical gradients). Accumulated ammonia in 
the medullary interstitium of the ascending limb of the loop of Henle is quickly 
reabsorbed by the DCT of the MTAL via co-transporters (blocked by loop diuretics). 
This allows for urinary acidification and buffering, with the Renin-angiotension-
aldosterone system (RAAS) dose-dependently influencing renal ammoniagenesis by 
directly increasing MTAL absorption via co-transporters effects. In health, 70% of 
renal ammonia is released into the circulation (renal vein) with only 30% excreted 
in urine. However, though ammonia excretion is not directly correlated to plasma 
levels,(98) with advancing liver disease the kidney becomes an important source of 
ammonia.(109, 115, 139) Autoregulation maintains renal blood flow (RBF) and 
glomerular filtration over a wide range of blood pressures, but increased 
noradrenaline (NA) with renal syndromes of liver failure (e.g. HRS), reduces RBF 
and perfusion, or use of diuretic therapy(140) further reduces ammonia excretion. 
Animal models allow study of the influence of renal metabolism on 
hyperammonaemia.(141-143) In PCS rats, in response to moderate 
hyperammonaemia (arterial levels ~ 250 µmol),(142)  the kidneys seemingly adapt 
by increasing glutamine uptake and/or decreasing plasma release(115) to reverse the 
normal 30/70 urinary excretion/renal venous release ratio and cause a shift to 
ammonia excretion. However, in PCS rats 6-hrs post induction of ALF, severe 
hyperammonaemia (arterial levels ~ 950 µmol) was associated with a reduced 
ammonia excretion and net renal ammonia production.(142) Elevated renal ammonia 
release in this model was likely triggered by increased muscle glutamine production 
and renal uptake. Furthermore, in ALF pigs there is a significant decline in renal 
glutamine uptake and ammonia excretion in urine with time,(109) indicating that in 
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more advanced disease the ability of the kidney to compensate for hyperammonaemia 
by excreting ammonia is overrun.  
Splanchnic vasodilation, associated with over-activated RAAS, is characteristic of 
cirrhosis.(114, 144) In patients with cirrhosis, correcting hypovolaemia may therefore 
increase renal ammonia excretion and reduces plasma ammonia(145) by reversing 
influence of an over-activated RAAS on renal perfusion. This is suggested by an 
improved renal ammonia excretion in patients with cirrhosis following emergency TIPS 
for variceal bleeding,(117) with a fall in renal ammonia circulatory release (to almost 
zero) at one hour post-TIPS. Limiting renal ammonia release into the circulation may 
be an early adaptive effect of TIPS, persisting as long as 25 months.(118) Collectively 
these observations support the presence of renal ammonia adaptation with early 
hyperammonaemia, which with worsening hyperammonaemia and renal dysfunction 
(e.g. diuretics, dehydration, HRS etc.) later switches to net renal ammonia production 
and circulatory release. However, the limited contribution of the kidney should be put 
in context compared to the impact of portosystemic shunting and failure of hepatic 
urea synthesis.  
 
Brain: Brain delivery, extraction and uptake of ammonia increases in ALF;(31, 116, 
146) correlating with arterial levels.(106) However, ammonia extraction data are 
variable, with some reporting extraction only in comatose patients, while others 
show 11%-15% extraction in the non-comatose. Ammonia detoxification (via the 
amidation of glutamate by GS) produces glutamine accumulation and thus osmotic 
stress,(2) - the ‘ammonia-glutamine-brain swelling hypothesis’. In ALF, brain 
glutamine correlates with arterial ammonia,(147) with around 66% of brain 
ammonia metabolised to glutamine and the rest pooling in the brain.(148) 
However, this brain pool does not occur with cirrhosis as plasma levels reach a 
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steady state. To maintain osmotic equilibrium as intracellular glutamine increases, 
astrocytes expel myo-inositol and other weaker osmolytes. However, due to the 
rapidity of ALF, dramatic shifts in ammonia outstrip compensatory mechanisms 
leading to oedema. In cirrhosis, there is some protection from intracranial 
hypertension and brain edema because of the more gradual increase in plasma 
ammonia concentration allowing time for a compensatory expulsion of weaker 
intracellular osmolytes,(149) though oedema may still occur.(150) However, one 
should stress that although never formally studied, net brain ammonia detoxifying 
capacity is minimal compared to skeletal muscle due to its mass. 
Some argue that oxidative stress and free-radical production rather than 
intracellular glutamine are more closely associated with (MAPK-dependent) 
astrocyte swelling(151, 152) and worsening HE;(153, 154) explaining how 
antioxidants and hypothermia may limit oedema.(155-158) However, ammonia is 
still central as both are secondary to ammonia metabolism following glutamine 
breakdown by mitochondrial PAG.  
In ALF, elevated brain ammonia may also negatively influence cerebral energy 
metabolism(38, 159, 160). Inefficient ‘anaerobic’ glucose breakdown (less ATP per 
glucose than through the Kreb’s cycle) and direct inhibition of alpha-ketoglutarate 
dehydrogenase (the rate limiting step in the Kreb’s cycle), increases lactate and 
alanine synthesis.(38, 161) Astrocyte glutamate and ammonia uptake is also 
dependent on ATP requiring Na+-K+-ATPase co-transporter;(162) though much of 
the uptake occurs along ionic gradients without the need for energy. Furthermore, 
high glutamate levels that occur with a disrupted ‘malate–aspartate shuttle’ may 
also impair energy metabolism.(163) 
Neurotoxicity: In neuronal tissue, ammonia is converted to glutamate (via 
glutamate dehydrogenase), depleting the brain of a-ketoglutarate and so inhibit the 
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Kreb’s cycle.(108, 164) The resulting fall in oxaloacetate reduces ATP 
availability.(38, 160) In the absence of aerobic oxidative phosphorylation and 
Kreb’s cycle activity, cell damage and neural cell death occur. Neurotransmission is 
further impaired by depletion of glutamate stores (due to glutamine formation) and 
thus NMDA, GABA and benzodiazepine receptor activation. This could dampen 
inhibitory synapses (increasing excitability), or inhibit excitatory pathways.  
Infection is observed in more than 80% of patients with ALF,(25) and frequently 
precipitates HE.(25, 26, 28, 153) In the brain this interaction may take place in 
astrocytes as they detoxify ammonia which may result in swelling(2), have an 
extensive inflammatory mediator repertoire, and regulate cerebral blood flow 
(possibly through an arachidonic acid and cyclooxygenase dependent 
pathway).(165) Thus, hyperammonaemia may ‘activate’ astrocytes ‘unlocking’ the 
blood-brain barrier, making them susceptible to endotoxaemia through a 
cyclooxygenase (COX)-dependent mechanism.(166) Taken together, disrupted 
ammonia, amino acid and cerebral energy metabolism influenced by inflammatory 
responses, effects neuronal and glial cell function with direct effects on glial cell 
osmotic gradients, cerebral blood flow and thus development of HE.  
 
Lung: Ammonia lung tissue levels are in the milimolar range and about 5-10x 
circulating levels.(109) However, as suggested by studies in ALF pigs, there is a 
wide variation in lung ammonia metabolism probably due to differential regional 
arterial-venous and blood flow differences. However, in real terms the lungs 
contribute little to whole body ammonia.(109) 
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Heart: There is limited data on the heart’s contribution to ammonia and glutamine 
metabolism with liver failure, but given the significant presence of GS(83)  and 
PAG(96) the heart muscle could potentially have an impact. 
 
Collectively the evidence for interorgan ammonia and amino acid metabolism in the 
post-absorptive state in both health and liver disease suggests that aside from the 
liver, systemic ammonia levels are chiefly determined by intestinal and renal 
ammonia metabolism, though with progressive liver disease skeletal muscle and the 
brain may have an increasingly significant roles. 
 
In conclusion, this chapter highlights the importance of interorgan ammonia and 
amino acid metabolism in health and diseased states with systemic ammonia 
predominately due to intestinal and renal ammonia efflux, with skeletal muscle 
providing a target for ammonia detoxification. This greater understanding may 
prove efficacious when developing future therapies to ameliorate the 
hyperammonemic state of liver disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
65
Figure 1: Intestinal ammonia and amino acid production 
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Schematic represents the relative contribution of circulating and dietary nitrogenous compounds in the small 
and large bowel to circulating ammonia. The small and large bowel contribute equally (50% each) of gut-
derived ammonia. In the small bowel this ammonia is equally derived from luminal bacterial breakdown 
products (dietary nitrogen) and the rest from the conversion of circulating glutamine (from the superior 
mesenteric artery). In the large bowel only 8% is derived from circulating glutamine, 42% is derived from 
circulating alanine, but the majority is sourced from bacterial breakdown products in the lumen. Some 80% 
of gut-derived ammonia is converted to urea, the remaining 20% ends up as circulating ammonia.   
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Figure 2: Schematic of the interaction between the Urea and Kreb’s cycle 
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The urea cycle is closely linked to the Kreb’s cycle deriving one of its nitrogens through transamination of 
oxalacetate to form asparate and returns fumarate to that cycle. This allows amino acids formed by the urea 
cycle to be used as a source of fuel in the Kreb’s cycle; which is important as energy is expended through 
the urea cycle (~20% of the energy derived from metabolism of gluconeogenic amino acids). 
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Figure 3: Ammonia detoxification: glutamine cycling and ureagenesis 
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The compartmentalised hepatic urea and glutamine synthesis is very important in systemic ammonia 
detoxification, incorporating hepatic phosphate-activated glutaminase (PAG), acinar, and ‘intracellular 
glutamine cycling’ between periportal and perivenous hepatocytes. The highly abundant periportal 
hepatocytes contain the urea cycle culminating in the conversion of ammonia arriving from the portal vein 
to urea, the major end product of nitrogen metabolism. Periportal PAG converts any intestinal-derived 
glutamine into ammonia with a low-affinity and high capacity for its product (ammonia). PAG is also critical 
to the urea cycle, by providing intramitochondrial glutamate for N-acetylglutamate synthesis, activating 
CPT. Therefore, the bigger the supply of intestinal ammonia (and glutamine), the bigger its turnover to 
urea. Perivenous hepatocytes (7% of hepatocytes) surrounding terminal venules and are hugely abundant 
in glutamine synthetase (GS) (high affinity, but low capacity for ammonia) convert ammonia to glutamine. 
Therefore, if any ammonia escapes periportal hepatocytes, it can be scavenged and detoxified by 
perivenous hepatocytes to glutamine, which along with ammonia is passed into the hepatic vein. 
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Figure 4: Renal ammonia and amino acid homeostasis 
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Glutamine (GLN) is the main substrate for renal ammoniagenesis. In the proximal collecting tubule (PCT), 
glutamine is converted to ammonia (NH3) and glutamate (GLU) by phosphate-activated glutaminase (PAG), 
with renal PAG strongly inhibited by glutamate (not ammonia). Glutamate dehydrogenase (GDH) converts 
GLU to ammonia and α-ketoglutarate (α-KG) (energy substrate for Kreb’s cycle). Ammonia (NH3) is excreted 
into tubular fluid by non-ionic diffusion (along the pH gradient) and ionic diffusion after conversion to 
ammonium (NH4
+) along electrical gradients via co-transporters (e.g. Na+-NH4
+). Conversion of NH4
+ back to 
NH3 and the countercurrent multiplier system sees NH3 accumulate in the medullary interstitium of the 
ascending limb of the loop of Henle. This is quickly reabsorbed by the distal collecting tubules (DCT) of the 
medullary thick ascending limb (MTAL) as NH4
+ via the Na+-K+- NH4
+-2Cl- co-transporter (blocked by loop 
diuretics) allowing for urinary acidification and necessary buffering effect. Activation of the Renin-
angiotension-aldosterone system (RAAS) dose dependently influences renal ammoniagenesis by directly 
increasing MTAL absorption via effects on co-transporters. In health, 70% of renal ammonia is released into 
the circulation (renal vein) with only 30% excreted in urine. However, with liver failure despite an initial 
increase in renal excretion with mild hyperammonaemia (renal adaption), triggered by increased muscle 
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glutamine release and renal uptake (shifting GS and glutaminase activity), this is eventually overrun; as the 
kidney becomes a net ammonia producer given significant falls in glutamine uptake and ammonia excretion. 
Autoregulation maintains renal blood flow (RBF) and glomerular filtration over a wide range of blood 
pressures, but increased noradrenaline (NA) with renal syndromes of liver failure (e.g. HRS), reduces RBF 
and perfusion. Compromised renal function e.g. HRS) further reduces ammonia excretion. Metabolic acidosis 
also leads to net ammonia production (compensatory), by stimulating PCT GLN uptake and increased α-KG 
(and NH3) with net circulating bicarbonate (HCO3
-) synthesis. Therefore more NH3 is excreted as HCO3
- is 
conserved to compensate for the acidosis. 
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Figure 5: Skeletal muscle ammonia and amino acid metabolism 
 
      
The interaction between key enzymatic processes in both skeletal muscle and liver have a profound 
influence on whole body ammonia and amino acid metabolism. Energy utilisation and increasing production 
of waste nitrogenous compounds such as ammonia, drives increased muscle glutamine synthetase (GS) 
activity and conversion to non-toxic glutamine which can be released into the general circulation, taken up 
by the liver and converted to urea (for excretion). The effect of phosphate-activated glutaminase (PAG) 
which catalyses the reciprocal reaction is less significant as it is markedly less abundant than GS. 
Additionally muscle pyruvate is transaminated to alanine by ALT and then transported to the liver. Once in 
the liver, alanine (with α-ketoglutarate) is converted to pyruvate and glutamine (also by ALT). The 
generated liver pyruvate can be incorporated into the Kreb’s cycle by pyruvate dehydrogenase (PDH), 
oxidatively decarboxylated to acetyl coA and thus used as a substrate for gluconeogenesis which can be 
recycled back to muscle. - The ‘glucose-alanine cycle’. The glutamate produced by this reaction also allows 
for the formation of ammonia (and glutamine) by liver PAG and later urea; with α-ketoglutarate recycled 
from glutamine dehydrogenase (GDH). The ‘glucose-alanine cycle’ therefore allows skeletal muscle to 
eliminate nitrogen while replenishing its energy supply. Therefore with the significant catabolism of 
fulminant liver failure low circulating glucose and high alanine levels, increases the relative importance of 
this pathway. 
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Figure 6: Interorgan ammonia metabolism in health and cirrhosis 
 
 
 
 
 
 
 
 
 
 
 
 
In healthy individuals, the liver removes ammonia by detoxification into urea. In patients with cirrhosis, the 
metabolic capacity of liver is reduced, resulting in hyperammonaemia. The muscle then becomes an 
important organ for ammonia detoxification to glutamine. Glutamine acts as a temporary buffer that can 
both regenerate ammonia in the enterocyte and excrete ammonia via the kidneys. 
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Chapter 1.3 
 
Hepatic Encephalopathy: 
 
The Role of Inflammation 
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Introduction 
Inflammation is the generalised response to injury and has come under increasing 
scrutiny as a precipitating factor in hepatic encephalopathy (HE). The ‘systemic 
inflammatory response syndrome’ (SIRS) refers to the clinical manifestation of 
inflammation (Table 1),(167) describing the consequences of dysregulated host 
responses following activation of a normally quiescent system, involving leucocytes, 
endothelial cells and cytokine networks. The clinical signs observed include body 
temperature, heart, tachypnea or, white blood cell count. Fever and leukocytosis 
are features of the acute-phase reaction, while tachycardia is often the initial sign of 
haemodynamic compromise. Tachypnea may be related to the increased metabolic 
stress due to infection and inflammation, but may also be an ominous sign of 
inadequate perfusion resulting in the onset of anaerobic cellular metabolism. Two or 
more of these criteria are necessary to diagnose SIRS, with it principally arising 
from overt infective sources. Although SIRS criteria are generally non-specific, they 
allow for an objective classification of critically ill patients, at least in the research 
setting. In advanced liver disease there is an increased susceptibility to both 
bacterial and fungal infections,(28) with more than 80% of patients with acute liver 
failure (ALF) having coexistent infection(25) with increased mortality. In liver 
failure, significant SIRS is associated with elevated circulating proinflammatory 
cytokines(27) which are independently associated with progression of HE.(29, 168, 
169) SIRS is therefore closely linked to progression to advanced HE(26, 28, 169, 
170) and independently - intracranial pressure (ICP),(169) likely by inflammation 
modulating the susceptibility of the brain to the effects of hyperammonaemia. It is 
also worth highlighting that SIRS can also originate from non-infectious (aseptic) 
sources, like drug-induced ALF, or ischaemic insult. This chapter discusses the 
current evidence supporting a role for inflammation in the development of HE. 
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Evidence for a role of inflammation in liver dysfunction 
In the study by Rolando & colleagues,(28) from 887 ALF patients admitted over an 
11-year period, the presence of SIRS components (Table 1) were recorded on 
admission and during episodes of infection. Fifty-seven percent of patients 
manifested a SIRS during their illness. There was a maximum of 1, 2, and 3 
concurrent SIRS components in 19%, 27% and 11% of patients respectively. In the 
39.8% of patients who did not become infected, the presence of a SIRS on 
admission was associated with worsening severity of encephalopathy and death. 
Not unsurprisingly, those patients with proven infection more often developed a 
more significant SIRS. In the 31% of patients with bacterial infection, the extent of 
the SIRS correlated with mortality. In those with a SIRS of 0, 1, 2, or 3, the 
mortality was 16.7%, 28.4%, 41.2%, and 64.7% respectively. Similar correlations 
between SIRS and mortality were seen with fungal infection, bacteraemia, and 
bacterial chest infection. In patients with severe sepsis or septic shock, 59% and 
98% died respectively; demonstrating the close association between infection, SIRS 
and progressive HE. However, it was interesting to note that for patients with a 
SIRS manifesting worsening encephalopathy, the proportions of those who were 
infected compared to the non-infected patients were similar. These results tend to 
implicate proinflammatory mediators (e.g. cytokines and chemokines) as the key 
factors in the inflammatory response, rather than the microbial pathogen itself. So 
these findings suggest that in ALF, a SIRS independent of underlying infection is 
involved in the progression of encephalopathy and worsening prognosis.  
We have previously reported a patient listed for transplant following paracetamol-
induced ALF, who underwent a hepatectomy for critical hepatic necrosis after 
developing severe uncontrolled intracranial hypertension.(29) Hepatectomy resulted 
in stabilisation of both systemic and cerebral haemodynamics. The patient remained 
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anhepatic for 14 hours and was successfully bridged to orthotopic liver 
transplantation (OLT). Hepatectomy was associated with a sharp and sustained 
reduction in circulating proinflammatory cytokines, again suggesting that liver 
derived proinflammatory cytokines may be important in the pathogenesis of 
intracranial hypertension in patients with ALF. Elevated cerebral blood flow (CBF) 
fell from 73ml/100g/min pre-hepatectomy, to 43ml/100g/min 4 hours post-
hepatectomy (normal range: 40-55 ml/100g/min), and remained within normal 
limits post transplantation. In this patient the haemodynamic changes noted were 
independent of arterial ammonia, which remained essentially stable (189-
210µmol/l) pre- and post-hepatectomy, though fell post transplantation (89µmol/l). 
This observation pointed to a link between increasing CBF and ICP.  
Further to these observations, Vaquero and colleagues,(26) as part of the U.S. 
acute liver failure study, undertook a prospective study of 227 consecutive patients 
with stage I-II HE, with the aim of identifying the predictive factors of worsening HE 
and the relationship with a SIRS and/or infection. At admission variables were 
analysed in acetaminophen (paracetamol) (n=96) and non-acetaminophen (n=131) 
ALF. In the acetaminophen group (on multivariate analysis) predictive factors of 
worsening HE were acquisition of infection (p<0.01) and increased leukocyte levels 
at admission (p<0.01). By contrast in non-acetaminophen patients, only increased 
pulse rate (p<0.05) and AST levels (p<0.05) at admission were predictors. In 
patients who progressed to deep HE, the first confirmed infection preceded 
progression in 79% of acetaminophen patients compared with 52% of non-
acetaminophen patients. In patients with negative microbiologic cultures, a 
worsening SIRS (0, 1, and ≥2) at admission was associated with severity of HE, 
25%, 35% and 50% respectively (P<0.05). This again shows the importance of 
infection and/or the resulting systemic inflammatory response in the progression of 
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HE in ALF. It is worth noting that current laboratory techniques for confirming 
endotoxaemia/infection are imprecise, such that high SIRS could reflect underlying 
infection even if not detected. 
 
Nature of liver injury 
There is interest in what possible interplay exists between inflammation, chronicity 
of liver disease and presentation of HE. Research has often focused on ALF, due to 
the defining encephalopathy that ensues. Increased ICP and cerebral oedema, 
though typical of ALF, is rare in patients with cirrhosis.(2, 3) However, there are 
case reports of similar effects with acute liver injury superimposed on a background 
of cirrhosis, termed ‘acute-on-chronic liver disease’ (ACLF), defining a group of 
patients with a chronic ‘phenotype’ who appear clinically indistinct from those with 
ALF. In these patients the trigger for acute deterioration is often the presence of a 
precipitating event such as sepsis, or an increased ammonia load (secondary to 
gastrointestinal bleeding or the creation of a portosystemic shunt). One such 
precipitant in cirrhotic patients is ‘transjugular intrahepatic portosystemic shunts’ 
(TIPS), used to manage uncontrolled variceal haemorrhage, or diuretic resistant 
ascites. In study of 56 patients who underwent emergency TIPS for uncontrolled 
variceal haemorrhage, 4 developed features of ACLF, with marked deterioration in 
liver function tests (LFTs) and elevated ICP.(32) From subgroup analysis there were 
no clear causal factors making patients more susceptible to ACLF following insertion 
of a TIPS. Although there was a trend to lower plasma sodium in the patients who 
developed intracranial hypertension post-TIPS, this was not statistically significant. 
However, out of the 4 who developed ACLF, 1 had developed aspiration pneumonia 
prior to developing a raised ICP and cerebral oedema. Also, another 2 of the 4 
cases had evidence of cerebral ischaemia post-mortem.
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ischaemia are associated with a significant proinflammatory cytokine response, 
hinting at a role for inflammation in the progression of encephalopathy in ALF.  
 
The role of inflammation in acute liver failure 
As already discussed, studies in patients with ALF have shown the rapid progression 
to severe HE in those with evidence of a SIRS, suggesting a possible link between 
inflammation and HE(26, 28) especially in those with more advanced disease (rising 
ICP and cerebral oedema). Though hyperammonaemia has been widely implicated, 
the mechanism for these changes remains unknown.  
 
Inflammation - Effects on cerebral blood flow in ALF: There is growing 
evidence that disruption to CBF autoregulation may underlie the pathogenesis of 
increased ICP in patients with ALF.(171) This is potentially through alterations in 
the inflammatory milieu; addressed in a section of this chapter called – ‘Multicellular 
inflammatory interactions and cerebral haemodynamics’. A recent study was 
undertaken to determine the role of inflammation in the pathogenesis of ICP in 
patients with ALF and its interplay with CBF and ammonia.(169) Twenty-one 
patients with ALF were studied from the time they were ventilated for severe 
encephalopathy, until receiving specific treatment for increased ICP. Depending 
upon the ICP, the patients were divided into two groups - group 1 (n=8) requiring 
specific treatment for ICP>20 mmHg (mean ICP=32 mmHg (range 28-54) and 
group 2 (n=13) those with ICP≤20mmHg (mean ICP=15 (range 10-20) mmHg) not 
requiring treatment. In the group 1 patients, inflammatory markers, arterial 
ammonia and CBF were significantly higher. Significantly, both tumour necrosis 
factor-alpha (TNF-α) levels, and ICP directly correlated with CBF (r2 = 0.80 and r2 = 
0.74 respectively). Interestingly, in 4 patients from group 2 who developed isolated 
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surges of increased ICP, there were associated increases in markers of 
inflammation, TNF-α and CBF. These results support some of our earlier findings 
and support the hypothesis that inflammation plays an important synergistic role in 
the pathogenesis of increased ICP, possibly through its effects on CBF. However, 
one should understand that brain ammonia may remain stable with worsening 
disease as ammonia delivery reduces with falling CBF.  
 
Hypothermia - Modulation of inflammation and haemodynamics in ALF: 
20% of patients with ALF die from increased ICP while awaiting transplantation. 
However, there has been anecdotal evidence for the beneficial role of hypothermia 
treatment for intracranial hypertension in neuropathological disorders and also more 
recently ALF. Given the established role of cytokines in pyrexia (i.e. interleukin-1 
(IL-1)) and ALF, it has been hypothesised that the beneficial effects of hypothermia 
are enacted by cytokine responses. The clinical effects and pathophysiological basis 
of hypothermia was studied in 14 ALF patients awaiting OLT who had increased ICP 
unresponsive to standard medical therapy.(156) Core temperature was reduced to 
32-33°C using cooling blankets. Thirteen patients were successfully bridged to OLT 
with a median of 32 hours (range, 10-118 hours) of cooling. They underwent OLT 
with no significant complications related to cooling either before or after OLT and 
had complete neurological recovery. ICP was significantly reduced (p<0.0001) from 
36.5 ± 2.7mmHg before cooling to 16.3 ± 0.7mmHg at 4 hours, which was 
sustained at 24 hours (16.8 ± 1.5mmHg). Mean arterial pressure (MAP) and 
cerebral perfusion pressure (CPP) increased significantly, and the requirement for 
inotropes was reduced significantly. Hypothermia was seen to produce a sustained 
and significant reduction in CBF, brain cytokine production (p=0.01), markers of 
oxidative stress, arterial ammonia concentration and also ammonia brain 
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metabolism. This study shows that hypothermia reduces ICP by impacting on 
cytokine responses and other pathophysiological mechanisms and acts an effective 
and safe bridge to OLT. 
 
The role of inflammation in cirrhosis 
The pathophysiological basis of ACLF is just as unclear, but the systemic 
inflammation is equally thought to be important. On the background of a correlation 
between SIRS and progression of HE in ALF, the hypothesis that SIRS mediators 
such as nitric oxide (NO) and proinflammatory cytokines may exacerbate the 
neuropsychological effects of hyperammonaemia in well compensated cirrhosis was 
tested.(170) Hyperammonaemia was induced (with an oral amino acid solution to 
simulate an upper G.I bleed) in 10 patients with cirrhosis 24-36 hours after 
admission with clinical evidence of infection. They were followed during a period of 
treatment with conservative management (including antibiotics) and after resolution 
of the infection. The hyperammonaemia generated in response to the amino-acid 
solution was similar prior to, and after resolution of the inflammation/infection. With 
treatment of the infection there were significant reductions in the white cell count 
(WCC), C-reactive protein (CRP), nitrate/nitrite (p=0.002), and the 
proinflammatory cytokines - IL-6, IL-1β and TNF-α (0.002, 0.03 and 0.03 
respectively). An earlier study demonstrated that the hyperammonaemia induced 
by a simulated bleed alone has no significant neuropsychological deterioration in 
stable cirrhotics.(172) In this study, in those patients with a SIRS, the induced 
hyperammonaemia resulted in a significant worsening of neuropsychological scores 
that was not seen in patients without a SIRS. Significantly, the neuropsychological 
effect resolved following resolution of the infection and SIRS. On the background of 
hyperammonaemia, such inflammatory related neurological changes with the 
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associated reduction in cytokines and nitric oxide, suggest that inflammation and its 
mediators may be important in modulating the cerebral effect of ammonia in 
cirrhosis and ACLF.   
 
Inflammation - Role in minimal hepatic encephalopathy: It is now recognised 
that minimal hepatic encephalopathy (MHE) is common in patients with cirrhosis. In 
cirrhotic patients who are well post transplantation, reversal of abnormalities in 
neuropsychological function may not always be complete(173) as is often believed. 
This observation, points to factors other than ammonia in the pathogenesis of less 
severe encephalopathy. The extent to which precipitants of HE such as infection and 
ammonia interact with each other to cause different grades of encephalopathy is 
still little understood. A further study was set up to determine whether the presence 
of MHE was associated with ammonia levels, inflammation and severity of liver 
disease.(174) Eightyfour patients with cirrhosis were put through a 
neuropsychological test battery and had serum samples taken. These parameters 
were tested prior to, and 4 hours after induction of hyperammonaemia by oral 
administration of an amino acid (n=60) or a placebo solution (n=24). 
Administration of the amino acid solution did induce deterioration of some 
neuropsychological function tests, but none developed overt HE. In those who 
received placebo there was no deterioration in neuropsychological function. The 
immediate recall was the most affected test, with 55% (33/60) deteriorating from 
baseline, 43% (26/60) deteriorated from baseline with ‘trails B test’ (although 16 
had abnormal baselines), 18.3% (11/60) with ‘digit symbol substitution test’ and 
15% (9/60) with ‘choice reaction time’. However, this neuropsychological 
deterioration following induced hyperammonaemia was independent of the 
magnitude of change in plasma ammonia and severity of liver disease, yet 
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significantly greater in those with evidence of inflammation. These data indicate a 
role for ammonia in HE, but suggest that the presence and severity of MHE is 
independent of the actual plasma ammonia concentration and stage of liver disease. 
Significantly, inflammation again would appear to play an important role in 
determining the baseline neuropsychological state and also in modulating the 
neuropsychological effects of ammonia.  
 
Inflammation: role of the molecular adsorbents recirculating system: 
Recently, there has been a lot of interest in liver support systems as a therapy for 
liver failure. In patients with ACLF, ‘the molecular adsorbents recirculating system’ 
(MARS) improves individual organ function.  But the mechanism by which it exerts 
an effect in the treatment of HE is still unclear. Given data showing the likely 
importance of mediators of inflammation in HE, a study was performed to 
determine if the therapeutic effect of MARS similarly involved inflammatory 
mediators and/or ammonia.(175) Eighteen patients with acutely decompensated 
alcohol-related cirrhosis precipitated by inflammation were randomised to receive 
either standard medical therapy (SMT) alone, or SMT with MARS therapy over 7 
days and inflammatory mediators and ammonia measured. Compared to SMT, 
encephalopathy improved significantly with MARS (p<0.01). However, we did not 
observe any significant change in plasma cytokines and ammonia levels in either 
group, nor did malondialdehyde (MDA), an indicator of oxidative stress. In fact the 
only indicator of inflammation that correlated with the observed clinical 
improvement with MARS therapy was the nitrate/nitrite ratio (NOx), p<0.05. The 
improvement seen with MARS could not be explained by haemodynamic changes 
either, as both MAP and renal function remained unchanged. It therefore appears 
that in inflammation-related ACLF, albumin dialysis using MARS results in 
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improvement of encephalopathy, independent of changes of ammonia, cytokines, or 
improved haemodynamics; possibly via a NO-dependent pathway.  
 
The role of the blood brain barrier 
Ordinarily the blood brain barrier remains intact during liver disease(176, 177) and 
should theoretically prevent the entry of cytokines from the systemic circulation into 
the brain. However, data from other neuropathological inflammatory states show 
that proinflammatory cytokines (e.g. TNF-α and IL-1) may produce brain swelling 
by inducing an increase in the permeability of the blood brain barrier (e.g. bacterial 
meningitis(178, 179)). Evidence from cell-culture studies supports TNF-α 
modulation of barrier permeability.(180) In one such study intracisternal 
administration of TNF-α caused a dose-dependent increase in barrier 
permeability,(179) while systemic administration of TNF-α appears less effective in 
disrupting the barrier.(181, 182) Despite an earlier animal study of liver failure 
describing some degree of barrier disruption,(183) this has not been a consistent 
finding. Such inconsistencies in the barrier integrity of animal models of liver failure 
may be due to differences in HE severity, with the more advanced brain sequelae 
associated with a loss of barrier integrity. Support for barrier breakdown during the 
late stages of disease has recently been provided in a recent communication 
demonstrating a loss of blood brain barrier integrity with severe sepsis.(184) In rats 
that were made septic using caecal ligation and puncture, brain electron-microscopy 
showed severely swollen astrocytes with evidence of breakdown of the tight-
junctions with entry of lanthanum into the brain.(184)  
There is a direct correlation between HE grade and the presence of a systemic 
inflammatory response. However, given that cytokines are 15–20 kD in size and 
cannot directly cross an intact blood–brain barrier, it was thought that they may not 
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have a direct effect on brain microvessel endothelial cells.(185) However other 
studies suggest alternative routes of activation of the brain by peripheral 
cytokines.(186) Researchers have shown direct brain signalling to the brain via the 
vagus nerve by the peripheral and autonomic nervous systems.(187) In the 
periphery, inflammatory mediators acting on vagal afferents will activate the 
nucleus tractus solitarius, the primary projection of the vagus nerve(188) and 
subdiaphragmatic vagotomy will abrogate the induction of IL-1β messenger RNA in 
rat brain by peripheral IL-1β.(189) It is possible that cytokines cross the blood brain 
barrier by active transport or enter the brain at areas that lack a barrier. However, 
evidence supports a role for secondary messengers in response to cytokines binding 
to their receptors expressed on brain microvessel endothelial cells,(190) e.g. TNF-α, 
IL-1β and bacterial lipopolysaccharide (LPS) activation of cGMP-dependent protein 
kinases leading to inducible NO synthase (iNOS) production.(191, 192) Without 
activation by microbial pathogens or proinflammatory cytokines, free-radicals and 
oxidative stress are likely to be just as crucial in the pathogenesis of ammonia-
induced neurotoxicity. In hyperammonaemia, free-radical production may be 
mediated by NMDA-receptor activation and ammonia-induced mitochondrial 
dysfunction.(193) This could also be a source of reactive oxygen species such as 
peroxynitrite (OONO•), which mediates NO-induced blood brain barrier damage. 
Furthermore, antioxidants have beneficial effects in experimental animal models of 
HE,(155) and hyperammonaemia.(194)  
 
Local cerebral inflammatory response in progression of encephalopathy 
 
Given all the presented data on the systemic inflammatory response, it is important 
to discuss what local triggers may enact this circulatory response. The most obvious 
organ-specific inflammatory insult involved in HE would clearly be the hepato-
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cerebral axis. However, the extent of liver inflammation does not directly correlate 
with HE grade. With an intact barrier during progressive HE, theoretically the brain 
should not mount a direct response to systemic derived cytokines as part of SIRS. 
However, certain cell types within the brain may self-propagate a cytokine response 
(discussed later). A study was therefore undertaken to assess if an exaggerated 
brain net production (flux) of brain cytokines in response to acute liver injury exists 
as a possible trigger for HE.(195) The ‘flux’ of an organ (e.g. jugulovenous–arterial 
x CBF) is a better determinant of organ metabolism than the arterial-venous 
concentration gradient, as it eliminates blood flow across the organ as a 
confounding variable. Sixteen mechanically ventilated ALF patients were studied 
with the measurement of CBF (Kety-Schmidt technique) and ICP (Camino subdural 
catheter).(195) Study groups were divided by differing ICP into 1) normal, 2) 
controlled (>20mmhg), or 3) uncontrolled ICP (>25 mmHg) despite treatment 
(mannitol and/or haemofiltration). Blood was sampled from an artery and the 
reverse jugular catheter to measure proinflammatory cytokines and ammonia. 
Plasma ammonia between groups was not statistically significant. However, there 
was a good correlation between arterial proinflammatory cytokines and ICP (r2 = 
0.34, 0.50 and 0.52; for IL-6, IL-1β and TNF-α respectively).(195) There was also a 
positive cerebral cytokine flux in ALF patients with uncontrolled ICP.(195) 
Additionally, in 3 patients studied longitudinally (serial sampling) over 72 hours, 
brain proinflammatory cytokine production was only seen with uncontrolled ICP 
(Figure 1).(195) These results indicate significant activation of brain 
proinflammatory cytokines in patients with advanced HE and a possible 
compromised blood brain barrier at this late stage (given the appearance of these 
cytokines in the jugular bulb catheter). Such results allude to a critical role of brain-
derived proinflammatory cytokines in the transition of a patient to the advanced 
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stage of intracranial hypertension where they may become refractory to standard 
medical intervention. This cerebral cytokine flux may be the critical trigger for CBF 
modulation, increased blood brain barrier permeability and intracranial 
hypertension. However, it is equally probable this cerebral cytokine flux is the 
response to an already activated systemic trigger such as cytokines, which then 
critically modulate cerebral inflammatory response. Earlier studies suggest the 
systemic inflammatory state of ALF patients may represent an effect of progressive 
liver necrosis and/or associated infection. Modulation of hepatic cytokine release 
may be the pathophysiological basis for the benefit of hepatectomy in ALF shown in 
previous studies.(29, 196, 197) All these studies support the paradigm of a likely 
systemic cytokine driven inflammatory cascade as the important determinant of 
cerebral effects in acute liver injury, modulating or modified by any local brain 
inflammatory response). 
 
Multicellular inflammatory interactions and cerebral haemodynamics 
The presented studies do not allow one to draw any conclusions as to which cell 
types in the brain are involved in inflammatory responses (as demonstrated by 
proinflammatory cytokine production), but a number of cell lines in the 
neurovascular unit are capable of cytokine responses such as glial cells (astrocytes 
and microglia), pericytes, brain microvascular endothelial cells as well as migrating 
cells from the circulation. Astrocytes are thought to be the cells most likely to be 
involved because they are known to be central to blood brain barrier integrity, have 
an extensive cytokine repertoire(198) and swell in ALF. As cytokines are able to 
modulate glial cell activation this finding could explain the effects of cytokines at the 
barrier and resultant effect on cerebral haemodynamics seen in ALF. This would 
suggest that the transition of patients with ALF to uncontrolled ICP may indicate a 
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critical neuropathological change involving modulation of cerebral haemodynamics 
triggered by proinflammatory cytokine responses.(169) This hypothesis will have to 
be tested in appropriate studies.  
Cerebral autoregulation is an important concept,(199) which describes the 
maintenance of a constant CBF over wide MAP, with buffering of CPP ([CPP = MAP – 
ICP] with a normal range of 60-160mmHg) by dilatation or constriction of cerebral 
resistance vessels. In ALF, there is dysregulated cerebral autoregulation, with rising 
ICP directly correlated with ICP.(169) In contrast with the hyperaemia seen in ALF, 
cirrhosis is associated with cerebral oligaemia, except in a few cases where a 
second hit leads to ACLF, which has a phenotype similar to ALF. It remains unclear 
how much myogenic (smooth muscle), neurogenic, metabolic (energy demands) or 
multiple brain cell types (e.g. smooth muscle cells, neuronal inputs, astrocytes, 
pericytes and endothelial cells) interact to trigger changes in cerebral 
haemodynamics. The smooth muscle of arterioles contracts more as stretching 
increases, activating phospholipase C and arachidonic acid (AA) pathways (and 
derivatives) to orchestrate changes in potassium-dependent calcium channels and 
thus action potentials along the muscle. In regards to neuronal innervation, 
noradrenaline (NA) (locus coeruleus), serotonin (raphe nucleus) and dopamine 
(mesencephalic ventral tegmental area) nerve endings trigger constriction, while 
acetylcholine (Ach) (basal forebrain) and glutamatergic nerve endings cause dilation 
(along with elevation of intracellular calcium). Current reports highlight the effects 
of both neuronal activation and cyclooxygenase (COX)/AA and NO inflammatory 
pathways on astrocytes.(165, 200, 201) However, their findings (especially 
between Zonta et.al. and Mulligan et.al.) draw differing conclusions on the relative 
downstream effect on activation of this differing pathways on vascular tone; 
Mulligan et.al., demonstrating NA induced astrocyte AA production leading to 
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arteriolar constriction via 20 HETE, and Zonta et.al., pointing to NA induced 
astrocyte AA activation and COX-dependent PGE2 induced vasoconstriction. In 
regards to energy demands, metabolically active neurons may lead to glutamate 
overspill, causing downstream activation of astrocytes with production of AA 
derivates such as epoxyeicosatrienoic acid (EET) a vasodilator, formed by 
cytochrome (CYP) P450. EET diffuses to nearby arteriolar smooth muscle to 
antagonise HETE (a vasoconstrictive AA derivative(201)) by activation of 
potassium-dependent calcium channels. But control of cerebral vascular tone is not 
as simple as the dynamic balance between AA products such as HETE (constrictor) 
and EET (dilator), as there are many other vasoactive metabolites. Astrocytes may 
release other vasoactive signals (e.g. thromboxane A2, prostaglandins (PgE and 
PgF) and prostacyclin). The potassium-dependent calcium channels, may also be 
affected by other mediators (e.g. NO, extracellular potassium, adenosine and 
prostacyclin). Neither should it be forgotten that glutaminergic neurons produce the 
powerful vasodilator NO, or the involvement of other brain cell types like microglia 
and endothelial cells (especially with their significant NO secondary messenger role 
linking systemic to brain inflammatory effects). 
A recent study has shown a 2-3-fold increase in brain (as well as plasma and 
cerebrospinal fluid) mRNA expression of the proinflammatory cytokines (TNF-α, IL-
1β and IL-6) at coma stages of encephalopathy with induction of ALF (hepatic 
devascularised rats) which correlated to HE severity and progression of brain 
oedema.(202) Microglial activation (indicated by upregulation of CD11b/c 
immunoreactivity) was also noted along with mild hypothermia delaying the onset 
of encephalopathy, prevented brain oedema and concomitantly attenuating brain 
(p<0.001), plasma and CSF proinflammatory cytokines.(202) This beneficial anti-
inflammatory effect on microglia has also been recently demonstrated in a further 
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study utilising the anti-inflammatory agent, Minocycline.(203) These findings 
support much of the data presented above, and indicates that in ALF the brain can 
produce cytokines with evidence of actual production in those with uncontrolled 
increases in ICP. This study and other more recent work by the same group(203) 
begin to implicate microglia in the progression to HE on the background of evidence 
linking microglia in neuroinflammation (evident on positron emission tomography 
studies(204, 205)) influenced by systemic inflammatory responses.(206) 
Furthermore, recent studies suggest a critical bidirectional role for pericytes in 
cerebral haemodynamics.(207) Pericytes are mesenchymal-like, multipotent 
(relatively undifferentiated cells) with immune ‘macrophage-like’ antigen presenting 
properties. They also contractile and wrap around cerebral capillaries often enclosed 
within the basal lamina, especially at junctions, though less abundant in arterioles & 
venuoles. Interestingly, though capillaries lack smooth muscle, 65% of NA 
(purinergic) nerve terminals end here. These properties allow for pericytes to 
regulate cerebral blood flow downstream from arterioles in response to sympathetic 
neuronal signalling, with NA and ischaemia directly causing constriction, reversed 
by glutamate.(207) This suggests a possible hierarchy for cellular interactions 
regulating cerebral haemodynamics (e.g. smooth muscle cells, neuronal inputs, 
astrocytes, pericytes and endothelial cells). If one was to extrapolate these findings 
to the pathophysiology of HE, one could hypothesise that in conjunction with the 
role of astrocytes on cerebral haemodynamics,(165) pericytes may be the 
gatekeepers of microvessel tone (resistance vessels), accounting for both the 
oligaemia of cirrhosis (with possible chronic pericyte over-activation) and 
hyperaemia of ACLF and ALF (with pericyte inhibition). Given the reported effects of 
both neuronal activation and COX/AA and inflammatory pathways on both these cell 
types,(165, 200, 201, 207) one can begin to better understand the paradigm for HE 
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pathogenesis, with the fundamental roles of ammonia (via effects on astrocytes), 
inflammation and cerebral haemodynamics. However, whether it is the systemic 
inflammatory response that triggers brain inflammatory responses remains unclear.  
 
In conclusion, this chapter outlines the existing data on the potential role of 
inflammation in progression of HE. The evidence presented supports the hypothesis 
that inflammatory responses are integral to the progression of hepatic 
encephalopathy via modulation of the cerebral affect of ammonia which impact on 
CBF autoregulation, ICP, barrier integrity and likely neuronal function. Further work 
will be necessary to elucidate the mechanisms of such inflammatory mediators at 
the neurovascular interface and cellular levels, but should lead to a better 
understanding of the role of inflammation in HE which may allow for the 
development of novel interventions targeting inflammatory pathways to treat HE.  
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Figure 1: Longitudinal cytokine fluxes following intervention for ALF 
 
 
 
Represents the change over time of ICP and cerebral cytokine fluxes (TNF-α, IL-1β and IL-6) in a patient 
with ALF and raised ICP that is uncontrolled with standard medical therapy, patient 1. However, the 
application of hypothermia resulted in a rapid reduction in the production of cytokines from the brain to 
values not significantly different to zero [Adapted from a figure published by Wright G, Shawcross D, 
Olde Damink SW, Jalan R. Brain cytokine flux in acute liver failure and its relationship with intracranial 
hypertension. Metab Brain Dis 2007;22:375-388]. 
 
 
 
10 20 30 40 50 60
-1000
0
1000
2000
3000
4000
5000
6000
TNF-a IL-6 IL-1bICP
0
10
20
30
40
50
Mannitol Mannitol OLTMannitolMannitol CVVH Cool
Time (Hours)
C
er
eb
ra
l 
cy
to
k
in
e 
fl
u
x
 (
p
g
/1
0
0
g
 t
is
su
e/
m
in
)
IC
P
 (m
m
H
g
)
  
 
 
91
Table 1: SIRS components  
 
SIRS components
Respiratory Rate ≥ 20 breaths/min, or PaCO2 ≤4.3 kPa
Cardiovascular Heart rate ≥90 beats/min
Metabolic Temperature ≥38°C (or ≤36°C)
Biochemical White cell count ≥12 (or ≤4  x109/L), or ≥10% immature neutrophils
 
 
Each SIRS component scores 1; in presence of infection a score of ≥2 indicates sepsis [Adapted from the 
following publication - American College of Chest Physicians/Society of Critical Care Medicine Consensus 
Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in 
sepsis". Crit. Care Med. 20 (6): 864–74. 1992]. 
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Chapter 1.4 
 
Hepatic Encephalopathy: 
 
Management of HE 
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Introduction 
The wide spectrum of neuropsychiatric presentations of HE has lead to a plethora of 
therapeutic approaches. The type of treatment used is predominately dictated by 
the chronicity and severity of encephalopathy, with a need for more interventional 
therapies for those patients with acute liver injury advanced HE compared to those 
with MHE. Irrespective, reduction of plasma ammonia remains the central strategy, 
although randomised controlled trials point to the potential usefulness in particular 
circumstances of novel strategies like Flumazenil and Bromocriptine (see later). This 
chapter discusses the current evidence supporting the use of these principle 
therapeutic interventions for both the general management of chronic HE and that 
necessary for more acute and advanced disease. 
 
GENERAL MANAGEMENT OF CHRONIC ENCEPHALOPATHY (Table 1) 
 
Ammonia lowering strategies 
 
Gastric lavage 
Gastric lavage is only indicated where HE is precipitated in patients with cirrhosis by 
an acute upper gastrointestinal bleeding. 
 
Dietary protein supplementation  
Patients with cirrhosis (especially if alcohol-induced), usually have a poor nutritional 
reserve due to anorexia, poor diet, malabsorption, and altered metabolic state. 
Hospitalized patients are often hypermetabolic and hypercatabolic, worsened by 
complications such as gastrointestinal bleeding, continued anorexia and fasting for 
tests. The vogue for dietary protein restriction for patients with cirrhosis as a 
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plausible intervention for HE has recently been dispelled following a clinical trial 
showing that protein restriction does not improve HE, but may instead be 
potentially harmful.(208) In this study, the group treated with low-protein diet were 
shown to have increased protein catabolism. Current evidence suggests that protein 
requirements are increased in patients with cirrhosis. High protein diets are 
therefore well-tolerated in patients with cirrhosis,(41) with protein restriction but 
high calorie intake with inborn errors of metabolism the only exception. As such the 
consensus review by the ‘European Society for Parenteral and Enteral Nutrition’ 
(ESPEN) recommends a normal, or higher supply of dietary proteins (1-1.5 g/kg 
protein and 25-40 kcal/kg per day).(41, 42)    
 
Branched-chain amino acids (BCAAs) 
BCAAs are chiefly derived from dairy products and vegetables, make up 25% of 
total dietary protein content. They are a good substrate for protein synthesis, both 
conserving and restoring muscle mass in advanced liver disease. In cirrhosis, poor 
dietary intake leads to a deficiency of BCAA and resultant accumulation of aromatic 
amino acids. This creates a marked protein-energy deficit and increases false 
neurotransmitter precursors, altering glutaminergic neurotransmission. In the few 
‘high protein diet’ intolerant and severely malnourished patients, BCAA supplements 
may be useful to provide the necessary nitrogen intake without a decline in mental 
state. As BCAA are under the influence of circulating insulin, the insulin resistance 
state of cirrhosis, limits their nutritional benefit unless systemic insulin replacement 
is implemented. Also, enteral nutrition (whether oral or nasogastric) is preferential 
to parenteral nutrition as prolonged TPN may induce fatty liver and inflammation 
especially in patients with short-bowel syndrome and also increases the risk of 
infection. However, a number of meta-analyses have failed to find consensus on the 
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use of BCAA in cirrhosis from a wealth of conflicting data.(209, 210) In most 
cirrhotic patients a modified eating pattern, based on several meals and a late 
evening snack, usually provides an adequate nutritional intake.(209, 211) 
 
Glycaemic control 
Disturbed glycaemic and lipid control is common in progressive liver disease and 
worsened by the stress response in critically unwell patients. Therefore in the 
hospitalized patient, once feeding has commenced, tight glycaemic control using 
insulin may be necessary to 1) reduce oxidative stress (which triggers insulin 
resistance), limit mitochondrial liver damage, and improve endothelial activation 
(e.g. NO production), which will improve blood flow, limiting tissue injury, and 
improve outcome.(212, 213) 
 
Vitamins and nutrients 
Cirrhosis also leads to deficiencies of lipid-soluble vitamins, minerals and 
micronutrients. For example, Zinc is a cofactor in the urea cycle(214) and also 
found in vesicles of predominately glutamatergic presynaptic terminals thereby 
having a role in neurotransmission.(215) Zinc supplementation (600mg/day) has 
been studied without obvious benefit, though replacement should be considered if 
the patient is deficient.(216) Manganese has also been implicated, as autopsy 
specimens from patients with hepatic coma and pallidal MR images of patients with 
HE suggest manganese deposition in the basal ganglia is involved.(11, 217) 
However, as with earlier studies evaluating the role of gut bacterial products like 
Mercaptans, Phenols and medium- and short-chain fatty acids,(218) there has been 
little cumulative evidence to support targeted treatment strategies to influence the 
management of HE.  
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Prebiotics, Probiotics and Synbiotics 
Ammonia produced by the gut is derived impart from the deamination of dietary 
amino acids by bacteria, with a small contribution from the urea produced by 
urease-positive bacteria. In the critically ill and malnourished patient, levels of the 
predominant defensive bacteria strains (Bifidobacterium spp. and Lactobacillus 
spp.) decline. Antibiotics may further lead to ammonia-producing bacteria 
ameliorating hyperammonaemia. Biotics refer to "of, relating to, or caused by living 
organisms." In the digestive system, Prebiotics (non-digestible food compounds 
that stimulate the growth and/or activity of other beneficial bacteria (Probiotics)), 
and synbiotics (symbiosis of pro- and prebiotics), contain living/non-living non-
pathogenic micro-organisms utilized as food ingredients, may have a role in the 
treatment of HE. They are thought to exert an effect in HE by 1) reducing intestinal 
ammonia production by enterocyte glutaminase, 2) reduce bacterial translocation, 
3) modulate proinflammatory responses, and 4) modulate gut permeability.(219) 
Furthermore, probiotics bypass the small bowel and get fermented by colonic 
bacteria to form lactic, acetic and butyric acids, and gas (mainly hydrogen); any 
resultant intestinal hurry may increase the expulsion of ammoniagenic bacteria. In 
randomised placebo controlled trials,(220) probiotics have been shown to reduce 
gut ammonia production and inflammation(220, 221) with synbiotics leading to an 
improvement in MHE (associated with an increase in faecal pH, reduced plasma 
endotoxin and ammonia levels).(220, 221) It is worth noting that fermentable fibres 
alone were also beneficial in that study. This is not unexpected as the common 
effect of probiotics, as with prebiotics, aside from a decline of substrate for other 
bacteria(222) and reduction on bacterial translocation, is the fermentation of non-
absorbed sugars (e.g. mono-, di- & oligosaccharides). This fermentation of sugars 
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leads to the production of differential amounts of lactic acid, ethanol and CO2 to 
modulate intestinal acidity and gas production. 
 
Purgatives 
A purgative is an agent, which cleanses the bowel by increasing the evacuation of 
luminal contents. This is beneficial in HE as it allows for reduced intestinal ammonia 
production and despite limited evidence from randomised controlled trials remain 
the most widely used therapy for HE. 
 
Non-absorbable disaccharides: It remains unclear how non-absorbable 
disaccharides exert a beneficial effect. There has been many proposed mechanisms 
1) enhanced growth of non-urease producing bacteria,(223) 2) catharsis secondary 
to bowel acidification reducing ammonia absorption,(224, 225) 3) proliferation of 
healthy bacteria by providing additional carbohydrate and thus nitrogen (even as 
ammonia) into protein and/or 4) providing carbon and energy and so spare 
bacterial ammonia metabolism.(226) More specifically, after consumption lactulose 
(a sugar) passes through the small bowel completely undigested (unlike glucose, 
sucrose and lactose, which are easily fermented in the small bowel). Once in the 
colon, lactulose is fermented by anaerobic bacteria (especially Bacteroides spp. 
(species)) Fermentation of lactulose by colonic bacteria yields important products 
like the weak acids - Lactic, Acetic & Butyric acid; along with gases like hydrogen 
(H2) which modulate intestinal acidity and gas production. This leads to acidification 
of ammonia into ammonium, which is poorly absorbed. However, physiologically a 
total daily dose of 10–20g is small compared to 500–1000g faeces/day, such that 
the impact on acidity/reduced faecal pH on the faecal flora are likely to be limited. 
This is further suggested by the understanding that Mannitol and Sorbitol both 
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cause low Ph but neither improve HE.(227) The production of H2 in the colon may 
be more important as 1 Litre of H2 gas is produced from just 7g of lactulose causing 
flatulence and intestinal hurry, shifting massive amounts of colonic bacteria.(228) 
However, it may be the provision of energy in preference to ammonia that accounts 
for the benefit of non-absorbable disaccharides. Furthermore, as lactulose is non-
absorbed, it should not have any significant impact on glycaemic control and can be 
used in diabetic patients. 
However, a comprehensive meta-analysis of non-absorbable disaccharides has 
suggested that previous data from randomised and controlled clinical trials do not 
support its routine use in clinical practice.(47) There is limited but better evidence 
from randomised control trials for the treatment of MHE, with lactulose reportedly 
conferring improved neuropsychometric and quality of life scores,(229) while also 
preventing recurrence of HE in patients with cirrhosis.(230)The impact of other 
therapies initiated at the same time often confounds any benefit on HE severity by 
the established ammonia-lowering effect of non-absorbable disaccharides. 
Compliance, adverse effects, clinical safely and cost effectiveness are necessary 
concerns. The limited side effect profile of non-absorbable disaccharides has been at 
the crux of liberal lactulose prescribing practices. However, it is often overlooked 
that aggressive use of lactulose causes significant gaseous distension, discomfort 
and diarrhoea, which may lead to poor compliance. More alarmingly frank 
dehydration, pre-renal uraemia, hyponatraemia, marked intestinal distension or 
aspiration of lactulose does occur. Therefore, although non-absorbable 
disaccharides are relatively cheap, their cost-effectiveness should not be assumed 
and should be balanced against clinical outcomes that are difficult considering the 
multi-factorial causes and the differing therapies employed in HE. Therefore we 
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should be more reserved in our judgment when considering Lactulose as the ‘gold 
standard’ for the treatment of HE, justifying placebo-controlled trials of new agents. 
 
Other purgatives: Enemas are beneficial as a means of expelling ammonia 
producing gut flora by both cleansing and colonic acidification,(231) but are no 
better than oral purgatives like lactulose. Therefore if bowel motions can be 
maintained at ≥ 2/day, then enemas may not offer any additional benefit.  
 
Non-absorbable antibiotics  
The contribution of intestinal urease-positive bacteria to gut ammonia production is 
mainly in the colon rather than gastric mucosa (e.g. Helicobacter pylori), due to 
their number and more alkaline colonic pH which favours enhanced ammonia 
diffusion, such that Helicobacter pylori eradication has no therapeutic benefit.(232) 
Oral, non-absorbable, synthetic anti-bacterial agents such as Neomycin and 
Rifaximin have been used to inhibit the growth or kill susceptible ammoniagenic 
bacterial species; showing comparable efficacy to lactulose.(233) Rifaximin is a 
synthetic antibiotic related to Rifamycin, with wide antibacterial activity against both 
aerobic and anaerobic gram-negative and gram-positive bacteria. Rifaximin is 
efficacious, with a superior safety profile and thus preferred to neomycin.(234, 235) 
However, though used extensively in North America and Europe, rifaximin can only 
be prescribed on a named patient bases in the UK. Therefore, although not evidence 
based, non-absorbable antibiotics are reserved for patients who fail to respond to 
non-absorbable disaccharides.  
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Modulators of interorgan ammonia metabolism (Figure 1) 
 
The concept of manipulating endogenous biosynthetic pathways to eliminate non–
urea waste nitrogen as a substitute for defective urea synthesis is not new.(236) 
Despite abnormal urea-cycle functioning, decreasing total body nitrogen by 
promoting the synthesis of non-urea nitrogen-containing metabolites that have high 
excretion rates appears to be of benefit. 
 
Arginine supplementation: L-arginine is an important dietary substrate for the 
urea cycle, which allows for ammonia detoxification to urea (via arginase). Unlike 
the essential BCAA, which can only be derived from ones diet, L-arginine is a semi-
essential amino acid, as although metabolically produced, in some disease states 
may require dietary supplementation. In cases of the childhood urea cycle disorders 
(e.g. deficiency of carbamyl phosphate synthetase (CPT), ornithine 
transcarbamylase (OTC), argininosuccinate synthetase (AS) and argininosuccinase 
(AL)), dietary restriction of L-arginine triggers the rapid development (15-68 hours) 
of symptomatic hyperammonaemia (e.g. vomiting, lethargy, or irritability).(237) In 
these disorders there is a significant reduction in urea production, with nitrogen 
instead accumulating as glutamine (predominately), ammonia and to a limited 
extent alanine and glutamate. In AS and AL deficiency, provision of additional 
dietary L-arginine promotes the synthesis of citrulline (1 waste nitrogen atom per 
molecule) and argininosuccinate (2 waste nitrogen atoms per molecule), allowing 
for the urinary excretion of nitrogen as urinary waste products; with OTC deficiency, 
citrulline is preferentially supplemented. The underlying mechanism for this is 
independent of CPT synthesis, as suggested by orotic aciduria (the direct product of 
CPT) with arginine deficiency; accumulating substrates driven down alternative 
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pathways. In acute liver failure (ALF), systemic hypotension and cerebral edema 
may be associated with increased plasma nitric oxide (NO) levels. L-arginine is the 
rate-limiting substrate for NO production via nitric oxide synthetase (NOS) but is 
deficient in ALF due possibly to increased arginase activity in the liver that converts 
it to urea and ornithine. This may point to a potential benefit for L-arginine 
supplementation. Yet there have been no good studies evaluating a role for L-
arginine supplementation in hepatic encephalopathy, though studies exploring 
whether correcting L-arginine deficiency alters either portal hypertension or cerebral 
oedema via either arginase dependent reduction in hyperammonaemia and/or 
NO/ADMA dependent mechanism(s). 
 
Phenylbutyrate: Phenylbutyrate, which is converted to phenylacetate in vivo, is 
used for the hyperammonaemia associated with urea cycle enzyme 
deficiencies.(238) Phenylacetate covalently combines with circulating glutamine to 
form phenylacetylglutamine, which is excreted by the kidneys. In such metabolic 
disorders characterized by elevated glutamine levels, this excess can be mopped up 
by phenylacetate, thereby removing glutamine as a substrate for ammoniagenesis. 
Phenylbutyrate has been trialed in HE associated with liver failure, but with little 
effect. This probably relates to the need for a high glutamate state, which is absent 
in liver failure.  
 
Sodium Benzoate: This drug similarly increases the renal excretion of ammonia, 
but instead excretes it as hippuric acid (hippurate), which contains one waste 
nitrogen atom per molecule; hippurate being the glycine conjugate of benzoic acid 
via an amino acid acylation step.(236) Benzoate has been shown to improve the HE 
that occurs with inborn errors of metabolism.(239) For patients deficient in CPS or 
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OTC, administration of sodium benzoate stimulates hippurate synthesis and 
excretion as urinary waste nitrogen. Also, in at least one double-blind randomised 
control trial was found to be as effective as lactulose in the treatment of acute 
portosystemic HE.(240)  
 
Combined intravenous sodium phenylbutyrate and benzoate (Ammonul, 
Ucyclyd Pharma): Combined therapy has proved very beneficial for the treatment of 
urea-cycle disorders. In a recent 25 year open-labeled study, combination therapy 
lead to a 79% reduction in plasma ammonia and 84% improved survival 
(dependent on peak ammonia level and age – poor in neonates and 98% in late 
onset disease).(241) This compares favorably with 16% survival in neonates and 
72% with late onset disease in patients without therapy.(242) However, as the N-
acyltransferases that conjugate glutamine to phenylacetate and glycine to benzoate 
are located in the liver and kidney, the severe hapatotoxicity of ALF may eventually 
lead to response failure, especially with saturation of enzyme capacity (e.g. 
phenylacetate to PAG).(243, 244) 
 
L-ornithine L-aspartate (LOLA): The concept of delivery of L-ornithine to the 
muscle is the basis of the agent L-ornithine L-aspartate (LOLA) for ammonia 
lowering in cirrhosis. LOLA provides L-ornithine and L-aspartate as substrates for 
glutamate production. There have been a number of clinical studies using of 
LOLA.(245-247) In a double-blind randomized control study of cirrhotics with mild 
HE, one week of LOLA reduced ammonia and improved mental function.(245) A 
cross-over study showed that 20-40g/day of LOLA infusions ameliorated post-
prandial increases in ammonia following oral protein loading.(248) However, 
increased plasma glutamate, unchanged glutamine and increased urea production 
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with the higher doses(248) conflicts with the muscle ammonia detoxification 
hypothesis. Notably the 40g dose also induced hyperglycaemia and 
hyperinsulinaemia.(248) Liver failure models further suggest that LOLA reduces 
brain oedema of advanced HE.(249) As yet, there are no studies in patients with 
ALF and its use in ALF is currently not recommended. Critically, there are concerns 
that the ammonia-lowering effects of LOLA may be only transient, as there are 
reports of ‘rebound hyperammonaemia’ and HE recurrence on discontinuing 
LOLA.(132) This means that though initially ammonia levels fall with infusion of 
LOLA, soon after its discontinuation it begins to rise back to pre-treatment levels. 
This could be explained by the significant rise in glutamine levels evoked by the 
LOLA, eventually becoming a source for ammoniagenesis by the kidney and 
intestinal (through glutaminase).(133) In addition, aspartate is unlikely to offer an 
additional beneficial effect as its infusion (in animal models) does not reduce 
ammonia and thus an unlikely biologically active precursor of 
glutamate/glutamine.(250)  
 
 
OTHERS 
 
Acarbose 
The hypoglycaemic agent acarbose, which stimulates gut motility, acts through the 
inhibition of glucose absorption in the gut by promoting intestinal saccharolytic 
bacterial flora in preference to proteolytic flora, so reducing substrate for ammonia 
production. In a cross-over randomised trial of cirrhotic patients with low-grade HE 
and type 2 diabetes mellitus, 8 weeks of acarbose (100mgs TDS) significantly 
decreased ammonia blood levels, intellectual function, decreased fasting glucose 
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(33%), decreased postprandial glucose (50%) and significantly lowered 
glycosylated haemoglobin levels.(251) However, acarbose has not found 
widespread acceptance for its use in the treatment of HE outside of this select 
group of patients with co-existent type-2 diabetes mellitus.  
 
Bromocriptine 
Bromocriptine, a dopamine agonist, has been used with limited success for 
disturbances in dopaminergic neurotransmission associated with chronic intractable 
HE,(252, 253) but such studies failed to show a clear benefit over standard 
therapy.(254) Furthermore, in cirrhotic patients with ascites it can induce 
hyponatraemia.(255) However, there is anecdotal evidence to suggest a benefit in a 
small number of cirrhotic patients with low-grade encephalopathy associated with 
development of basal ganglia injury and resultant dopamine deficiency. 
 
Correction of precipitating factors (Table 2) 
An acute admission with worsening encephalopathy is often precipitated by a 
number of defined causal factors which can frequently be anticipated and thus pre-
emptively corrected, as prompt action may lead to a improvement in HE. Though 
ACLF may be triggered by such uncommon events as sedatives or tranquilizers, 
vascular occlusion (hepatic vein or portal vein thrombosis) and hepatocellular 
carcinoma transformation, it is important to outline the management of the more 
common precipitants: 
• Constipation  
• Electrolyte and acid-base imbalance (discussed later)  
• Infection (discussed later) 
• Gastrointestinal bleeding  
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• Portosystemic shunts 
 
Constipation: Enemas are beneficial as a means of expelling ammonia producing 
gut flora either due by cleansing or colonic acidification.(231)  However, there is 
only limited evidence to show a benefit over the use of oral purgatives like 
lactulose. Therefore if bowel motions can be maintained at ≥ 2/day, enemas are 
only used as an adjunct to the primarily used non-absorbable disaccharides.  
 
Infections: In addition to that discussed later, bacterial infections predispose to 
variceal bleeding in cirrhotic patients. A meta-analysis of antibiotic use in variceal 
bleeding, reported a 30% decrease in rate of infection and 9% improvement in 
short-term survival.(256, 257)  
 
Gastrointestinal bleeding: Due to the high protein content of blood and thus 
nitrogenous load, there is increased intestinal ammonia production. This 
ammoniagenic blood meal and precipitation of HE is potentially related to an 
absence of the branched-chain amino acid – isoleucine that protects the inhibitory 
effect of ammonia on the TCA cycle in neuronal cells (see chapter 1.2).  
 
TIPS insertion: The creation of a portosystemic shunt (used to stabilise patients 
with uncontrolled variceal bleeding or intractable ascites) may induce HE (especially 
within the first few months). Prophylaxis against encephalopathy with Lactitol (60 
g/day) or rifaximin (1200 mg/day) is not proven to be effective during the first 
month post-TIPS.(258) Therefore careful selection of patients for a TIPS or surgical 
shunt is necessary.  
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ACUTE SEVERE HE: INTRACRANIAL HYPERTENSION AND OEDEMA (Table 1) 
   
ALF is characterised by rapid progression of HE to coma stages and is characterised 
by cerebral oedema and intracranial hypertension, accounting for the 30% mortality 
rate in ALF.(259) At this point the need to treat the multi-organ effects of ALF, are 
inseparable from treating its cerebral effects. Early ventilation, intensive care unit 
admission and judicious use of available therapies have lead to a significant decline 
in deaths as a result of cerebral oedema. Aiding liver recovery by prompt and 
specific treatment of the cause of acute liver injury, treating precipitating factors 
such as dehydration, electrolyte and acid-base imbalance,(140), infection(170) and 
ameliorating hyperammonaemia remain at the forefront of therapy. The following 
therapeutic strategies are utilized in the management of severe HE requiring 
ventilation.  
 
GENERAL 
Early airway maintenance is necessary to protect the airway and prevent high 
carbon dioxide tension and hypoxia which can result in cerebral hyperaemia.(260) 
Sedation and mechanical ventilation is also essential to safely manage the 
aggressive HE patients. Once intubated the head should be elevated by 10-20° with 
minimal intervention and extreme care when moving or turning a patient; to 
optimise intracranial pressure (ICP) without compromising the cerebral perfusion 
pressure.(261, 262) Airway protection will also reduce the likelihood of aspiration, 
pneumonia, defective gas exchange and infection. Sedative requirements (e.g. 
Fentanyl, Midazolam or Propofol) are low with worsening severity of HE, but are 
likely to increase with recovery.  
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Propofol  
Propofol is a useful short-acting sedative with a rapid onset of action (within 
seconds) and very short half-life. In a dose of 6 mg/kg/hr, propofol reduces CBF 
through decreasing cerebral oxygen consumption and reducing ICP and is of proven 
benefit in treating refractory seizures. In a study if seven patients with ALF treated 
with a propofol infusion of 50 µg/kg/min, propofol maintained the ICP within normal 
limits in six. One patient died from increased ICP and one during OLT.(263) Propofol 
is also rapidly deactivated via a conjugation reaction both hepatically and extra-
hepatically, this non-renal and non-hepatic dependent metabolic clearance makes it 
a superior sedative agent over benzodiazepines or opioids, as it is less likely to 
accumulate. It does however have the disadvantage of leading to hypotension.(263) 
 
Circulatory support & fluid management 
ALF is a hyperdynamic state with high cardiac output, low mean arterial pressure, 
and low systemic vascular resistance.(264) Generalized vasodilatation, which 
produces profound activation of the neurohormonal system, culminates in 
vasoconstriction of regional vascular beds.(265) Mean arterial pressure should be 
maintained at a level to keep the cerebral perfusion pressure between 50-65 
mmHg.(266) The onset of multiorgan failure often necessitates use of inotropes. 
Circulatory failure often becomes refractory to inotropes and up to 70% of patients 
die.(267) A routine short synacthen test on admission to guide the use of steroids is 
important as adrenal insufficiency is a common complication of ALF.(268)  
 
Renal Support 
Renal dysfunction is common (~50-75%) due to either pre-renal, hepatorenal or 
nephrotoxic (e.g. acetaminophen) causes;(269) usually requires support with 
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haemofiltration(267) with continuous (compared to intermittent) 
haemofiltration(270) may avoid rapid water shifts seen with intermittent 
therapy,(271) to provide greater haemodynamic stability and improved cerebral 
perfusion pressure.(270, 272) Due to impaired hepatic lactate metabolism, lactate-
free dialysates are preferred.(273) 
 
Electrolyte imbalance 
Electrolyte imbalance should be corrected aggressively. Hyponatraemia ≤125 
mmol/L may precipitate cerebral oedema and is a contraindication for orthotopic 
liver transplant (OLT).(32, 274) Induced hypernatraemia has been shown to 
improve ICP and reduce inotropic requirements in traumatic brain injury,(275) and 
recently was shown to be useful in ALF.(275) 
 
Antibiotic/antimicrobial agent 
The incidence of sepsis in ALF is a significant factor in mortality rate and 
contraindication to transplantation with 75% developing bacterial infection and 30% 
fungal infections,(276, 277) from the respiratory and urinary tracts, ascites and 
iatrogenic sources. Administration of broad-spectrum antibiotics/antifungal therapy 
should be initiated at the first sign of infection, with focused treatment once the 
organism is identified. Despite the absence of randomised control trials of 
prophylactic antimicrobials in ALF, the use of systemic antibiotics in ALF is 
widespread.(25, 28) 
 
Glycaemic control 
Both hyper and hypoglycaemia need rapid correction as they may worsen brain 
oedema. The role of tight glycaemic control in ALF has not been ascertained but 
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must be instituted with caution because of the tendency for development of 
hypoglycaemia.  
 
SPECIFIC 
 
Mannitol 
Mannitol (an osmotic diuretic) increases brain capillary osmolality, drawing water 
from the brain tissue into the capillaries and has been shown to significantly reduce 
the extent of cerebral oedema and improve survival.(278, 279) Bolus doses of 20% 
mannitol at 1g/kg are preferred. Plasma osmolality should be kept <320 Osm/l. If 
patient is oligouric, mannitol may accumulate and can only be used with 
concomitant haemofiltration.  
 
Dexamethasone 
In ALF, reducing inflammation (whether systemic or local) by utilizing the anti-
inflammatory effects of steroids may improve cerebral haemodynamics and 
prevent/treat intracranial hypertension.(28, 29, 280) However, trials using 
dexamethasone in advanced ALF have shown little effect on the frequency of 
cerebral oedema or survival.(278) 
 
Mild hypothermia  
Induced hypothermia may act on multiple pathogenic mechanisms involved in 
development of HE. For many years induced hypothermia has been used to limit the 
development of intracranial hypertension associated with head injury. In animal 
models of ALF the use of hypothermia has been demonstrated to significantly 
reduce brain water, duration of encephalopathy and improve outcome compared to 
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euthermic animals.(183, 281, 282) Using cooling blankets to induce moderate 
hypothermia (target core temp. 32–33°C) can lead to a reduction in ICP; even in 
patients unresponsive to mannitol and/or ultrafiltration and acts as a bridge to 
OLT.(146, 156) Hypothermia also significantly improves cardiovascular 
haemodynamics manifested by increased mean arterial pressure and systemic 
vascular resistance with reduced noradrenaline requirements.(156)The mechanisms 
underlying the protective effect of mild hypothermia may relate to a reduction in 
arterial ammonia and also brain ammonia extraction and flux.(116, 146) As yet, 
there is no data from randomized control trials on the use of hypothermia in ALF, 
but its use is widespread in patients with uncontrolled intracranial hypertension. 
 
Thiopental sodium 
By inducing cerebral vasoconstriction through inhibition of NOS, Intermittent bolus 
injections (1.5-3.5 mg/kg) or continuous infusion of thiopental, reduce elevations of 
ICP.(283) However, its use is limited to intractable increases in ICP unresponsive to 
other therapies, because of profound negative effects on systemic haemodynamics 
like reduced mean arterial pressure and thereby cerebral perfusion pressure.  
 
Indomethacin 
Non-steroidal anti-inflammatory (NSAIDS) may modulate brain function(284) via 
effects on multiple inflammatory pathways (e.g. antipyretic), as well as possible 
direct effects on cognitive function (via modulation of the glutamate-nitric oxide-
cyclic GMP pathway),(285) and via effects on prostanoids regulation of cerebral 
vascular tone and cerebral blood flow (CBF). Indomethacin, a nonselective 
cyclooxygenase (COX) inhibitor,(286) when given at a dose of 0.5mg/kg in selected 
patients can reduce ICP and cerebral oedema independent of a change in cerebral 
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blood flow.(287) However, its use is limited by nephrotoxicity, platelet dysfunction 
and risk of gastrointestinal bleeding. Poor brain penetration of NSAIDs at 
therapeutic levels requires high doses which increases the risk of toxicity.(285, 288) 
 
Anti epileptic drugs (AEDs)  
In a randomised study of 42 ALF patients with grade 3-4 HE, subclinical seizures 
were less frequent with the use of the anti-epileptic drug Phenytoin, which acts 
upon the Na/K ATPase, and also limit development of ICP and cerebral oedema 
(p<0.03);(289) though this is contended in a recent study from India.(290) 
However, caution should be taken as Phenytoin is hepatically cleared and with a 
failing liver its clearance may become saturated, shifting the elimination from first- 
to zero-order kinetics and predisposing to intoxication.(291) In this situation even 
extracorporeal elimination may prove difficult due to the high level of protein 
binding of phenytoin. Also the associated hypoalbuminaemic state with liver failure, 
even if the total phenytoin concentration is only moderately elevated, its free 
fraction may be very high;(291)  again potentially causing severe neurologic signs 
of phenytoin intoxication (e.g. sedation, cerebellar ataxia, ophthalmoparesis, and 
paradoxical seizures).  
 
N-acetylcysteine (NAC) 
In a case of acetaminophen overdose, NAC must be continued irrespective of the 
time between the overdose and presentation and acetaminophen level as it can 
prevent progression to fulminant hepatic failure and reduces mortality (58% vs. 
38%) especially in those who progress to grade III–IV HE (51 vs. 75%).(292) There 
is less convincing evidence for NAC in non-acetaminophen overdose (20% vs. 
48%).(293, 294) In non-acetaminophen ALF, NAC may improve survival by its 
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effects on cardiac output, oxygen extraction and consumption, and due to its anti-
oxidant effects that ameliorate the significant oxidative stresses that occurs with 
liver failure. 
 
Flumazenil  
In a large placebo controlled trial focusing on intensive care patients with advanced 
HE (grade ІІІ-ІV), the short-acting benzodiazepine-receptor antagonist flumazenil 
was shown to rapidly improve the neurological score in 15% and 
electroencephalogram (EEG) findings in 30% of patients within minutes of its 
administration.(295) However, flumazenil does not lead to any lasting effect or 
correct HE, unless co-administered with a long-acting therapy,(296) and as such is 
not recommended.  
 
Liver support and transplantation 
 
Orthotopic liver transplantation: Although OLT offers definitive therapy for liver 
failure by dramatically improving the clinical status with a return to a normal mental 
state, there is evidence to suggest that minimal HE may persist in certain patients 
due to some as yet unknown irreversible changes in the brain.(173) The incongruity 
that exists between donor organs and recipients has lead to a plethora of 
extracorporeal liver assist devices (ELADs)(297, 298) and even partial 
hepatectomy(29, 196) to aid or supplant the failing liver. ELAD’s are either:  
• Biological (including hybrid & combination) devices: which use either 
immortalised hepatocytes cultured in bioreactors or whole animal livers to 
mimic endogenous excretory and synthetic liver function.  
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• Non-biological devices: which use extracorporeal blood purification to dialyse 
albumin-bound hydrophobic substances (e.g. ammonia, bilirubin, bile acids, 
aromatic amino acid metabolites and medium-chain fatty acids).  
 
The extracorporeal devices under clinical evaluation include the following: 
 
Molecular Adsorbent Recirculating System (MARS): provides counter-current 
haemodialysis against albumin and bicarbonate circuits.(297) 
 
Single-Pass Albumin Dialysis (SPAD): provides counter-current albumin dialysis 
against high flow blood in a fibre haemodiafilter, which unlike MARS is discarded 
after passing the filter. As it uses a standard renal dialysis device continuous veno-
venous haemodiafiltration is possible.(299) 
 
Prometheus system: provides direct albumin adsorption with high-flux 
haemodialysis after selective filtration of the albumin fraction through a specific 
polysulfon filter.(300) 
 
All these devices successfully remove protein-bound toxins, but may have more 
variable effects on systemic (versus portal) haemodynamics; and worsen 
coagulopathy. Currently the clinical benefit of such devices is unclear, although they 
may offer a bridge to transplantation or liver recovery.   
 
In conclusion, for HE, ammonia-lowering therapies remain the cornerstone of 
standard medical care for this debilitating condition, along with wider measures to 
treat precipitating factors and the specific interventions for the cerebral sequelae of 
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advanced disease. As highlighted in chapter 1.3, knowledge garnered from a 
greater understanding of interorgan ammonia and amino acid metabolism and the 
pathophysiological basis of HE are most likely to lead to the development of new 
therapeutic approaches.(133) However, even current best treatment(s) lack 
conclusive evidence from clinical studies to-date,(47, 48) such that with the advent 
of new (and existing drugs) there is a requirement for robust randomized controlled 
trials to drive an evidence based approach to the treatment of HE. 
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 Table 1: Treatment stratagems used in HE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HE grade: I-II HE grade:  III - IV
V General management 
HYPERAMMOEMIA 
Dietary protein supplementation 
Purgatives 
• Non - absorbable disaccharides 
• Enemas 
on - absorbable antibiotics  
Modulation of  interorgan ammonia 
• L - ornithine, L- aspartate (LOLA) 
• Sodium benzoate 
Others 
Flumazenil ,  Bromocriptine ,  Acarbose 
EMERGIG THERAPIES   
Probiotics 
Cerebral oedema & elevated ICP 
General 
• Ventilate 
• Sedate (e.g.   Propofol     ) 
Specific 
• Antimicrobials 
• Hypertonic saline 
• Mannitol 
• Dexmethasone 
• Induced hypothermia 
• Thiopentone 
• Indomethacin 
• Anti - epileptic drugs  
• N - acetylcysteine     (NAC) 
Transplantation 
Orthotopic liver transplant (OLT) 
Partial hepatectomy  
Liver assist devices 
• 
• 
• Phenylacetate 
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Table 2: Precipitating Factors In Hepatic Encephalopathy 
 
Precipitating Factors In HE
Constipation
Dehydration
Gastrointestinal bleeding
Infection
Excessive dietary protein
Hypokalaemia
Hypoglycaemia
Hypothyroidism
Hypoxia
Metabolic alkalosis
Anaemia
Azotaemia/uraemia
Medications (narcotics, sedatives, etc.)
Hepatoma
TIPS, surgical shunt
Vascular occlusion
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Figure 1: Therapies - interorgan ammonia and amino acid metabolism 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In liver failure, the relative activities of cellular glutamine synthetase (GS) and phosphate-activated 
glutaminase (PAG) in different organs influence interorgan ammonia and amino acid metabolism. With a 
loss of hepatic urea cycle capacity, hyperammonaemia is predominately due to worsening intestinal and 
renal ammonia efflux, with skeletal muscle having the potential to increase its ability to detoxify 
ammonia. Though the brain also detoxifies ammonia, this is counterproductive as resultant astrocyte 
glutamine accumulation induces brain swelling. This schematic highlights not only current standard 
therapies for hyperammonaemia, which principally act on individual organs (e.g. purgatives targeting 
intestinal ammonia production), but also newer interventions targeting multiple organs (e.g. LOLA). 
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Abstract 
This study explores the hypothesis that the inflammatory response induced by 
administration of lipopolysaccharide (LPS) exacerbates brain oedema in cirrhotic 
rats with cirrhosis; and if so whether this is associated with altered brain 
metabolism of ammonia or anatomical disturbance of the blood-brain barrier. Adult 
Sprague-Dawley rats 4-weeks after bile-duct ligation (BDL)/sham-operation, or 
naïve rats fed a hyperammonemic diet (HD) were injected with LPS (0.5 mg/kg, I.P) 
or saline and sacrificed 3-hours later. LPS administration increased brain water in 
HD, BDL and sham-operated groups significantly (p<0.05), but this was associated 
with progression to pre-coma stages only in BDL rats. LPS induced cytotoxic brain 
swelling with maintained anatomical integrity of the blood-barrier. Plasma/brain 
ammonia levels were higher in HD and BDL rats than sham-operated controls, and 
did not change with LPS administration. Brain glutamine/myo-inositol ratio was 
increased in the HD group but reduced in the BDL animals. There was a background 
proinflammatory cytokine response in the brains of cirrhotic rats, and plasma/brain 
TNF-α & IL-6 significantly increased in LPS-treated animals. Plasma nitrite/nitrate 
levels increased significantly in LPS groups compared with non-LPS controls but 
frontal cortex nitrotyrosine levels only increased in the BDL + LPS rats (p<0.05: 
versus BDL controls). In conclusion, injection of LPS into cirrhotic rats induces pre-
coma and exacerbates cytotoxic oedema due to the synergistic effect of 
hyperammonaemia and the induced inflammatory response. Although the exact 
mechanism of how hyperammonaemia and LPS facilitate cytotoxic oedema and pre-
coma in cirrhosis is not clear, this data supports an important role for the 
nitrosation of brain proteins. 
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Background 
Hepatic encephalopathy (HE) is an important complication of cirrhosis, the severity 
of which can vary widely from mild sleep disturbance through neuropsychological 
impairment to coma, brain herniation and death. Though a common, and defining 
characteristic of acute liver failure (ALF),(301) the development of advanced 
cerebral oedema in cirrhosis is thought to be rare. However, severe brain swelling 
and intracranial hypertension has been reported in patients with cirrhosis who have 
severe precipitating illness, such as uncontrolled gastrointestinal bleeding, insertion 
of a transjugular intrahepatic shunt and/or severe sepsis.(32, 302, 303)  
Although the exact pathogenesis of HE is not clear, ammonia is thought to play a 
central role and its levels have been shown to correlate with the severity of HE in 
cirrhotic patients.(23) Furthermore, arterial ammonia levels predict brain herniation 
in patients with ALF.(22) Ammonia is thought to produce astrocytic brain oedema 
through the accumulation of glutamine which is the detoxification product of 
ammonia metabolism resulting in increased osmotic stress.(150, 304) Indeed, 
extracellular glutamine levels were shown to correlate with the severity of 
intracranial hypertension.(147) Yet comparatively, in cirrhosis Myo-inositol (a sugar 
involved in phosphoinositide synthesis) is reduced with increasing concentrations of 
glutamine; some investigators suggesting that myo-inositol and other weaker 
intracellular osmolytes are expelled from the cell to compensate for the entry of 
glutamine.(305)  
In patients with ALF, the severity of inflammation (often secondary to infection) 
correlates with the progression to advanced stages of encephalopathy and 
intracranial hypertension.(26, 28) Recently, our group reported a correlation 
between the severity of increased intracranial pressure and the circulating levels of 
proinflammatory cytokines in ALF patients.(169) Brain cytokine production has also 
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been observed in a group of ALF patients with uncontrolled intracranial 
hypertension.(10, 169) In patients with cirrhosis, it has been shown that induced 
hyperammonaemia results in significant worsening of neuropsychological function in 
those patients with evidence of an inflammatory response due to bacterial infection. 
This effect was not found after resolution of the infection following antibiotic 
therapy.(170)  
These data strongly indicate a possible synergy between hyperammonaemia and 
inflammation in the development of HE, but it is not clear whether it is the 
background cirrhotic state or the associated hyperammonaemia that predisposes to 
the effects of the superimposed inflammation. This raises a number of lines of 
investigation: 
 
Research Hypothesis 
On a background of chronic liver failure, systemic inflammation and 
hyperammonaemia act synergistically to sensitise the brain to their effects and 
allow for advancing encephalopathy.  
 
Research questions 
5. Do systemic changes in ammonia and inflammation act synergistically to effect 
the progression and complications associated with HE as indicated by the depth 
of coma or cerebral oedema?  
6. With progression of HE, is there an anatomical or functional alteration of the 
blood brain barrier? 
7. Does the LPS challenged BDL rat model represent clinical ACLF?  
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8. On a background of hyperammonaemia and systemic inflammation, are the 
cerebral effects associated with HE due to alterations in brain ammonia and 
amino acid metabolism, and/or cerebral inflammatory responses?  
 
Aim of study 
Based on the above questions, it was necessary to undertake the following study to 
explore the hypothesis that the inflammatory response induced by administration of 
bacterial cell wall LPS, exacerbates brain oedema in cirrhotic rats; and if so whether 
the oedema is associated with altered brain metabolism of ammonia or anatomical 
disturbance of the blood-brain barrier. I chose to perform this study using our well-
characterised BDL model of cirrhosis and diet induced hyperammonemic rats. 
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Methods 
All animal experiments were conducted according to Home Office guidelines under 
the UK Animals in Scientific Procedures Act 1986. Male Sprague-Dawley rats (body 
weight 230–280g) were obtained from the comparative biological unit at the Royal 
Free and University College Medical School, University College London. All rats were 
housed in the unit and given free access to standard rodent chow and water, with a 
light/dark cycle of 12 hours, at a temperature of 19–23°C and humidity of 
approximately 50%. 
Animal models 
Bile-duct Ligation: Under anaesthesia (diazepam 1mg/kg intravenous (I.V), followed 
by Hypnorm® 150µl/kg intramuscular (I.M), Janssen Pharmaceutica, Belgium) all 
rats underwent bile duct ligation to induce biliary cirrhosis, or a sham operation as 
described previously.(306) One BDL and 1 sham-operated rat died within 36 hours 
of the operation due to anaesthetic complications. 
Non-cirrhotic hyperammonemic animals: Naïve rats (n=14) were administered a 
high protein/ammoniagenic diet (HD) for 7 days prior to administration of 
LPS/Saline 3 hours before termination (as outlined above). The diet consisted of a 
liquid rodent feed (Bioserve, Frenchtown, NJ 08825, USA) and a tailor-made 
mixture mimicking the amino-acid composition of haemoglobin molecule 
(4g/Kg/day Nutricia, Cuijk, The Netherlands) as described previously(115, 307) 
mixed with commercially available gelatin to prevent sedimentation. This regimen 
produces chronic hyperammonaemia to levels that are similar to that observed in 
BDL animals. 
Study Design 
Twenty-eight days after surgery, the operated rats (BDL and sham) were 
randomised into four groups, with BDL or sham-operated rats injected with LPS 
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(Salmonella typhimurium spp., 0.5 mg/kg I.P made up to 0.5ml in saline or saline 
alone: 1) Sham-operated + saline (n=7), 2) Sham-operated + LPS (n=7), 3) BDL + 
saline (n=6) and 4) BDL + LPS (n=6). The HD rats were also randomised to receive 
LPS (n=7) or saline (n=7).  
As per protocol, the rats were allowed free access to food and water (ad lib) for a 
period of 3 hours post-intervention in a temperature controlled environment and 
were then sacrificed by exsanguination under anaesthesia (Hypnorm™ 200µL/kg 
I.M), 20 minutes after diazepam (1mg/kg I.P). In all study groups over this 3 hour 
post-intervention period, food intake was minimal, likely reflective of the effect of 
anaesthesia. Blood was withdrawn from the descending aorta and immediately put 
into ice cold heparin/EDTA containing tubes (until full exsanguination), centrifuged 
at 4oC, and the plasma collected and stored at -80°C until assayed.  
Assessment of level of consciousness 
The conscious levels of rats used in this study were rated using an established 
neurological scale.(308) It was rated as either normal, with loss of the scatter reflex 
(c.f. Grade 1 encephalopathy) and ataxia (c.f. Grade 2 encephalopathy), together 
representing pre-coma stages, or loss of the righting reflex (c.f. Grade 3-4 
encephalopathy) representing the coma stage. In a previous study(306) it was 
established that 3 hours after administration of LPS, BDL rats all reached pre-coma 
or early coma stages.  Therefore, in the current experiments all rats were sacrificed 
3 h after injection of LPS or saline. 
Brain water measurement 
Though many distinct areas of the brain demonstrate perivascular oedema, with 
certain areas now considered to have a more direct associated with 
neurobehavioural change at non-overt HE (e.g. anterior cingulate cortex(309)) the 
‘frontal’ cortex was chosen as the primary area of interest based on our own 
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experience and prior validated studies(37, 310, 311) as it displays consistent 
oedema and correlative coma and alterations in amino acid concentrations with 
injury.   
At the time of death, the whole brain was rapidly removed and 2mm2 samples were 
dissected from the frontal cortex (grey matter) and the cerebellar cortex. Brain 
tissue water content (as a measure of cerebral oedema) was determined using a 
previously described gravimetric technique.(312) Tissue samples were coded with 
separate investigators (Dr Gavin Wright, Dr Nathan Davies, Dr Stephen Hodges, Dr 
Vanessa Stadlbauer) collecting tissue samples or, performing gravimetry (in 
adjoining rooms). 
The gravimetric technique, illustrated in Figure 3, allows the percent gram water 
per gram tissue of samples less than 2 mm3 to be determined within minutes to an 
accuracy of greater than 1%. A modified technique was used; - two mixtures of 
kerosene and bromobenzene were used in the preparation of the gradient. One litre 
of mixture A was prepared from 278 ml of kerosene and 100 ml bromobenzene to 
give a specific gravity of 0.9750. One litre of mixture B was prepared from 279 ml 
kerosene and 180 ml of bromobenzene to give a specific gravity of 1.0650. A flask 
containing 100ml of mixture B was placed 40 cm above an empty 100ml graduated 
cylinder. 100ml of mixture A was then placed 43cm above mixture B. 
The fluid kinetics of this system is such that a linear gradient column is produced if 
the outflow from the constantly mixed ‘Mixture B’ to the graduated cylinder is 
exactly twice the outflow from A to B. This was accomplished by using two equal 
lengths of polyethylene outflow tubing of length 80cm and internal diameter 
0.76mm were used and bound together (with tape 3cm from the end) extending 
from flask B to the graduate and a further 80 cm single length of tubing from Flask 
A to Flask B. By this technique, the specific gravity at the very bottom of the 
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graduated cylinder is equal to that of Mixture B (1.065), while the specific gravity at 
the top is equal to the arithmetic mean of the two solutions (1.020). A steady flow 
to the surface of the graduated cylinder was maintained by gradually lowering the 
cylinder in 2 mm increments as the fluid level increased. When a cylinder volume of 
100ml was reached the tubes were clamped. The gradient was then permitted to 
stabilise for 15 minutes and calibrated with standards made up of potassium 
sulphate (K2S04) of known specific gravity. The concentrations of the K2S04 solutions 
were 2.99g, 2.67g, 2.35g and 1.7g/50ml (50g of dH20), corresponding to specific 
gravities of 1.045, 1.040, 1.035 and 1.025. One drop of each standard was gently 
placed in the column by means of a small syringe. The depth of equilibration was 
recorded at the end of 2 minutes. The forebrain and cerebellum was cut into 2 mm3 
pieces and placed gently in the column by needle tip. The depth of equilibration was 
recorded at the end of 2 minutes. 6 pieces for each brain area were recorded. The 
specific gravity of the samples was calculated using the gradient of the line (y= mx 
+ c) generated from a graph of the specific gravity of the K2S04 standards (x axis) 
and the column position (y axis). Using a constant (c) to represent the specific 
gravity of the solid component (1.298 in rat frontal cortex and 1.269 in rat 
cerebellum) the percentage brain water can be calculated using the following 
formula: [c/(c-1)] / SpG] – [1/(c-1)] x 100% 
Measurement of plasma biochemistry 
Plasma samples (200µl) were analysed for: ALT, albumin, total protein, ammonia, 
bilirubin, urea and electrolytes using a Cobas integra 400 multianalyser with the 
appropriate kits (Roche-diagnostics, Burgess Hill, West Sussex UK). 
Measurement of ammonia 
Plasma: Ammonia was measured in the deproteinised plasma using the well 
validated indophenol detection method as described previously.(313) In brief, 
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plasma samples were deproteinised by the addition of trichloroacetic acid (15% 
final) and centrifuged at 10,000 rpm for 10 minutes at 4oC. The supernatant (50µl) 
was incubated in a 96 well plate at 30oC for 3 hours in 200µl of a solution 
containing phenol (10mM), nitroprusside (10mM), sodium hypochlorite (10mM) and 
sodium hydroxide (0.5mM). The concentration was determined against a standard 
curve measured at 630nm in a 96 well plate reader as above.    
Brain: The cerebral cortex (100µg) was homogenised and deproteinised (using a 
glass tube Teflon pestle homogeniser) in 300µl of ice-cold cell lysis buffer solution. 
After centrifugation at 12,000g for 10 minutes at 4°C, the supernatants were 
collected, and ammonia measured using absorbance photometry (Cobas integra 400 
multianalyser; Roche diagnostics, UK). 
Brain Proton magnetic resonance spectroscopy (1H-MRS) 
Snap frozen cortical brain samples were processed and analysed by 1H-NMR using a 
previously described technique (by Dr Claudia Zwingmann, Germany).(38) 1H-NMR 
spectra were recorded on a Bruker WB 360 spectrometer using a 5-mm QNP probe, 
100-200 accumulations, repetition time 16 s, spectral width 3623 Hz, data size 16 
K, zero filling to 32 K. Chemical shifts were referenced to lactate at 1.33 ppm. Total 
metabolite concentrations (µmol/g ww) were analysed from 1H-NMR spectra of PCA 
extracts using (trimethylsilyl)propionic-2,2,3,3d4-acid as external standard.(314) 
Measurement of Nitrite/nitrate 
Combined NO2/NO3 levels were determined from the heparinised plasma samples by 
a modified Greiss test, which involves colorimetric detection with Griess reagents, 
using methods described previously (by Dr Nathan Davies at the Institute of 
Hepatology, UCL).(175, 315, 316) The modified assay used combined reduction of 
nitrate and measurement of nitrite in a single step. Reduction was achieved with 
vanadium(III), which has a lower toxicity than previously used cadmium and did 
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not require removal prior to nitrite measurement. Vanadium(III) can be used to 
reduce nitrate to NO at >80°C for chemiluminescent detection, but at lower 
temperatures, nitrate reduction by vanadium(III) is halted following nitrite 
formation. Trapping with Griess reagents eliminates the need for chemiluminescent 
detectors, giving simultaneous detection of nitrate and nitrite in microtitre plate 
format. In this study plasma samples were diluted and centrifugally separated to 
remove proteins though a 12-kd cut-off filter (Vectaspin, Whatman, Maidstone, UK). 
The nitrite and nitrate in the filtrate were determined against a standard curve 
measured at 550 nm as above, utilizing methods described by Miranda et al.(316) 
Nitrite concentrations were measured in the filtrate by chemiluminescence as 
described previously.(306) In brief, sample aliquots were injected into an anaerobic 
(Argon-purged) reaction vessel containing either Sodium iodine (NaI) in glacial 
acetic acid (nitrite reduction) or hot vanadium (III) chloride (VCl3) in Hydrogen 
chloride (95°C; nitrite and nitrate reduction). The resulting NO was drawn by 
vacuum into the detector, where it reacted with O3. This chemiluminescent reaction 
was quantified and integrated with a photomultiplier tube/computer system. 
Measurement of brain tissue nitrotyrosine levels 
Brain tissue was homogenised in buffer and proteins precipitated by mixing with 
methanol/chloroform (1:2). Brain tissue homogenates were analysed for 
nitrotyrosine (NT) and tyrosine levels which were quantitated using a stable 
isotope-dilution gas chromatography/negative ion chemical ionisation mass 
spectrometry method (by Dr A Mani and Dr Kevin Moore at the Royal Free Hospital 
Medical School, UK).(317-319) This method prevents the artifactual nitration of 
tyrosine that occurs during acidic hydrolysis conditions. This method has an intra-
assay and inter-assay variation of less than 5%. All results are expressed in relation 
to dry weight of protein as measured by direct weighing prior to hydrolysis.  
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Measurement of plasma & brain cytokine levels 
Snap frozen and stored (-80°C fridge) 100µg cortical brain samples were 
homogenised cell lysis buffer solution. Following protein concentration quantification 
of brain homogenates, equilibrated brain protein samples (50µl) were loaded onto 
TNF-α (Bender MedSystems; Vienna Austria), IL-1β (Biosource International Inc., 
Nivelles, Belgium) and IL-6 (Biosource International Inc., Nivelles, Belgium) ELISA 
96 well plate kits and read using a 96 well plate reader at 450nm (Sunrise, Tecan, 
Salzburg, Austria) according to manufacturer’s instructions. 
Histopathological assessment 
A further 24 rats (n=4) BDL + LPS, (n=4) BDL + saline, (n=4) sham-operated + 
LPS, (n=4) sham-operated + saline, (n=4) HD and (n=4) HD + LPS) were 
anaesthetised for brain tissue collection (Diazepam IP 1mg/kg: Hypnorm, IM. 
200µL/kg). Following an extended thoracotomy the rats were perfused with a 
heparinised saline rinse before administering fixative through the left ventricle, 
preceding superior vena cava puncture. A perfusion system was used which 
incorporated a manually controlled hand-held sphygmomanometer to maintain a 
consistent perfusion pressure (between 100-110mmHg) and thus tissue perfusion to 
limit vessel collapse, which may occur with venosection. The fixative (a 2.5% 
gluteraldehyde and 2% paraformaldehyde in 0.1M coccodylate buffer Ph 7.2) 
contained 2% Lanthanum nitrate (Agar Scientific Ltd, U.K), a low molecular weight 
(MW 139.8) ionic tracer used to evaluate the integrity of the blood brain barrier. 
Following removal, the brain was stored in fixative and refrigerated at 4ºC until 
processing for microscopy (performed primarily by Dr G Wright, assisted by 
Professor DC Davies, Dr Raymond Moss and Dr HF Brooks at The Department of 
Anatomy, St Georges University Medical School). 2 mm3 sections of cerebellar and 
frontal were processed into Spur’s resin (Agar Scientific Ltd, U.K). Briefly, selected 
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pieces of tissue were rinsed in coccodylate buffer and post fixed in 1% osmium 
tetroxide in coccodylate buffer (0.2 M, pH7.2). After re-rinsing in buffer, the tissue 
was dehydrated in ascending alcohols (50%, 70%, 90%, 95% and 100%), before 
being immersed in propylene oxide and finally embedded in Spur’s resin. Semi-thin 
(1-2µm) sections were cut, stained with 1% toludine blue and viewed in a light 
microscope to determine the orientation of the tissue blocks. Selected sections of 
the cortex were picked up and placed on copper grids, stained with aqueous uranyl 
acetate(18)  and washed with distilled water followed by Sato’s lead citrate(19)  for 
20 min each. The sections viewed were then viewed in a Hitachi 7100 transmission 
electron microscope at 75kV. Digital images were captured with a Gatan column 
mounted CCD camera at a resolution of 1024 x 1024 pixels and archived on a 
personal computer. All materials and reagents were obtained from the Sigma 
chemical company (Poole, UK) unless otherwise stated. All materials and reagents 
were of a suitable laboratory grade and obtained from the Sigma chemical company 
(Poole, UK) unless otherwise stated. 
Statistics 
Data are expressed as mean (±SEM). Significance of difference was tested with 
ANOVA, the unpaired t-test and Mann Whitney test, indicated in figure legends; 
p<0.05 was taken to be statistically significant. Software used included Microsoft 
Excel 2003 (Microsoft Corp., Redmond, WA) and GraphPad Prism 4.0 (GraphPad 
software, Inc., San Diego, CA).  
 
 
 
 
 
  
 
 
131
Results  
All rats continued to gain weight following surgery. From the final weight taken 
immediately prior to termination, BDL rats (mean of 320g; n=12) were found to be 
marginally heavier compared to sham-operated controls (mean of 296g; n=14); 
p=0.01. This difference was attributed to the presence of ascites. At 28 days, all 
BDL rats were deeply jaundiced. Although there is a reported anorexic effect with 
BDL, this was not evident in this study with daily intake of feed no different 
between groups. 
Any potential shock was reduced as the study rats were used to handling and 
because of the anaesthetic protocol used. This was indicated by the maintenance of 
systemic hemodynamics seen within our study groups (MAP, Mean ± SEM: sham-
operated, 118 ± 3.83; BDL 104 ± 6; HD 132 ± 7; p >0.5), with the effect of LPS on 
hemodynamics (over 3 hours) already well characterised by our group.(320) 
Conscious level and Brain water 
All rats were still alive 3 hours after injection of LPS or saline. Following injection of 
LPS, the BDL rats had a progressive, and marked deterioration in their conscious 
level starting within 30-60 minutes, reaching pre-coma stages at the 3-hour 
sacrifice time point. The BDL, sham-operated and HD rats administered saline and 
the sham-operated and HD rats administered LPS remained fully alert. There was a 
significant increase in the water content in the frontal cortex of rats administered 
LPS compared with the corresponding saline-administered controls (sham-operated, 
p=0.01; BDL, p=0.01; and HD, P=0.05: Table 1, Figure 4). There was no significant 
difference in the brain water content between saline-treated sham-operated and 
BDL groups (p=0.237). Compared to sham-operated saline-administered controls, 
frontal brain water was significantly increased in BDL + LPS (p=0.01), HD  
(p=0.001) and HD + LPS (p=0.001) groups. There was no significant difference in 
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the brain water content between the LPS-administered groups. There was no effect 
of LPS on cerebellar water content in any of the groups studied (data not shown). 
Biochemistry 
In BDL rats, ALT, bilirubin and albumin levels were consistent with cirrhosis (Table 
2) and the bilirubin was significantly elevated compared to sham-operation and HD 
groups (p<0.001), respectively. There was no significant impact following LPS 
administration in BDL, sham-operated or HD rats except for an expected, and 
previously well described, rise in ALT and urea seen in the BDL rats. Plasma glucose 
and albumin were lower in the BDL animals, but the renal function, sodium, 
potassium and plasma osmolarity were not significantly different between groups 
(Table 2). 
Ammonia 
Compared to sham-operated saline control rats, there was a significantly elevated 
arterial ammonia level in BDL (p=0.019), HD (p=0.049) and HD + LPS challenged 
(p=0.042) rats (Figure 5, Table 1); significance between two groups established 
using T-test analysis. There was no significant difference found between BDL and 
HD saline-treated groups (p=0.237). The brain ammonia concentration was found 
to be elevated in BDL and HD rats compared with sham-operated rats. LPS 
administration did not alter brain ammonia concentrations significantly from the 
respective saline-treated animals (Table 3). 
Proton NMR spectroscopy 
There was no statistical difference in brain tissue osmolytes following administration 
of LPS to any of the test groups compared to the saline control (Table 3, Figure 6). 
There was a significant decrease in brain glutamine levels in BDL compared to sham 
(p<0.03), and significant increase compared to HD (p=0.01) saline-treated rats. A 
significant decrease in brain Myo-inositol levels was found in BDL + saline and HD 
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(±LPS/saline) rats compared to sham-operated rats (BDL, p=0.01; HD + LPS, 
p=0.005; and HD, p=0.014, respectively). Also, the brain glutamine/myo-inositol 
ratio was significantly higher in our HD (±LPS/saline) rats compared to sham/BDL 
±LPS/saline rats (p<0.001 for each case). 
Plasma and Brain Cytokines 
Following administration of LPS in sham-operated and BDL rats there was a 
significant rise in the plasma levels of the proinflammatory cytokines TNF-α and IL-
6 (p<0.001: compared to each corresponding saline control group), which was also 
observed in HD rats (p<0.05, Table 4). In saline-treated BDL rats, the levels of 
brain IL-6 and TNF-α were increased 1.6- and 1.5-fold respectively compared to the 
sham-operated group; though this only reached significance for measured IL-6 
concentrations, most likely due to intra-group variation (p=0.05, unpaired t-test). 
This background inflammatory response, in which brain TNF-α was augmented by 5-
fold following administration of LPS in BDL rats, was found to be not statistically 
significant. 
Nitrite/Nitrate (NOx) 
The plasma concentration of NOx (Figure 7A, Table 1) was significantly higher in 
rats treated with LPS compared to the non-LPS-administered groups (sham-
operated, p=0.017; BDL, p=0.008 and HD, p=0.05, respectively). In saline-treated 
controls, BDL rats also had higher NOx levels compared to sham-operated controls 
(p=0.05). Similarly, the BDL, sham-operated and HD rats treated with LPS also had 
higher plasma nitrite values compared to their respective saline-treated control rats 
(sham-operated, p=0.045, BDL, p=0.038 and HD, p=0.05: Figure 7B: Table 1). 
Brain Nitrotyrosine/Tyrosine ratio 
The only significantly increased NT/T ratio was observed in the LPS-administered 
BDL rats compared to saline-treated BDL controls (p<0.05: Figure 7C, Table 1); 
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calculated using the Newman-Keuls Multiple Comparison Test (to determine 
differences between all groups). The administration of LPS had no significant effect 
on sham-operated or HD rats. 
Electron Microscopy 
Figures 8A-F: are transmission electron micrographs (Scale bar, 2 µm) showing 
representative cerebral microvessels and the perivascular astrocytes for each 
treatment group.  
Sham-operated rats: Figure 8a, shows a fully intact and well-perfused microvessel 
with no surrounding astrocytic, perivascular changes. Lanthanum nitrate particles 
line the microvessel luminal wall, suggesting an intact blood brain barrier to this 
tracer. 
BDL rats: Figure 8b, shows a partially collapsed microvessel, although the 
endothelium barrier appears intact due to the fact that the lanthanum particles are 
clearly retained in the microvessel lumen. There is only minimal brain water 
accumulation observed in the astrocytic, perivascular tissue.  
Sham-operated + LPS rats: Figure 8c, shows mild astrocytic, perivascular oedema 
despite an otherwise intact blood brain barrier as suggested by the retained 
lanthanum. 
BDL + LPS rats: Figure 8d, shows greater disruption of structure than found in the 
other sham and BDL experimental groups, evident by the massive astrocytic, 
perivascular oedema and collapsed microvessel. However, the blood brain barrier 
still appeared intact with no leakage of the lanthanum nitrate into either the 
endothelial cell cytoplasm or perivascular space. 
HD rats: Figure 8e, shows a partially collapsed microvessel, although the 
endothelium barrier appears intact due to the retention of the lanthanum particles 
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in the microvessel lumen. There is massive brain water accumulation in the 
astrocytic, perivascular tissue.  
HD + LPS rats: Figure 8f, shows similar disruption of structure to that found in BDL 
+ LPS and HD rats, but with more significant astrocytic, perivascular oedema and 
collapsed microvessel. However, the blood brain barrier still appeared intact with no 
leakage of the lanthanum nitrate into either the endothelial cell cytoplasm or 
perivascular space. 
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Discussion 
An important observation of our study was the finding that the administration of 
LPS to sham-operated, HD and BDL rats resulted in marked brain water increases. 
The greatest increase in brain water was seen in the HD rats administered LPS; 
which occurred without any observed effect on the level of consciousness. Only the 
BDL animals administered LPS reached pre-coma stages at 3 hours after 
administration of LPS. This lack of correlation between increased brain water and 
preserved mental state, in all rats except the LPS-treated BDL rats, suggests that 
factors in addition to hyperammonaemia and brain swelling contribute to the effects 
on consciousness found in HE.  
The histological analysis (Figure 8) confirms the data obtained from brain water 
measurements, which show significant worsening of brain oedema in all groups 
following administration of LPS (Figure 4). This increase in brain water was 
characterised by astrocytic oedema that is indistinguishable from the well 
documented brain oedema seen in hyperammonemic liver failure models.(321, 322) 
The ionic tracer lanthanum nitrate (MW 433), was used as a highly reproducible 
method for EM detection of blood brain barrier integrity to paracellular 
movement.(323) Retention of lanthanum within the vessel wall in all the groups 
clearly indicates that the anatomical integrity of the blood brain barrier is 
maintained. Our observation differs from earlier findings in the rat models of ALF 
where the blood-brain barrier was observed to be compromised.(322, 323) The 
discrepancies between these earlier observations and our study may suggest a 
specific phenomenon of cytotoxic oedema in cirrhotic rats compared with a 
combined cytotoxic and vasogenic oedema in ALF.  
Astrocyte oedema in the non-cirrhotic, hyperammonemic (HD) rats was associated 
with an increase in glutamine, reduction in myo-inositol and a marked increase in 
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the glutamine/myo-inositol ratio in keeping with the ammonia-glutamine-brain 
water hypothesis. Of note, is the observation that the severity of astrocytic oedema 
seen in the saline-treated BDL rats was markedly less despite similar degrees of 
plasma and brain ammonia levels as seen with the LPS-administered BDL group 
likely related to decreased glutamine, myo-inositol and glutamine/myo-inositol 
ratio, though non-statistical. Our observation adds to the existing debate about the 
role of glutamine in the development of astrocytic oedema during 
hyperammonaemia. (324)  
The mechanism of the observed astrocytic swelling in BDL rats is therefore unclear, 
and possibly regulated by the effects of inflammation. The increase in brain oedema 
following LPS administration in each of the groups does not directly correlate with 
plasma and brain ammonia levels or brain ammonia metabolism as there was no 
difference in the ammonia, glutamine or myo-inositol levels between the rats 
administered LPS and the respective control groups. It has been previously shown 
that administration of LPS resulted in a sustained increase in TNF-α and F2-
Isoprostane levels in the BDL rats 3 hours post-injection compared with sham-
operated rats administered LPS.(306) In support of this argument, higher NO levels 
are observed in BDL, sham-operated and HD rats following administration of LPS. In 
order to explore whether this altered peripheral inflammatory response was 
reflected in the brain, plasma and brain proinflammatory cytokine levels were 
measured. Our results show that LPS administration not only results in an increase 
in systemic cytokine response but also increases brain tissue TNF-α confirming our 
previous observation that a systemic inflammatory response may initiate brain 
inflammation during liver failure despite retained anatomical barrier integrity.  
The BDL rats administered LPS showed significantly higher levels of nitrosation of 
brain proteins compared with all other groups. Ammonia-induced nitrosation of 
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astrocytic proteins has been demonstrated in isolated astrocytes and astroglial 
tissue in brain sections of portacaval anastomosed rats,(325) but 
hyperammonaemia is unlikely to be the sole mechanism for protein nitration as the 
NT/T ratio was not elevated in the hyperammonemic saline-treated BDL and HD 
rats. Similarly, LPS itself can lead to nitrosation of proteins in the brain,(326) but 
the observation of only a minimal increase in the NT/T ratio in sham-operated and 
HD rats administered LPS also argues against this being the only mechanism for 
protein nitrosation. It is conceivable that hyperammonaemia and LPS together 
provide an environment for nitrosation of brain proteins. However, the observation 
that the NT/T ratio remained unchanged in the HD rats administered LPS argues 
against the above hypothesis. The significant elevation of plasma NT/T and TNF-α 
levels in the LPS-treated BDL rats, has lead us to hypothesise that the subliminal 
inflammation that is a feature of BDL(327) may ‘prime’ the animal to the effect of 
ongoing hyperammonaemia and subsequent endotoxaemic/inflammatory insult. 
This hypothesis is supported by the recent demonstration in astrocyte cell cultures 
that physiological levels of TNF-α seen in liver failure, induces tyrosine 
nitration.(328) 
As discussed, the differential progression to pre-coma observed in the LPS-treated 
BDL rats appeared not to directly correlate with any alteration in plasma and brain 
ammonia, electrolytes, brain osmolytes glutamine and myo-inositol, or even the 
degree of astrocytic oedema; despite changes consistent with the water-glutamine-
brain osmolyte hypothesis. These observations appear to dissociate extent of 
cerebral oedema to degree of coma. It is possible that in the BDL rats’ 
hyperammonaemia in some way acts synergistically with the systemic inflammatory 
response to alter the level of consciousness. This concept fits with our recent 
observation in cirrhotic patients, where induction of hyperammonaemia resulted in 
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worsening of neuropsychological tests when the patients were infected and showed 
evidence of an inflammatory response.(170) Following treatment of infection, 
similarly induced hyperammonaemia did not result in an alteration of 
neuropsychological function, supporting the hypothesis that ammonia and 
inflammation may be synergistic.(170) Also, our suggestion of synergy between 
hyperammonaemia and inflammation is also supported by the recent observation 
that BDL rats that were fed a high ammonia diet (and which showed evidence of 
low level of inflammation), developed increases in brain water.(327) However, 
hyperammonaemia and inflammation were present in the LPS-treated HD rats 
without any observed change in conscious level. Given the extent of brain oedema 
observed in the HD rats, with or without administration of LPS, it is surprising to 
note that there was no impact on the level of consciousness. This would suggest 
that there is an as yet undetermined additional factor critical in the progression to 
coma in cirrhotic rats. On this background of cirrhosis, hyperammonaemia and 
superimposed inflammation may then facilitate nitrosation of brain proteins, which 
may be important to neurological function.  
The LPS-administered BDL model used in the present study was developed to 
encapsulate the pathophysiologic features of acute-on-chronic liver failure, which is 
starting to be recognised as a distinct clinical and pathophysiological entity. 
Accordingly, chronic liver disease was induced by ligation of the bile duct, which 
induces secondary biliary cirrhosis, and the superimposed injury was provided by 
the administration of LPS. This model contains the essential clinical features of 
cirrhosis - encephalopathy and mild renal dysfunction with exaggerated 
inflammatory response. Clinically, the animals are haemodynamically stable and 
following LPS are observed to have the typical changes in blood pressure response 
during the 3-hour time frame of the study.(320) Blood electrolytes and osmolarity 
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are maintained, reducing confounding effects. Whether the increase in brain 
oedema is associated with alterations in cerebral blood flow is not clear but the 
electron microscopic appearances of collapsed blood vessels possibly indicate 
reduced cerebral blood flow, which is in keeping with the observation of increased 
cerebrovascular resistance in humans with advanced cirrhosis.(329) 
 
In conclusion, this study provides further evidence to indicate that on a 
background of cirrhosis and hyperammonaemia; superimposed inflammation has an 
important synergistic role in the development of HE. Further studies are needed to 
determine how ammonia and LPS facilitate cytotoxic oedema and pre-coma in 
cirrhosis and determine the role of nitrosation of brain proteins. 
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Legends to figures  
 
Where symbols have been used, they represent the following statistical significance 
between groups; - *p<0.05, **p<0.01 and ***p<0.001 compared to sham-
operated rats; $p<0.05, $$p<0.01 and $$$p<0.010: compared to respective saline 
control rat; #p<0.05, ##p<0.01 and ###p<0.001 compared to HD. 
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 Figure 1: Production of Bile duct-ligated rat model of cirrhosis 
  
Production of bile duct-ligated rat models is associated with the development with jaundice, dark urine and ascites Production of bile duct-ligated rat models 
with A) distended abdomen (gross ascites), B) Ascites and dark urine, C) Ascites, D) Cirrhotic liver, E) Distended gall-bladder F) Splenomegaly, G) Jaundice 
and H) Pale stools (compared to a normal pellet stool with sham-operation 
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Figure 2: Schematic of apparatus used with the Gravimetric technique 
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Figure 3: Perfusion & fixation apparatus  
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Figure 4: Frontal cortex brain water content 
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Compared to sham-operated rats, there was a significant increase in percentage frontal brain water 
content in HD (p<0.01$$) and HD + LPS (p<0.01$) rats. There was no significant difference found 
between sham-operated and BDL saline-treated groups (p=0.237). Following LPS administration, there 
was an increase in brain water in sham-operated (p<0.01**), BDL (p<0.01$$), and HD (p<0.01$) rats. 
Significance was calculated using the Newman-Keuls Multiple Comparison Test (to determine differences 
between all groups).  
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Figure 5: Plasma ammonia levels 
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Plasma ammonia levels as determined by the indophenol detection method. Compared to sham-operated 
saline control rats, there was significantly elevated arterial ammonia in BDL (p=0.019*), HD (p=0.049*) 
and HD + LPS challenged (p=0.042*) rats. There was no significant difference found between the BDL 
and HD saline-treated groups (p=0.237). Significance between two groups was established using T-test 
analysis. 
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Figure 6: 1H-NMR spectra of brain extracts 
 
 
 
 
 
 
 
Segments of 1H-NMR spectra of brain extracts obtained from a sham-operated control, and from rats 
with BDL and HD. Peak assignment abbreviations: Asp: aspartate; Cho: choline-containing compounds; 
Cr: creatine; Gln: glutamine; myo-Ins: myo-inositol; NAA: N-acetyl-aspartate; Tau: taurine. 
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 Figures 7a-c  
                           
Sham
Sham
 +
 LPS
BDL
BDL +
 LPS
HD 
HD +
 LPS
0
50
100
150
200
$
$
$
*
N
it
ra
te
/N
it
ri
te
- 
N
O
x
: 
(m
M
)
 
                        
Sham
Sham
 +
 LPS
BDL
BDL +
 LPS
HD HD +
 LPS
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
$
$
$
N
it
ri
te
 (
N
O
2
2
- )
(µ
M
)
 
                      
Sham
Sham
 +
 LPS
BDL
BDL & LPS
HD HD + LPS
0
50
100
150
200
250
$
N
it
ro
ty
ro
si
n
e
/t
y
ro
si
n
e
 (
N
T
/T
) 
ra
ti
o
 (
p
g
/n
g
)
 
 
Fig A. Plasma nitrite/nitrate levels: There was a significant increase in plasma nitrite/nitrate levels 
with administration of LPS in BDL (p<0.05$), sham-operated (p<0.05$) and HD (p<0.05$) rats compared 
to the respective saline-treated controls; as determined using the T-test to compare 2 groups. A 
significant difference was also found between BDL + saline versus sham-operated + saline rats 
A 
B 
C 
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(p<0.05*). B. Plasma nitrite levels: There was a significant increase in plasma nitrite levels with 
administration of LPS in BDL (p<0.05$), sham-operated (p<0.05$) and HD (p<0.05$) rats; as determined 
using the T-test to compare 2 groups. C. Brain nitrotyrosine levels: There was a significant increase in 
brain nitrotyrosine level in LPS-treated BDL rats compared to saline-treated BDL rats (p=0.01$$), as 
determined using the T-test to compare 2 groups.   
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Figure 8 
 
              
 
Figure 8 A-F: Brain histology: Transitional Electron micrographs (Scale bar, 1 µm), of frontal cortical 
brain sections from, A) Sham-operated rat, showing normal microvessel architecture and lanthanum 
retained within the microvessel lumen; B) BDL rat, showing a collapsed microvessel with moderate 
perimicrovessel oedema and lanthanum retained within the microvessel lumen; C) LPS-treated sham-
operated rat, showing early perimicrovessel oedema and lanthanum retained within the microvessel 
lumen; D) LPS-treated BDL rat, showing a significantly collapsed microvessel with severe 
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perimicrovessel oedema, yet lanthanum still retained within the microvessel lumen; E) HD rat  showing 
a partially collapsed microvessel, with intact endothelium shown by the retention of the lanthanum 
particles in the lumen; pronounced perivascular oedema can be seen. F) HD + LPS-treated rats, 
showing similar disruption of structure to that found in BDL + LPS and HD rats, but with greater 
perivascular oedema and partial microvessel collapse. The blood brain barrier appears intact with no 
leakage of the lanthanum nitrate from the vessel lumen. Abbreviations; (MV) = Microvessel, (E) = 
Perimicrovessel oedema and (Ln) = the ionic tracer ‘lanthanum nitrate’ which is be visualised as small 
black densities opposing the luminal surface of the microvessel. 
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Table 1: Brain water, plasma ammonia, and brain nitrate, nitrite and nitrated proteins 
  
Sham Sham + LPS BDL BDL + LPS HD HD + LPS
Frontal brain water (%) 79.7 ± 0.3 80.9 ± 0.2** 79.9 ± 0.3 80.8 ± 0.2**/$$ 81.1 ± 0.1*** 81.8 ± 0.2***/$
Plasma ammonia (µmol/L) 134 ± 12 127 ± 13 168 ± 14* 172 ± 37* 231 ± 47* 180 ± 38*
Nitrite/Nitrate 39 ± 6 139.7 ± 38* 59 ± 5* 125 ± 14*/$ 44 ± 9 86 ± 19$
Nitrite 1.2 ± 0.3 1.9 ± 0.2* 1.5 ± 0.1 2.9 ± 0.5*/$ 1.2 ± 0.0 2.2 ± 0.4*/$
NT/T 26 ± 10 60 ± 35* 12 ± 2 139 ± 56*/$ 13 ± 1 9 ± 1
 
           
Values are given as mean ± standard error of mean (SEM) of duplicate samples from at least (n=6) rats per group. Statistical analysis was determined using 
the Mann-Whitney U test (for nitrite/nitrate studies) or an unpaired T-test (nitrite alone) to compare corresponding LPS and saline-treated groups. Inter group 
differences for brain water, NT/T ratios were calculated using the Newman-Keuls Multiple Comparison Test. Symbols represent;- *p<0.05, **p<0.01 and 
***p<0.001 compared to sham-operated rats; and  $p<0.05, $$p<0.01 and $$$p<0.010: compared to respective saline control rat. Abbreviations: BDL, bile duct 
ligation; HD, high ammonia diet; LPS, lipopolysaccharide. 
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Table 2:  Plasma biochemical measurements  
Sham Sham + LPS BDL BDL + LPS HD HD + LPS
ALT (U/L) 70 ± 6 90 ± 12 98 ± 15 168 ± 54* 31 ± 2 37 ± 4
Bilirubin (µmol/L) 10 ± 3 24 ± 6 180 ± 18* 181 ± 14* 28 ± 3 32 ± 3
Creatinine (µmol/L) 22 ± 1 24 ± 3 18 ± 0.0 27 ± 5 39 ± 2 32 ± 2
Urea (mmol/L) 5 ± 0.2 5 ± 0.6 5 ± 0.6 9 ± 0.4*$ 7 ± 0.6 6 ± 0.9
Albumin (g/L) 35 ± 2 38 ± 1 26 ± 1* 24 ± 2* 39 ± 0.7 40 ± 0.7
Total protein (g/L) 46 ± 3 48 ± 2 54 ± 3 48 ± 3 51 ± 0.9 51 ± 1
Sodium (mmol/L) 139 ± 2 133 ± 3 141 ± 3 141 ± 3 134 ± 5 141 ± 5
Potassium (mmol/L) 4 ± 0.2 4 ± 0.6 6 ± 0.5 6 ± 0.5 5 ± 0.4 5 ± 0.1
Chloride (mmol/L) 104 ± 1 97 ± 2 106 ± 2 105 ± 3 97 ± 0.9 99 ± 0.9
Osmolarity (mOsm/L) 283 ± 22 270 ± 22 280 ± 23 282 ± 23 280 ± 41 289 ± 40
 
Values are given as mean ± standard error of mean (SEM) of duplicate samples from at least (n=6) rats per group. Statistical analysis was determined using 
the Newman-Keuls Multiple Comparison Test. Symbols represent;- *p<0.05, **p<0.01 and ***p<0.001 compared to sham-operated rats; and  $p<0.05, 
$$p<0.01 and $$$p<0.010: compared to respective saline control rat. Abbreviations: BDL, bile duct ligation; HD, high ammonia diet; LPS, lipopolysaccharide. 
 
 
 
 
 154 
 
Table 3: Brain osmolyte profile as analysed by Proton NMR spectroscopy and brain ammonia 
 
Sham Sham + LPS BDL BDL + LPS HD HD + LPS
Brain Ammonia (µmol/g ww) 0.27 ± 0.08 1.2 ± 0.17 1.0 ± 0.36 2.0 ± 0.66 0.61 ± 0.15 0.80 ± 0.26
Glutamine (µmol/g ww) 4.4 ± 0.21# 4.4 ± 0.12 3.5 ± 0.26### 3.8 ± 0.16 5.4 ± 0.31 5.6 ± 0.24
Myo-inositol (µmol/g ww) 5.6 ± 0.31 5.6 ± 0.31 4.7 ± 0.28 5.5 ± 0.19 4.4 ± 0.23 4.8 ± 0.10
Creatine (µmol/g ww) 7.4 ± 0.11 7.3 ± 0.23 6.6 ± 0.32 6.9 ± 0.34 6.7 ± 0.21 7.5 ± 0.26
NAA (µmol/g ww) 4.1 ± 0.45### 4.1 ± 0.52 2.8 ± 0.14### 3.2 ± 0.13 6.1 ± 0.26 6.3 ± 0.26
Glutamine/Myo-inositol ratio 0.80 ± 0.06### 0.81 ± 0.06 0.73 ± 0.06### 0.69 ± 0.09 1.2 ± 0.09 1.2 ± 0.03
     
 
Values are given as mean ± standard error of mean (SEM) of duplicate samples from at least (n=6) rats per group. Where symbols have been used, they 
represent the following statistical significance between groups;- *p<0.05, **p<0.01 and ***p<0.001 compared to sham-operated rats; $p<0.05, $$p<0.01 and 
$$$p<0.010: compared to respective saline control rat; #p<0.05, ##p<0.01 and ###p<0.001 compared to HD. 
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Table 4: Plasma and brain cytokine profile  
 
Sham Sham + LPS BDL BDL + LPS HD HD + LPS
Plasma TNF-α (nmol/L) 0.03 ±0.02 0.19 ± 0.0 0.05 ± 0.02 1.7 ± 0.13### 0.02 ± 0.001 0.84 ± 0.40#
Plasma IL-6 (nmol/L) 0.053 ± 0.005 2.3 ± 0.27### 0.094 ± 0.035 2.1 ± 0.22### 0.077 ± 0.042 0.89 ± 0.42#
Brain TNF-α (nmol/L) 0.008 ± 0.001 0.065 ± 0.012 0.011 ± 0.002 0.055 ± 0.046 0.057 ± 0.019 0.060 ± 0.033
Brain IL-6 (nmol/L) 1.3 ± 0.24 1.4 ± 0.13 2.1 ± 0.20 2.0 ± 0.50 1.8 ± 0.14 2.0 ± 0.23
 
         
Values are given as mean ± standard error of mean (SEM) of duplicate samples from at least (n=6) rats per group. Statistical significance was calculated using 
Newman-Keuls Multiple Comparison Test. Where symbols have been used, they represent the following statistical significance between groups;- *p<0.05, 
**p<0.01 and ***p<0.001 compared to sham-operated rats; $p<0.05, $$p<0.01 and $$$p<0.010: compared to respective saline control rat; #p<0.05, ##p<0.01 
and ###p<0.001 compared to HD. 
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Research answers 
1. Do systemic changes in ammonia and inflammation act synergistically to 
effect the progression and complications associated with HE as indicated by 
the depth of coma or cerebral oedema?  
 
In the BDL model of cirrhosis the presence of hyperammonaemia and LPS acted 
synergistically to worsen brain oedema and coma. 
 
2. With progression of HE, is there an anatomical or functional alteration of the 
blood brain barrier? 
 
In the LPS challenged BDL model, there was no anatomical disruption of the BBB 
on electron-microscopic analysis. 
 
3. On a background of hyperammonaemia and systemic inflammation, are the 
cerebral effects associated with HE due to alterations in brain ammonia and 
amino acid metabolism, and/or cerebral inflammatory responses?  
 
In the LPS challenged BDL model, systemic inflammation caused a profound 
elevation of an already present low-grade proinflammatory state within the brain 
of BDL and to a lesser extent hyperammonemic rats.  
 
4. Does the LPS challenged BDL rat model represent clinical of ACLF?  
 
Characterisation of the LPS treated BDL model provides us with the first 
reproducible model representative of clinical ACLF and allows for further studies 
into the metabolic & cellular mechanisms involved with the pathogenesis of HE in 
ACLF? 
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Abstract 
Treatment of hyperammonaemia and hepatic encephalopathy in cirrhosis is an 
unmet clinical need. The aims of this study were to determine whether the 
combination, L-ornithine and phenylacetate (administered as the pro-drug 
phenylbutyrate) - ‘OP’, are synergistic and produce sustained reduction in 
ammonia, by L-ornithine acting as a substrate for glutamine synthesis thereby 
detoxifying ammonia and the phenylacetate excreting the ornithine-derived 
glutamine as phenylacetylglutamine in the urine. Study 1: Sprague-Dawley (SD) 
rats were studied 4 weeks after bile-duct ligation (BDL) or Sham-operation. 
Three hours before termination, an internal carotid sampling catheter was 
inserted and intraperitoneal (IP) – saline (placebo), OP (0.6g/kg), 
phenylbutyrate (0.6g/kg) or L-ornithine (0.6g/kg), were administered after 
randomisation. BDL was associated with significantly higher arterial ammonia 
and brain water, and lower brain myo-inositol (p<0.001, respectively) compared 
with sham-operation which was significantly improved in the OP treated animals; 
arterial ammonia (p<0.05), brain water (p<0.05), brain myo-inositol (p<0.001) 
and urinary phenylacetylglutamine (p<0.01). Individually, L-ornithine or 
phenylbutyrate were similar to the BDL group. Study 2: Four week BDL rats 
were randomised to saline or OP (IP) administered for 3, 5 or 10 days. Arterial 
ammonia and amino acids, brain water and brain osmolytes, and urinary 
phenylacetylglutamine were measured. The results showed that the 
administration of OP was associated with sustained reduction in arterial 
ammonia, brain water and markedly increased urinary excretion of 
phenylacetylglutamine. Conclusion: The results of this study provide proof of 
concept that L-ornithine and phenylbutyrate act synergistically to produce 
sustained improvement in arterial ammonia, its brain metabolism and brain 
water.  
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Background  
Hepatic encephalopathy (HE) incorporates a spectrum of mental disturbances 
observed in patients with liver disease, ranging from minimal effects on quality 
of life, to coma and death.(6) Hyperammonaemia is considered central to the 
pathogenesis of HE, with arterial ammonia levels correlating with severity of 
intracranial hypertension and prediction of deaths from cerebral herniation in 
acute liver failure commensurate with an increase in brain delivery and uptake of 
ammonia.(116, 146) In cirrhosis, induction of hyperammonaemia has been 
shown to be associated with deterioration in neuropsychometric tests, worsening 
of brain osmolytes and increase in brain water.(307) The severity of HE in 
cirrhosis correlates with plasma ammonia levels confirming that ammonia 
lowering is an important goal for the treatment of HE. Therapy of 
hyperammonaemia and HE in patients with liver disease remains an unmet 
clinical need as the current ammonia-lowering therapies for HE have not been 
conclusively proven to be of value.(47, 48)  
Studies of interorgan metabolism in liver failure have suggested that when the 
ammonia removing capacity of the liver is reduced, the muscles, gut and the 
kidneys interact to try and maintain ammonia levels.(112, 115, 133, 330) 
Glutamine acts as both a sink for excess ammonia, by ammonia combining with 
glutamate to produce glutamine (through the enzyme glutamine synthetase), or 
as a source for ammonia release (through the enzyme glutaminase).(61) 
Skeletal muscle glutamine synthetase activity is normally low, but has been 
shown to be up-regulated in liver failure.(131) Therefore, supplying glutamate to 
the large mass of skeletal muscle, increasing glutamine production, can be an 
alternative therapeutic target for ammonia detoxification.  
As glutamate is not transported into muscle cells readily, glutamate can be 
provided to the muscle as L-ornithine, consuming ammonia to produce 
glutamine. This mode of delivery is utilised by the agent L-ornithine L-aspartate 
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(LOLA), which has been used for the treatment of the HE. However, although 
some randomised controlled trials with LOLA have reported reductions in plasma 
ammonia and improved psychometric test scores,(245, 248) recent observations 
suggest that the reduction in plasma ammonia with administration of LOLA 
maybe associated with a later increase in ammonia once LOLA is 
discontinued.(132) This is likely due to a significant rise in glutamine levels, 
which eventually becomes a source for ammoniagenesis by the kidney and gut 
through the effects of glutaminase.(133) This preliminary observation will have 
to be confirmed in future studies. Phenylacetate (administered as the pro-drug 
phenylbutyrate), which has been used to treat the hyperammonaemia of urea 
cycle enzyme deficiencies,(238) can effectively remove excess glutamine 
(derived from glutamate) to make phenylacetylglutamine which can be excreted 
by the kidneys, thereby removing it as a substrate for ammoniagenesis. 
However, unlike urea cycle enzyme deficiency where the liver is normal and 
usually the glutamine concentrations are markedly elevated; in cirrhosis the liver 
is dysfunctional and the plasma glutamine concentrations are variable being 
usually normal or mildly elevated;(115, 132, 133, 238, 307) making it unlikely 
that phenylacetate alone would be a useful treatment for HE.  
 
Research Hypothesis 
The above observations have led to the hypothesis for a novel ammonia-
lowering therapy, combining L-ornithine and phenylacetate (OP),(132) for the 
treatment of hyperammonaemia and HE. OP has the advantage that any 
ammonia trapped as glutamine (derived from the administered L-ornithine) will 
not be available for later return to the circulation, resulting in net removal and 
reduction in ammonia concentration, Figure 1. 
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Research question 
5. Can the novel therapeutic agent OP, by targeting inter-organ ammonia & 
amino acid metabolism, ameliorate the hyperammonaemia and development 
of advanced HE in cirrhotic rats? 
6. What are the interorgan pathophysiological mechanisms involved?  
7. Can ammonia lowering with OP last throughout a prolonged administration?  
8. By lowering ammonia, can OP lead to a reduction in brain water? 
 
Aim of study 
The aims of this proof of concept study were to determine whether the 
combination, L-ornithine and phenylacetate are synergistic in reducing 
hyperammonaemia by L-ornithine acting as a substrate for glutamine synthesis 
thereby detoxifying ammonia and phenylacetate excreting the ornithine derived 
glutamine as phenylacetylglutamine in the urine. To test our hypothesis(132) we 
chose our well characterised bile duct ligated (BDL) rat model of cirrhosis as it 
exhibits characteristic hyperammonaemia, alterations in brain osmolytes and 
cytotoxic brain oedema.(331) The first part of the study was a 3 hour study to 
determine whether L-ornithine and phenylacetate were synergistic in reducing 
ammonia in this model compared with L-ornithine or phenylacetate alone. The 
second part of the study was designed to determine whether administration of 
OP achieved sustained reduction in ammonia over a 10 day period. 
 
Declaration 
This work was undertaken with a proportion of the funding from a Sheila 
Sherlock entry-level fellowship awarded by the European Association for the 
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Methods 
All animal experiments were conducted according to Home Office guidelines 
under the UK Animals in Scientific Procedures Act 1986. Male Sprague-Dawley 
(SD) rats (body weight 230–280g) were obtained from the comparative 
biological unit at University College London. All rats were housed in the unit and 
given free access to standard rodent chow and water, with a light/dark cycle of 
12 hours, at a temperature of 19–23°C and humidity of approximately 50%. 
Animal models 
Bile-duct Ligation: Under anaesthesia (diazepam 1mg/kg intravenous (I.V), 
followed by Hypnorm® 150µl/kg intramuscular (I.M), Janssen Pharmaceutica, 
Belgium) all rats underwent bile duct ligation to induce biliary cirrhosis, or a 
Sham-operation as described previously.(306) In study 1, BDL rats were 
administered a high protein/ammoniagenic diet for 7 days prior to inclusion in 
the study. The diet consisted of a liquid rodent feed (Bioserve, Frenchtown, NJ 
08825, USA) and a tailor-made mixture mimicking the amino-acid composition 
of haemoglobin molecule (4g/Kg/day Nutricia, Cuijk, The Netherlands) as 
described previously(115, 307) mixed with commercially available gelatin to 
prevent sedimentation. As described previously, this regimen produces chronic 
hyperammonaemia.(331) 
Study Design 
The following two studies were performed sequentially. 
Study 1: Four weeks after surgery, the BDL animals were randomised into four 
groups. Three hours before termination, an intraperitoneal (IP) injection of, L-
ornithine (0.6g/kg), phenylbutyrate (0.6g/kg), combined L-ornithine (0.6g/kg) 
and phenylbutyrate (0.6g/kg), or saline (placebo) were administered; doses 
based on preliminary dosing experiments. The sham animals were treated in the 
same manner but administered saline IP. The final study groups were: (1) 
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Sham-operated + saline (n=7) (2) BDL + saline (n=7), (3) BDL + ornithine 
(n=7), (4) BDL + phenylbutyrate (n=8) and (5) BDL + OP (n=8).  
On the day of the experiment, following anaesthesia and immediately prior to 
the administration of study medication, a right internal carotid catheter 
(1.22mm portex fine bore polythene tubing, Scientific Laboratory supplies Ltd, 
Nottingham, UK) was inserted as previously described.(320) In brief, the 
procedure involved a midline cervical insertion with isolation and catheterisation 
of the right carotid artery (post-clamping). The catheter was held in place for the 
duration of the study by both a proximal and distal holding suture. Once in place 
blood sampling was undertaken. The catheter was kept patent by a heparinised 
saline block. The rats were allowed free access to food and water for the period 
of 3 hours post-intervention in a temperature controlled environment and were 
then sacrificed by exsanguination under anaesthesia (Hypnorm 200µL/kg I.M), 
20 minutes after diazepam (1mg/kg I.P). Blood was withdrawn from the 
descending aorta and immediately put into ice cold heparin/EDTA containing 
tubes (until full exsanguination), centrifuged at 3120 x g and 4oC, and the 
plasma collected and stored at -80°C until assayed. Urine samples were 
collected at the time of sacrifice by direct bladder puncture, and snap-frozen and 
also stored at -80°C. Brain samples, were also collected as described later. 
Study 2: BDL animals were randomised into four groups. All animals were 
sacrificed at 4-5 weeks after the initial surgery. Study medications included IP 
injection of, L-ornithine (0.3g/kg), phenylbutyrate (0.3g/kg), combined L-
ornithine (0.3g/kg) and phenylbutyrate (0.3g/kg), or saline (placebo) in two 
divided doses administered 10 hours apart. The sham animals were 
administered saline IP for 10 days prior to sacrifice. The final study groups were: 
(1) Sham-operated + saline (n=7) (2) BDL + saline (n=7), (3) BDL + OP for 3 
days (n=6) (4) BDL + OP for 5 days (n=6) and (5) BDL + OP for 10 days (n=6). 
As per protocol, the rats sacrificed by exsanguination under anaesthesia 
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(Hypnorm 200µL/kg I.M), 20 minutes after diazepam (1mg/kg I.P). Blood, urine 
and brain samples were collected as described above.  
Arterial ammonia, ornithine, glutamate and glutamine 
250µL of plasma was deproteinised with 20mg of dry sulfosalicylic acid and the 
amino acid concentrations analysed by high performance liquid chromatography 
(HLPC) as previously described(332) (performed and analysed by Dr Nathan 
Davies, the Institute of Hepatology, UCL). Then 900µL plasma was deproteinised 
with 90µL trichloroacetic acid (TCA) for measurement of plasma ammonia 
concentrations. The substrate concentrations were measured by using a COBAS 
Mira S (Roche Diagnostica, Hoffman-La Roche, Switzerland).(333) 
Brain water  
Immediately after death, the whole brain was rapidly removed and 50mm2 
samples were dissected from the frontal cortex (grey matter). Brain tissue water 
content was determined using a previously described dry weight technique.(322, 
334) 
Brain Proton magnetic resonance spectroscopy (1H-MRS) 
Snap frozen cortical brain samples were processed and analysed by 1H-NMR 
using a previously described technique(38)  using the brain tissue from animals 
in Study 1 (performed and analysed by Dr Claudia Zwingmann, University of 
Montreal, Canada). 1H-NMR spectra were recorded on a Bruker WB 360 
spectrometer using a 5-mm QNP probe, 100-200 accumulations, repetition time 
16 s, spectral width 3623 Hz, data size 16 K, zero filling to 32 K. Chemical shifts 
were referenced to lactate at 1.33 ppm. Total metabolite concentrations (µmol 
per gram wet weight) were analysed from 1H-NMR spectra of PCA extracts using 
(trimethylsilyl)propionic-2,2,3,3d4-acid as external standard.(314) 
Urinary phenylacetylglutamine 
The urine concentration of phenylacetylglutamine was measured using liquid 
chromatography tandem mass spectrometry (LCMS), based on a modified 
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method previously described(335) (performed and analysed by Dr L.M Ytrebo 
and O,M Fuskevag, University of Tromsø, Norway), In brief, the urine samples 
were prepared by adding 50µl of 0.1mol/L phosphate buffer solution (pH 2.4), 
50µl of 60µmol/L internal standard, 3-(4-hydroxyphenyl)propionic acid (Sigma-
Aldrich, Steinheim, Germany) and 50µl of urine in a 4.5 ml polypropylene tube 
(Sarstedt, Germany). To the same tube, 1ml of tert-buthyl methyl ether was 
added as the extractant. The tubes were capped, mixed by shaking for 1 min 
and centrifuged at 1700g for 180s. 750µl of the supernatant (in clean 
polypropylene tube) was evaporated to dryness under a stream of nitrogen at 
40°C. The residue was then reconstituted in 100µl mobile phase. Samples were 
analysed by LC/MS/MS using Waters AcquityTM UPLC system with an auto-
sampler and a binary solvent delivery system (Waters, Milford, MA) interfaced to 
Waters Micromass® Quattro Premier™ XE benchtop tandem quadrupole mass 
spectrometer (Waters, Manchester, UK). The chromatography was performed on 
a 100 x 2.1mm Waters AcquityTM BEH C18 1.7mm column. The mobile phase 
consisted of 50% methanol in 10mmol/L aqueous formic acid with a flow rate of 
0.2 ml/min (isocratic). The PAG standard was supplied by Bachem (Bubendorf, 
Switzerland). The method showed good linearity and reproducibility with a 
correlation coefficient (r) of >0.99 and a coefficient of variation of <5%.  
Statistics 
Data are expressed as mean ± SEM. Significance of difference was tested with 
Newman-Keuls multiple comparison test or two-way ANOVA; p<0.05 was taken 
to be statistically significant. Software used included Microsoft Excel 2003 
(Microsoft Corp., Redmond, WA) and GraphPad Prism 4.0 (GraphPad Software, 
Inc., San Diego, CA).  
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Results  
All rats continued to gain weight following surgery. From the final weight taken 
immediately prior to termination, BDL rats (mean ± SEM; 320g ± 14), were not 
significantly different to Sham-operated controls (mean ± SEM; 301g ± 19). The 
systemic hemodynamics in the BDL animals were well maintained as previously 
shown.(320, 331) All rats were alive after injection of study medication in each 
of the study groups. 
Arterial ammonia 
Study 1: Three hours after the administration of OP (0.6 mg/kg), the arterial 
ammonia levels were significantly reduced by 45% from the baseline value, from 
a mean ± SEM of 231.9 ± 18.7 to 150.7 ± 10.00 (p<0.05) (Figure 2A). The 
ammonia level was already reduced at 1 hour following administration of OP but 
did not reach statistical significance at this time (Table 1). The arterial ammonia 
levels achieved at the end of the 3 hour period in the OP animals was not 
significantly different to the sham animals. No significant change in ammonia 
was observed in the animals treated with placebo, L-ornithine (0.6 mg/kg) or 
phenylbutyrate (0.6 mg/kg) alone; Table 1 and Figure 2A. 
Study 2: Bile duct-ligation induced significant hyperammonaemia (p<0.001) 
compared to Sham-operated controls (Figure 2B). Following administration of OP 
(0.6 mg/kg), there was a sustained a significant reduction in arterial ammonia at 
3 (p<0.001), 5 and 10days (p<0.01, respectively) compared to BDL controls. 
Ornithine, Glutamate and Glutamine 
Study 1: There was a significant increase in the plasma ornithine concentration 
of the BDL rats administered L-ornithine (p<0.05) or OP (p<0.05), Table 1. This 
initial increase started to decline by 3 hours as the L-ornithine was metabolised. 
Following the increased circulating levels of ornithine and its later metabolism in 
the BDL + OP rats, an initial rise (at 1 hour) of glutamate was observed which 
then fell (at 3 hours), associated with a progressive rise in glutamine (from 1 
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hour) reaching statistical significance by T= 3 hours (p<0.05), Table 1. No 
significant change in ornithine level was observed in the phenylacetate alone 
group but the glutamine level at 3 hours was lower but this did not reach 
statistical significance. The changes in glutamate concentrations were not 
statistically significant in any of the groups. 
Study 2: There was a significant and sustained increase in the ornithine 
concentration in the entire OP treated animals compared with the placebo 
treated groups. Ornithine concentration was markedly higher in the animals 
treated for 5 and 10 days compared with the animals treated for 3 days (Table 
2). Similarly, glutamine concentrations were significantly higher in the OP 
treated animals reaching twice the concentrations observed in the placebo 
treated group. However, this was not significantly different between the animals 
treated for 3 days compared with the animals treated for 5 or 10-day periods. 
The change in glutamate concentration was not significantly different between 
any of the OP treated groups compared with the placebo treated group. 
Brain water  
Study 1: There was a significant increase in the water content in the frontal 
cortex of saline (and ammoniagenic feed) treated BDL rats compared with the 
corresponding Sham-operated rats, p<0.01; Figure 3A. This increase in brain 
water in BDL rats was significantly attenuated by administration of OP, 
compared with the BDL animals administered placebo (p<0.05) to values that 
were not significantly different to the Sham-operated controls. Brain water was 
not significantly different in the BDL rats given L-ornithine, or phenylbutyrate 
alone compared with the animals treated with placebo. 
Study 2: With administration of OP, over 3, 5 and 10 days, there was a marked 
and significant reduction in frontal brain water content in each of the groups 
(p<0.01, respectively) when compared with the placebo treated animals which 
have a higher brain water content compared with the sham animals (p<0.01) 
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(Figure 3B). The brain water content in each of the OP treated groups was not 
significantly different to the sham group. 
Proton NMR spectroscopy 
Study 1. In BDL animals, brain glutamine was not different but the brain myo-
inositol was lower (p<0.001, Figure 4), compared with Sham-operated controls, 
Table 2. Following administration of OP to BDL rats, there was a significant 
increase in brain myo-inositol levels (p<0.001, Figure 4). This resulted in a 
significant reduction in the glutamine/myo-inositol ratio (p<0.001) to values that 
were not significantly different to sham-operated controls. Following 
administration of L-ornithine or phenylbutyrate alone, there was no significant 
change in glutamine or myo-inositol levels, Figure 4 and Table 3.  
Urinary phenylacetylglutamine  
Study 1: In the sham group and the BDL animals treated with L-ornithine alone 
phenylacetate alone, the urinary concentration of phenylacetylglutamine was not 
significantly different to zero. There was a significant increase in urinary 
phenylacetylglutamine excretion following administration of OP to BDL rats 
compared to placebo treated BDL and Sham-operated control rats, p<0.01 
respectively; Figure 5A. 
Study 2: With administration of OP, over 6 hours, 3, 5 and 10 days, there was a 
significant increase in urinary phenylacetylglutamine excretion that increased 
with ongoing administration in each of the groups over the 10 day period 
(p<0.01, respectively) when compared to the sham animals and the placebo 
treated BDL control rats in whom the excretion of phenylacetylglutamine was not 
significantly different to zero (Figure 5B). The concentration of 
phenylacetylglutamine in the urine in the animals treated for 3, 5 and 10 days, 
was about 20 times higher in the urine compared with that observed at the 3 
hour time-point. In the acute study (Study 1), the concentration of 
phenylacetylglutamine at the 3 hours time point was approximately 
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10micromol/L which was increased to approximately 200micromol/L in the 
animals treated for 3, 5 and 10 days.  
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Discussion 
The results of this study demonstrates a synergy between L-ornithine and 
phenylacetate in reducing arterial ammonia levels in BDL rats to values that 
were not significantly different to sham operated controls. This reduction in 
ammonia was associated with a significant reduction in brain glutamine/myo-
inositol ratio, which was associated with a normalisation of brain water. These 
effects of OP were sustained during a 10-day period of administration with 
respect to both a marked reduction in ammonia and also in brain water without 
any evidence of a rebound increase in ammonia. According to the proposed 
hypothesis, the reduction in ammonia was associated with an increase in arterial 
glutamine and urinary phenylacetylglutamine.  
The observed reduction in ammonia in the OP treated animals was associated 
with an initial increase in circulating ornithine at 1 hour in both the OP and L-
ornithine treated rats, which at 3 hours was substantially reduced. In accordance 
with the first part of the hypothesis, an increase in the glutamine at 3 hours was 
also observed. These changes in glutamine levels are consistent with previous 
observations of increased skeletal muscle glutamine synthetase activity and the 
effect of administration of LOLA to devascularised rats.(249) In the BDL animals 
treated with OP for up to 5 and 10 days, the ornithine levels continued to 
increase to twice the values seen in the animals treated for up to 3 days but the 
glutamine levels remained similar in the animals treated for 6 hours or 3 days 
compared with the animals treated for 5 or 10 day period indicating perhaps that 
the doses of ornithine used in OP could be reduced. This will however need to be 
tested in future studies. 
The demonstration of phenylacetylglutamine in the urine of animals treated with 
OP supports the hypothesis that glutamine generated by the administration of L-
ornithine can be conjugated and excreted as phenylacetylglutamine by co-
administration of phenylbutyrate. It is interesting to note that the urinary 
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concentration of phenylacetylglutamine in the phenylacetate alone group was 
not significantly different to zero indicating possibly that the conjugation may 
require an elevated level of glutamine. This hypothesis will have to be tested in 
future studies. However, in the acute study (Study 1) there was a lack of 
stoichiometry between the reduction in arterial ammonia concentration and the 
increase in urinary phenylacetylglutamine. Although, this may be due to 
differences in conjugation pathways, as in humans, phenylacetylglutamine is the 
overwhelming renal excretion product of the reaction between phenylbutyrate 
and glutamine but in rats this association is less clear, as there are a number of 
additional by-products of phenylacetate metabolism.(336) It is more likely that 
the explanation may be related to kinetics of phenylacetylglutamine excretion. 
Phenylacetylglutamine is conjugated intracellularly and therefore requires time 
to be excreted from the system as illustrated by a 20-fold increase in the 
concentration of urinary phenylacetylglutamine in the animals treated for 3-10 
days. The measured high concentration of phenylacetylglutamine in the urine 
together with twice the concentration of arterial glutamine in the OP treated 
animals explains in great part the observed reduction in ammonia. More detailed 
pharmacokinetic modelling studies will be necessary to determine exact 
relationship between the reduction in ammonia, urinary excretion of 
phenylacetylglutamine and the increase in glutamine concentration. 
The results of ammonia reduction observed in the present study using OP has 
been confirmed in pigs with acute liver failure induced by hepatic 
devascularisation where over an 8 hour period the ammonia concentration was 
reduced by ~300µmol/L compared with a group treated with L-ornithine, 
phenylbutyrate or placebo indicating synergy between ornithine and 
phenylacetate.(337) Importantly, the effect was observed in animals that were 
effectively anhepatic. Similar increases in urinary phenylacetylglutamine were 
also demonstrated. Arterial ammonia was also shown to be reduced by about 
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30% over a 3 day period in 2 patients treated with a combination of L-ornithine 
and phenylacetate providing further proof for hypothesis.(132) 
The most important finding of this study was the observation that the elevated 
brain water observed in the BDL animals was reduced in the OP group to values 
that were not significantly different to the sham operated controls. Again, this 
effect was maintained throughout the 10 day period of administration as 
observed with ammonia-lowering. Although there was an unexpected increase in 
brain water with the administration of phenylbutyrate and L-ornithine alone, this 
was not statistically significant when compared to placebo treated BDL controls. 
The effect of OP on the brain water in BDL animals is consistent with the 
observations in the porcine acute liver failure model where administration of OP 
prevented the rise in intracranial pressure to levels that were not significantly to 
sham operated controls.(337) The reduction in arterial ammonia following OP in 
the 2 patients referred to above was associated with an improvement in the 
mental state,(132) an observation that will have to be tested in appropriate 
clinical trials.  
Several lines of investigations indicate that the cytotoxic brain oedema observed 
in patients with hyperammonaemia is associated with alterations in the brain 
osmolytes, which is characterised by an increased brain glutamine and likely 
compensatory reduction in myo-inositol.(149, 305, 338) Accordingly, the 
glutamine/myo-inositol ratio was used as a measure of this association, which 
was significantly higher in the BDL animals compared with placebo treated BDL 
controls, with a non-statistical 25% increase in glutamine and reduced myo-
inositol consistent with the hypothesis. Interestingly, the glutamine/myo-inositol 
ratio was reduced in the OP treated animals to levels that were not significantly 
different to Sham-operated controls; due largely to an increase in brain myo-
inositol levels was observed.(305, 307, 339) Although the rise in myo-inositol 
wih OP treatment in BDL rats is hard to explain and possibly counterintuitative to 
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the ‘ammmonia-glutamine-brain water hypothesis’, it is possible that other 
intracellular osmolytes (e.g. taurine), or energy metabolsm or temporal 
considerations (e.g. lactate) are potential further important compensatory 
factors; this will require ongoing study. 
In the groups treated with L-ornithine or phenylbutyrate alone, no significant 
changes in either glutamine or myo-inositol were observed. It is likely that the 
effect of OP on the brain osmolytes is due to a reduction in arterial ammonia, 
which was recently shown in devascularised pigs to be associated with a 
reduction in extracellular brain ammonia.(149) From the pathophysiological 
perspective, this prevention of reduction in myo-inositol may imply an increase 
in the brain buffering capacity to the effects of other precipitants such as a 
further hyperammonaemia or hyponatraemia; stimuli that are known to increase 
brain swelling.(33, 305) Similar corrections in brain osmolytes have been 
induced by treatment of clinically overt HE with Lactulose, which was principally 
shown to ameliorate reduction of brain myo-inositol with liver failure rather than 
correct the rise in intracellular glutamine.(340) Though the observed modulation 
of brain myo-inositol, which correlated with severity of HE, was observed after 1 
week of lactulose, it is known that changes in levels of intracellular osmolytes 
like myo-inositol occur within hours,(341) as observed in this study. In rats 
given IP inositol, the levels of myo-inositol in the brain cortex rise by 33% as 
early as 2 hours.(341) This is likely to be associated with a very early and 
demonstrable increase in the transcription of brain Na+/myo-inositol co-
transporter (SMIT) in response to certain insults like changes of osmotic 
gradient.(342)  
 
In conclusion, the results of this study provide support for our concept that 
combining L-ornithine with phenylbutyrate synergistically attenuates 
hyperammonaemia by increasing ammonia detoxification into glutamine and 
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eliminating the resultant glutamine as urinary phenylacetylglutamine. 
Furthermore this ammonia-lowering effect is sustained over the 10-day period of 
administration without any evidence of a rebound phenomenon. We also show 
that OP by reducing plasma ammonia modulates brain osmolytes, which is 
associated with a reduction in brain water. The data indicate that OP is likely to 
be beneficial for the treatment of HE, and as the individual components, i.e. L-
ornithine and phenylbutyrate are already in use in man, it is likely that these 
findings can be translated relatively quickly into appropriate clinical studies to 
determine exact dosing, pharmacokinetics, safety and efficacy.  
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Figure 1: Schematic demonstrating the glutamate-glutamine cycling and 
the hypothesised mechanism of action of the novel drug L-ornithine, 
phenylacetate (OP)  
 
 
OP acts to reduce ammonia concentration in liver failure. L-ornithine acts as a substrate for 
glutamine synthetase, thereby detoxifying ammonia into glutamine. Phenylacetate combines with the 
glutamine that is generated, excreting it as phenylacetylglutamine. 
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Figure 2: Changes in arterial ammonia 
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A) Shows a reduction in arterial ammonia concentration from baseline at 3 hours post administration 
of OP (**p<0.01) compared to BDL controls, and at 3 hours were no different to Sham controls. B) 
Shows a sustained reduction in arterial ammonia following administration of OP for 3 ($$$p<0.001), 5 
and 10days ($$p<0.01, respectively) compared to hyperammonemic (***p<0.001) BDL controls. 
Abbreviations: BDL, bile duct ligation; OP, L-ornithine, phenylacetate; P, Phenylbutyrate; and O, L-
ornithine. 
A 
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Figure 3: Frontal cortex brain water content:  
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A) There was a significantly higher water content in the frontal cortex of BDL rats (**p<0.01) 
compared with Sham-operated controls. Administration of OP resulted in a significant reduction in 
brain water ($p<0.05) compared to BDL controls. B) Shows a sustained reduction in frontal brain 
water content (%) following 3, 5 and 10days ($$p<0.01, respectively) administration of OP compared 
to BDL controls with an established high water content (**p<0.01).  Abbreviations: Sham-operated, 
Sham-control; BDL, bile duct ligation; OP, phenylbutyrate; O, L-ornithine and P, phenylacetate. 
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Figure 4: Absolute Brain Myo-inositol levels 
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Bile duct-ligation was associated with a significant reduction in brain myo-inositol level (***p<0.001) 
Sham-operated controls. Administration of OP to BDL rats significantly increased the myo-inositol 
level ($$$p<0.001) compared to BDL controls, to levels that were no different to Sham-operated 
controls. Administration of L-ornithine or phenylbutyrate alone had no statistically significant effect 
on myo-inositol levels compared to BDL controls. Abbreviations: Sham-operated, Sham-control; 
BDL, bile duct ligation; OP, phenylacetate; O, L-ornithine and P, phenylacetate. 
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Figure 5: Urinary phenylacetylglutamine excretion 
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A) There was a significant increase in urinary phenylacetylglutamine following administration of OP 
to BDL rats (**p<0.01) compared to both Sham-operated and BDL controls. B) Shows a profound 
and progressive increase in phenylacetylglutamine with OP administration over 3-10 days (*p<0.01, 
respectively); peaking at 5 days (**p<0.001) compared to BDL controls. Abbreviations: Sham-
operated, Sham-control; BDL, bile duct ligation; and OP, L-ornithine, phenylacetate. 
B 
A 
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Table 1: Longitudinal changes (over 3 hours) in the plasma Ammonia, Ornithine, Glutamate and Glutamine  
 
Plasma ammonia and amino acid concentrations (µmol/L)
Hours BDL BDL + O BDL + P BDL + OP
AMMONIA
0 202 ± 20 218 ± 31 211 ± 20 232 ± 19
1 211 ± 16 232 ± 44 300 ± 40 220 ± 24
3 198 ± 24 217 ± 14 256 ± 21 151 ± 10*
ORNITHINE
0 51 ± 5 48 ± 4 46 ± 2 68 ± 14
1 42 ± 2 448 ± 65* 49 ± 6 387 ± 35**
3 66 ± 2 114 ± 20 45 ± 2 239 ± 82
GLUTAMATE
0 151  ± 7 256 ± 63 139 ± 11 135 ± 6
1 126  ± 9 205 ± 74 207 ± 44 320 ± 55
3 165 ± 19 172 ± 14 174 ± 30 212 ± 53
GLUTAMINE
0 605 ± 40 487 ± 62 633 ± 25 442 ± 62
1 576 ± 25 663 ± 41 651 ± 35 663 ± 41
3 670 ± 11 649 ± 52 516 ± 58 735 ± 67*
 
 
Data are expressed as mean ± standard error of mean (SEM) Symbols represent; - *p<0.05, **p<0.001 and ***p<0.001 compared to baseline (T= 0hours) for that group. 
Abbreviations: BDL, bile duct ligation; OP, L-ornithine, phenylacetate; P, Phenylbutyrate; and O, L-ornithine. 
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Table 2: Longitudinal changes (over 10 days) in the plasma Ammonia, Ornithine, Glutamate and Glutamine 
 
 
Plasma ammonia and amino acid concentrations (µmol/L)
Sham-operated BDL BDL + OP 3 days BDL + OP 5 days BDL + OP 10 days
AMMONIA 67 ± 6 186 ± 20*** 69 ± 17$$$ 91 ± 24$$ 87 ± 23$$
ORNITHINE 60 ± 35 51 ± 54 322 ± 43$$ 1293 ± 395$$$ 1313 ± 279$$$
GLUTAMATE 101 ± 21 169 ± 21 256 ± 79 196 ± 27 238 ± 75
GLUTAMINE 490 ± 25 525 ± 36 1198 ± 291$$ 1297 ± 139$$ 1224 ± 143$$
 
 
Data are expressed as mean ± standard error of mean (SEM) Symbols represent; - *p<0.05, **p<0.001 and ***p<0.001 compared to Sham-operated control rats; $p<0.05, 
$$p<0.01 and $$$p<0.001 compared to BDL control rats. Abbreviations: BDL, bile duct ligation; OP, L-ornithine, phenylacetate; P, Phenylbutyrate; and O, L-ornithine. 
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Table 3: Brain osmolyte profile as analysed by Proton Magnetic Resonance Spectroscopy 
 
     
Sham-operated BDL BDL + O BDL + P BDL + OP
Glutamine (µmol/g ww) 4.4 ± 0.2 5.1 ± 0.2 4.8 ± 0.2 4.8 ± 0.2 5.1 ± 0.2
Myo-inositol (µmol/g ww) 5.7 ± 0.3 3.9 ± 0.2*** 4.4. ± 0.1 4.3 ± 0.2 5.4 ± 0.2$$$
Creatine (µmol/g ww) 7.4 ± 0.1 6.6 ± 0.3 6.8 ± 0.3 6.8 ± 0.2 7.5 ± 0.2
Frontal brain water % 76.1 ± 0.4 77.9 ± 0.4* 77.9 ± 0.3$ 79.2 ± 0.2$$$ 76.0 ± 0.7$
 
 
Data are expressed as mean ± standard error of mean (SEM) Symbols represent; - *p<0.05, **p<0.001 and ***p<0.001 compared to Sham-operated control rats; $p<0.05, 
$$p<0.001 and $$$p<0.001 compared to BDL control rats. Abbreviations: BDL, bile duct ligation; OP, L-ornithine, phenylacetate; P, Phenylbutyrate; and O, L-ornithine. The 
brain osmolyte absolute values are expressed in micromoles per gram wet weight (µmol/g ww). 
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Research answer 
1. Can the novel therapeutic agent OP, by targeting inter-organ ammonia & 
amino acid metabolism, ameliorate the hyperammonaemia and development 
of advanced HE in cirrhotic rats? 
 
In a bile duct-ligated rate model of secondary cirrhosis, OP, due to the 
synergistic action of L-ornithine and phenylacetate, ameliorated 
hyperammonaemia.  
 
2. Can any ammonia-lowering effect of OP last throughout a prolonged period 
of administration? 
 
OP was able to maintain a reduction in plasma ammonia throughout a 10 day 
period of administration. 
 
3. What are the inter-organ pathophysiological mechanisms involved?  
 
As hypothesised, OP increases muscle glutamine production (through provision 
of L-ornithine) with its combination with phenylacetate and eventual excretion in 
urine as phenylacetylglutamine. 
 
4. By lowering ammonia, can OP lead to a reduction in brain water? 
 
There was an observed reduction in brain water with administration of OP.  
 
5. What were the pathophysiological mechanisms involved?  
 
Reduction in brain water was likely related to the restoration of brain myo-
inositol levels driven by a reduction in extracellular brain ammonia induced by 
OP. 
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induced worsening in brain oedema and progression to pre-coma stages 
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Abstract 
In liver failure, inflammation synergistically modulates the cerebral effects of 
ammonia, with interventions targeting either hyperammonaemia or inflammation 
limiting progression of hepatic encephalopathy (HE). Aim: To test whether 
reduction in ammonia (with L-ornithine, phenylacetate - OP) prior to 
administration of LPS would prevent the deleterious brain consequence of LPS 
administration in a rat model of cirrhosis to mimic ‘acute-on-chronic liver failure’ 
(ACLF). Furthermore, to evaluate the role of the anti-TNF - Infliximab, on 
inflammatory pathways and in combination with OP. Method: Sprague-Dawley 
rats were studied 4 weeks post bile-duct ligation (BDL) or sham-operation 
(sham). BDL rats were randomised to 3 days intraperitoneal (IP) injections of OP 
(0.6g/kg, based on chapter 3 experiments) and/or Infliximab (10mg/kg, based 
on prior validated rat studies), or saline. Three hours before termination, all BDL 
rats received IP LPS (1mg/kg). Study groups were 1) sham 2) BDL + saline 3) 
BDL + LPS 4) BDL + LPS + OP, 5) BDL + LPS + Infliximab and 6) BDL + LPS + 
OP + Infliximab. Consciousness, brain water content, arterial ammonia, plasma 
biochemistry and regulatory (plasma and cortical brain) cytokines were 
assessed. Results: Survival analyses comparing BDL + saline, versus BDL + 
LPS rats was highly significant (Log-rank: p<0.0001), with OP significantly 
limiting progression to pre-coma/coma stages (Log-rank: p<0.009), but not with 
Infliximab. Compared to sham-operation, BDL was associated with significantly 
higher arterial ammonia (p<0.001), plasma TNF-α and IL-6 levels (p<0.05, 
respectively), but only a trend to increased brain water (p=0.07) and brain TNF-
α and IL-6 levels. Addition of LPS significantly worsened coma stage, brain water 
(p<0.01) and augmented plasma TNF-α and IL-6 levels (p<0.001, respectively) 
and brain TNF-α levels (p<0.05), though non-significant increase in brain IL-6 
levels. Giving OP to LPS-treated BDL rats significantly reduced arterial ammonia 
and brain water (p<0.001 and p<0.01, respectively), and lead to a non-
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significant reduction in plasma and brain cytokines. Infliximab, significantly 
reduced plasma TNF-α and IL-6 (p<0.001 and p<0.01, respectively) with only a 
trend to reduced brain water (p=0.167) and brain TNF-α and IL-6 levels. Co-
administered OP and Infliximab improved brain water (and coma score) but not 
significantly different to giving just OP alone (p=0.3). Conclusion: The findings 
of this study substantiate the predominant role of ammonia in priming the brain 
to the deleterious effect of LPS and suggest that a reduction in arterial ammonia 
concentration with OP may prevent LPS induced worsening of HE and brain 
oedema; though the mechanism of how ammonia primes the brain remains 
uncertain. 
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Background 
Several studies support the hypothesis that ammonia and inflammation are 
synergistic in the pathogenesis of hepatic encephalopathy.(28, 174, 331, 343) 
This relationship is best described in patients with acute liver failure (ALF), 
where high arterial ammonia levels(21) and marked systemic inflammatory 
response(26, 28, 169) have independently been shown to result in severe HE. At 
advanced stages, increasing intracranial pressure (ICP) is associated with a 
marked proinflammatory response in the brain which directly correlates with 
cerebral blood flow(169) and an efflux (indicating production) of brain 
proinflammatory cytokines at terminal stages.(195) With its persistent low-grade 
endotoxaemia,(344, 345) cerebral oedema(3, 338) and insidious 
hyperammonaemia, this relationship is also evident with cirrhosis. In otherwise 
stable patients with minimal HE (MHE), systemic inflammatory responses 
modulate the neuropsychological manifestations of induced 
hyperammonaemia,(170, 174) with antimicrobials ameliorating HE 
progression.(170, 174) Additionally, cirrhotic patients often remain stable until 
infection, or high ammonia loads (e.g. gastrointestinal bleeding) trigger 
progressive encephalopathy indicative of acute-on-chronic liver failure (ACLF), a 
condition which can produce a clinical syndrome that mimics ALF.(7)  
In bile duct-ligated (BDL) rat models of secondary biliary cirrhosis, there is a 
low-grade systemic and brain proinflammatory state indicated by elevated 
cytokines such as tumour necrosis factor-alpha (TNF-α))(327, 331) along with 
low-grade oedema.(331) In BDL rats, administration of LPS leads to a clinical 
situation that mimics clinical ACLF.(331) Our previous studies have shown that 
there is an exaggeration of both systemic and brain inflammatory response 
which results in worsening of the cytotoxic brain oedema resulting in a decline in 
consciousness to pre-coma/coma stages.(331) Experimentally, other groups 
have reported similar synergy with a recent study showing that treatment with 
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Minocycline reduces brain oedema in a devascularised animal model.(203) These 
data strongly support the hypothesis of a synergy between inflammation and 
ammonia in the pathogenesis of HE but how they interact to produce worsening 
of brain oedema is not clear.  
In a recent study from the Copenhagen group, naive rats exposed to ammonia 
followed by intravenous bacterial lipopolysaccharide (LPS), were shown to 
develop an inflammatory response, cerebral vasodilation and intracranial 
hypertension,(343) which did not occur in animals administered LPS alone 
indicating the important role of ammonia in ‘priming’ the brain to the deleterious 
effect of LPS. It is well known that astrocytes are the key cells in the brain that 
are involved in HE and swell in response to hyperammonaemia according to the 
ammonia-glutamine-brain swelling hypothesis. As astrocyte foot processes also 
form part of the blood-brain barrier ammonia-induced swelling of the astrocyte 
may exaggerate brain swelling in response to a superimposed inflammatory 
stimulus.(346) The above discussion allows one to put forward the hypothesis 
that reduction in ammonia in cirrhotic rats would prevent LPS induced worsening 
of brain oedema and rapid progression to pre-coma and coma stages. 
Recently, L-ornithine-phenylacetate (OP), a novel therapy targeting interorgan 
ammonia and amino acid metabolism,(132) has been shown to correct the 
hyperammonaemic state in animal models of cirrhosis(347) and ALF,(337) 
limiting brain oedema and rises in ICP. TNF-α is an important cytokine that has 
been implicated in the proinflammatory state associated with ALF and severe 
alcoholic hepatitis, with TNF-α deficient animals protected from brain oedema 
following induction of ALF.(348) Infliximab, a chimeric anti-TNF antibody is used 
clinically and has also been tested in alcoholic hepatitis patients(349, 350) and 
other especially rheumatological conditions. 
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Research hypothesis 
1. Reducing circulating ammonia in cirrhotic rats would prevent LPS induced 
worsening of brain oedema and rapid progression to pre-coma and coma 
stages  
2. Targeting both ammonia and inflammatory pathways will lead to a 
synergistic therapeutic benefit in the treatment of HE. 
 
Research question 
3. Can a reduction in ammonia in cirrhotic rats prevent LPS induced worsening 
of brain oedema and progression to pre-coma and coma stages? 
4. Does targeting hyperammonaemia and inflammation together provide 
therapeutic synergy in the treatment HE? 
 
Aim of study 
To test whether reduction in ammonia with OP (prior to administration of LPS), 
prevents the deleterious brain consequence of LPS administration. Furthermore, 
the role of anti-TNF and combination therapy was investigated. Conscious level 
and brain water content acted as the primary end-points.  
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Methods 
All animal experiments were conducted according to Home Office guidelines 
under the ‘UK Animals in Scientific Procedures Act’ 1986. Thirty-four male 
Sprague-Dawley rats, body weight 200–250g were obtained from the 
comparative biological unit at University College London.  All rats were housed in 
the unit and given free access to standard rodent chow and water, with a 
light/dark cycle of 12 hours, at a temperature of 19–23°C and humidity of 
approximately 50%. 
Animal models 
Bile-duct Ligation: Under anesthesia - intravenous (IV) diazepam (1mg/kg), 20 
minutes before intramuscular (IM) Hypnorm® (150µl/kg; Janssen 
Pharmaceutica, Belgium), all rats underwent bile duct-ligation (to induce 
secondary biliary cirrhosis), or sham-operation as described previously.(306)  
Study design 
Four weeks after surgery, BDL rats were randomised to receive 3 days of 
successive intraperitoneal (IP) injections of OP (0.6g/kg, based on chapter 3 
experiments) and/or 10mg/kg (based on prior validated rat studies(351)) of 
reconstituted Infliximab (Schering-Plough UK), the mouse chimeric anti-TNF-α 
monoclonal antibody, or saline (placebo). Three hours before termination, all 
BDL rats were administered IP - 1mg/kg LPS (Sigma. Poole, UK). As controls, 
sham-operated rats only received IP saline. Study groups were 1) sham-
operated, 2) BDL + saline, 3) BDL + LPS, 4) BDL + LPS + OP, 5) BDL + LPS + 
Infliximab, and 6) BDL + LPS + OP + Infliximab. The rats were allowed free 
access to food and water for the period of 3 hours post-intervention in a 
temperature controlled environment and were then sacrificed by exsanguination 
under anesthesia - IP Hypnorm® (200µL/kg), 20 minutes after IP diazepam 
(1mg/kg). Blood was withdrawn from the descending aorta and immediately, 
within seconds, put into ice cold heparin/EDTA containing tubes (until full 
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exsanguination), centrifuged at 3,120 x g and 4oC, and the plasma collected and 
stored at -80°C until assayed.  
Assessment of level of consciousness 
The conscious levels of rats used in this study were rated using an established 
neurological scale.(308) It was rated as either normal, with loss of the scatter 
reflex (c.f. Grade 1 encephalopathy) and ataxia (c.f. Grade 2 encephalopathy), 
together representing pre-coma stages, or loss of the righting reflex (c.f. Grade 
3-4 encephalopathy) representing the coma stage.  
Brain water  
Immediately after death, the whole brain was rapidly removed and 50mm2 
samples were dissected from the frontal cortex (grey matter). Brain tissue water 
content was determined using a previously described dry weight technique.(322, 
334) Briefly, oven dried Eppendorfs were weight (with a sensitive electronic 
scale), then 50mm2 wet frontal cortex samples placed into each respectively 
labelled eppendorf and reweighed; all samples where within 0.1 mg difference. 
The dry weight was determined after Eppendorfs loaded with individual brain 
samples were spun in a vacuumed Eppendorf centrifuge at 10,000 x g and 40°C 
for 2 days. Tissue water content was then calculated as % H2O = (1-dry wt/wet 
wt) x 100% 
Plasma biochemistry and arterial ammonia 
Substrate concentrations were measured using a COBAS Integra multiple 
analyser (Roche Diagnostics, UK) as previously described.(333) 
Plasma and cortical brain cytokines 
Plasma and cortical brain samples were snap frozen (-80°C) and stored. Prior to 
analysis, 100µg of cerebral cortex was homogenised and deproteinised (using a 
glass tube Teflon pestle homogeniser) in 300µl of ice-cold cell lysis buffer 
solution. After centrifugation at 12,000 x g for 10 minutes at 4°C, the 
supernatants were collected for processing. Following protein concentration 
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quantification of equilibrated brain protein samples and plasma supernatants 
(50µl) were analysed for cytokine levels (pg/ml) by flow cytometry using the 
Becton Dickinson (BD™ biosciences) rat inflammation cytometric bead array 
(CBA) kit as described by the manufacturer's instructions. These included the 
proinflammatory cytokines - TNF-α and interleukin-6 (IL-6). Samples were 
analysed by measuring the fluorescence produced by the CBA beads on a ‘FACS 
Canto™ II flow cytometry system (BD™ Sciences) and the data analysed with 
BD™ CTA software. 
Statistics 
Data are expressed as mean ± SEM. Significance of difference was tested with 
Newman-Keuls multiple comparison test or two-way ANOVA; p<0.05 was taken 
to be statistically significant. Paired t test or Wilcoxon Signed Rank test was 
used for comparison of two groups as appropriate. Kaplan-Meier survival 
analyses were performed for the time to pre-coma/coma in the different 
treatment groups and the log-rank test was used for statistical analysis of the 
data comparing the survival curves. Software used included Microsoft Excel 2003 
(Microsoft Corp., Redmond, WA) and GraphPad Prism 4.0 (GraphPad Software, 
Inc., San Diego, CA).  
Brain proton magnetic resonance spectroscopy  
1H-MRS was not utilised in this study as changes in brain osmolytes with OP 
were assessed in the experiments undertaken in chapter 3.  
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Results  
All rats continued to gain weight following surgery. From the final weight taken 
immediately prior to termination, BDL rats (mean ± SEM; 342g ± 42) were not 
significantly different to sham-operated controls (mean ± SEM; 380g ± 38). The 
systemic haemodynamics in the BDL animals were well maintained as previously 
shown.(320, 331) All rats were still alive 3 hours after injection of study 
medication.   
Neurobehavioral changes 
All rats were still alive 3 hours after injection of study medication, with sham-
operated rats administered saline remaining fully alert throughout the 3 hour 
study period. All rats administered LPS displayed pilo-erection or hunched 
posture within 30 to 60 minutes. LPS treated BDL rats began to show a marked 
deterioration in conscious level, reaching pre-coma (n=2/6) and coma (n=4/6) 
stages by 3 hours. In LPS treated BDL rats administered lone OP, only (n=3/6 
developed pre-coma/coma, while in LPS treated BDL rats administered lone 
Infliximab (n=5/6) developed pre-coma, with one progressing to coma (n=1/6). 
However, in LPS treated BDL rats co-administered OP + Infliximab, only (n=3/6) 
progressed to pre-coma/coma. Survival analyses comparing BDL + saline with 
BDL + LPS was highly significant (Log-rank: p<0.0001). Treatment of the BDL + 
LPS group with OP had significantly less progression to pre-coma/coma stages 
(Log-rank: p<0.009) which was not the case on treatment with Infliximab (Log-
rank: p=0.3; Figure 1). 
Brain water measurements  
Though there was a limited increase in the brain water content of the frontal 
cortex between saline administered sham-operated and BDL control groups, this 
did not reach statistical significance (Figure 2 and Table 1). There was a 
significant increase in brain water in LPS challenged BDL rats compared with 
saline-administered sham-operated and BDL controls (p<0.01, respectively). 
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This increase in brain water with LPS in BDL rats was significantly attenuated by 
administration of OP (p<0.01) but not with lone administration of Infliximab 
(p=0.167). Co-administration of OP and Infliximab significantly reduced brain 
water (p<0.05) to levels that not significantly different to saline treated BDL 
controls. However, this reduction was not statistically different from the lone OP 
treated group (p=0.3). 
Arterial ammonia 
When compared to sham-operated controls bile duct-ligation lead to a significant 
increase in plasma ammonia (p<0.001; Figure 3 & Table 1). Following the 
administration of OP (± Infliximab), the arterial ammonia levels were 
significantly reduced (p<0.001, respectively) when compared to BDL (± LPS) 
rats. No significant change in ammonia was observed following the 
administration of either LPS or Infliximab (p=0.5 and p=0.4 respectively).  
Plasma biochemistry 
Compared to sham-operated rats there was a significant increase in bilirubin 
(p<0.01) consistent with secondary cirrhosis following bile duct-ligation (Table 
1). In BDL rats, administration of LPS had no demonstrable effect on plasma 
biochemistry, with albumin, renal function, electrolytes and plasma osmolarity 
not statistically different between study groups.  
Plasma and cortical brain cytokines 
Throughout all study groups, the mean frontal cortical brain tissue cytokine 
levels were in the order of 10-fold higher compared to their respective 
circulating plasma levels. Multiple comparison group analysis revealed the 
following: 
Plasma cytokines: When compared to sham-operated rats, bile duct-ligation was 
associated with a significant increase in the plasma levels of the 
proinflammatory cytokines TNF-α and IL-6 (p<0.05, respectively; Table 2). In 
LPS challenged BDL rats, TNF-α and IL-6 levels were significantly elevated when 
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compared to sham-operated controls (p<0.001, respectively) and saline-treated 
BDL controls (p<0.01, respectively). In LPS treated BDL rats, lone 
administration of Infliximab significantly ameliorated elevated TNF-α and IL-6 
(p<0.001 and p<0.01, respectively). When compared to BDL + LPS rats, there 
was a significant reduction in plasma TNF-α (p<0.01) and non-significant trend 
towards reduction in IL-6 following lone administration of OP. In LPS treated BDL 
rats, co-administration of OP and Infliximab significantly ameliorated elevated 
TNF-α and IL-6 (p<0.001 and p<0.01, respectively), statistically no different to 
the effect with lone Infliximab.  
Cortical brain cytokines: When compared to sham-operated rats, bile duct-
ligation was associated with a marked but not significant increase in the brain 
levels of TNF-α and IL-6 (p>0.05, respectively; Table 2), which though 
augmented by LPS, still failed to reach significance. In LPS treated BDL rats, 
lone administration of Infliximab or OP, did ameliorate the elevated cortical brain 
tissue levels of TNF-α and IL-6 though this proved non-significant. Co-
administration of OP and Infliximab lead to a greater reduction in TNF-α and IL-
6, which only reached significance with IL-6 (p=0.03).  
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Discussion    
The results of this study show for the first time that reduction in arterial 
ammonia concentration using OP in BDL rats is associated with a reduction in 
LPS induced progression to pre-coma/coma which is associated with a marked 
attenuation in brain swelling. These data provide a strong argument in support 
of the hypothesis that, on the background of chronic liver disease (BDL), 
ammonia may prime the brain to the deleterious effect of LPS. These data may 
have important therapeutic consequences. As clinically overt HE in cirrhosis is 
usually associated with a precipitating illness such as infection, these data 
provide support for the hypothesis that if ammonia levels could be kept low in 
patients with existing cirrhosis, sepsis induced occurrence of HE could be 
prevented.   
The animal model chosen to explore this hypothesis, the LPS administered BDL 
rat, has been carefully characterised by our group and closely resembles the 
clinical situation of precipitated HE. BDL for 4-weeks prior to the study 
represents chronic liver disease with hyperammonaemia and a proinflammatory 
state (indicated by elevated arterial and brain cytokines). Additionally, the 
administration of LPS to this model is reflective of a second hit, and in this 
context represents an infective episode with evidence of exaggeration of the 
inflammatory response manifested by an increase in TNF–α and IL-6. I have 
previously shown by electron microscopy, that cirrhotic brain exhibits the 
classical ‘cytotoxic oedema’ even in the non-LPS treated group (chapter 2).(331) 
As ammonia and inflammation work simultaneously (and in synergy) to produce 
brain oedema and coma, this study used the BDL + LPS rat model to explore 
whether reduction in ammonia or inhibition of inflammation would prevent LPS 
induced worsening of brain oedema. For this study, OP was chosen to reduce 
arterial ammonia prior to LPS challenge following on from our recent 
observations in the BDL rat and devascularised pig models,(337, 347) which 
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confirmed that OP successfully reduces arterial ammonia concentration.(337, 
347) In order to explore the effect of inhibiting the inflammatory response, 
Infliximab, a chimeric anti-TNF antibody that targets the regulatory pathways 
influenced by the proinflammatory cytokine TNF-α, was used. This strategy was 
chosen based upon our previous studies showing that TNF responses in BDL 
animals treated with LPS were exaggerated(306) and our observations in 
humans about the critical role of TNF–α in the cerebral hyperaemia and 
intracranial hypertension with ALF.(169) Infliximab was shown to reduce 
inflammatory responses in patients with severe alcoholic hepatitis with 
improvement in vascular function.(349, 350, 352) As predicted, administration 
of Infliximab was associated with marked attenuation of the proinflammatory 
drive manifested by a reduction in arterial TNF-α and IL-6 concentrations. Of 
particular interest was the observation that OP treatment was to some extent 
associated with a reduction in plasma and brain proinflammatory cytokines. This 
finding further ties plasma and brain ammonia and inflammatory responses to 
HE pathogenesis.    
The most important observation of this study was the finding that reduction in 
ammonia with OP reduced LPS induced development of pre-coma/coma and 
worsening of brain oedema, which was not observed in the groups treated with 
Infliximab. It was therefore not surprising that co-administration of OP and 
Infliximab had similar effects to that observed in the OP treated group. These 
observations provide proof for the concept that ammonia may in some ways 
‘prime’ the brain to the effects of LPS. This conclusion is further supported by 
our previous observation that the administration of LPS alone to naive rats did 
not result in pre-coma/coma stages (chapter 2).(331) The failure of Infliximab to 
exert a significant effect is unlikely to be due to the dosing and regimen used as 
Infliximab was observed to adequately reduce plasma
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The mechanism of how ammonia may prime the brain to the effect of LPS is a 
matter of conjecture. Given the established central role of astrocytes (despite 
the possible impact of microglia(202, 203) and pericytes(207, 353)), recent 
reports of differential Toll-like receptors (TLRs) responses to microbial challenge 
on astroglial cells(354) may provide greater understanding of the interaction 
between inflammatory responses and ammonia(331, 355, 356) (e.g. neutrophil 
swelling and activation(356)); especially given any resultant influence on 
cerebral haemodynamics(201, 357, 358) and barrier integrity (whether 
mechanical or functional). TLRs are a class of receptors that recognise certain 
microbes (e.g. TLR-2 - lipopeptide on gram-positive bacteria and TLR-4 - LPS on 
gram-negative bacteria), stimulate proinflammatory cytokines and other 
mediators to activating innate (and adaptive) immunity. In the brain of BDL rats, 
our group have previously found up-regulation of TLR-2 and TLR-4, which was 
further augmented by LPS.(359) Our group has also demonstrated this pattern 
of TLR expression similarly influences neutrophil phagocytosis in patients with 
alcoholic hepatitis, triggered by humoral endotoxin.(355) Furthermore, we have 
also shown that administration of albumin was found to ameliorate TLR-2 and 
TLR–4 upregulation.(359) Such specific patterns of TLR upregulation may 
therefore prime the cirrhotic rat brain (and other organs(355, 359)) to further 
microbial challenge triggering a progression to ACLF. 
Although it appears that reduction in ammonia is the more important factor in 
prevention of LPS induced deterioration in HE and brain oedema, several lines of 
investigation indicate that inflammation may well be a necessary target of future 
therapies. Interventions suppressing proinflammatory responses that have been 
shown to be clinically beneficial include hypothermia and the cyclooxygenase 
(inhibitor Indomethacin in acute liver failure,(146) albumin(140) and albumin 
dialysis(140) and reduced bacterial translocation with probiotics(220)). 
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However, modulation of inflammatory processes is difficult as interventions that 
targeting inflammation may predispose to increased risk of infection. 
 
In conclusion, the findings of this study support a role for ammonia in priming 
the brain to the deleterious effect of LPS. Furthermore the findings suggest that 
a reduction in arterial ammonia concentration, possibly associated in a reduction 
in the proinflammatory state, with OP may prevent LPS induced worsening of HE 
and brain oedema. However, the mechanism of how ammonia primes the brain 
remains uncertain. 
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Figure 1. Time to pre-coma/coma with study intervention 
 
 
 
 
 
 
 
 
The Kaplan-Meier survival analyses were performed for the time to pre-coma/coma in the different 
treatment groups. Survival of BDL + saline compared to BDL + LPS rats was highly significant (Log-
rank: p<0.0001). In BDL + LPS rats, OP treatment lead to significantly less progression to pre-
coma/coma stages (Log-rank: p<0.009) which was not seen with Infliximab (Log-rank: p=0.3).  
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Figure 2. Frontal cortex brain water content 
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Shows that compared with sham-operated controls, there was a non-significant rise in frontal cortex 
water content in BDL rats, which was significantly augmented by LPS (**p<0.01). Administration of 
OP resulted in a significant reduction in brain water compared to LPS treated BDL rats ($$p<0.01). 
Co-administration of OP + Infliximab, resulted in a significant reduction ($p<0.05) in brain water 
compared to LPS treated BDL rats. Infliximab had a non-significant effect on brain water.   
Abbreviations: BDL, bile duct ligation; OP, L-ornithine, phenylacetate; LPS, lipopolysaccharide and 
aTNF, Infliximab. 
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Figure 3. Changes in arterial ammonia 
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Shows that compared with sham-operated controls, there was a significant rise in arterial ammonia 
in BDL rats (***p<0.001), with no additional effect with LPS. Following administration of OP (± 
Infliximab), there was a significant reduction in arterial ammonia concentration from baseline at 3 
hours ($$$p<0.001, respectively) and no different to sham controls. Abbreviations: BDL, bile duct 
ligation; OP, L-ornithine, phenylacetate; LPS, lipopolysaccharide and aTNF, Infliximab. 
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Table 1 
Sham BDL BDL + LPS BDL + LPS + OP BDL + LPS + aTNF BDL + LPS + OP + aTNF
Frontal brain water (%) 78.0 ± 0.1 78.7 ± 0.2 81.3 ± 0.6** 79.2 ± 0.4$$ 80.1 ± 0.4 78.5 ± 0.3$
Arterial ammonia (µmol/l) 86 ± 12 760 ± 55*** 796 ± 32*** 269 ± 108$$$ 706 ± 169*** 258 ± 143$$$
Bilirubin (mol/l) 16.0 ± 2.6 206 ± 3 212 ± 6 200 ± 9 195 ± 9 180 ± 18
Creatinine (mol/l) 20.5 ± 6.5 22 ± 1 24 ± 3 30 ± 2 26 ± 2 28 ± 0.0
Urea (mmol/l) 5.5 ± 0.4 5 ± 0.2 5 ± 0.6 6 ± 0.6 6 ± 0.3 5 ± 0.6
Albumin (g/l) 39 ± 1.8 35 ± 2 32 ± 1 35 ± 0.6 32 ± 1 30 ± 1
Total protein (g/l) 52.8 ± 2.8 46 ± 3 48 ± 2 45 ± 2 45 ± 2 54 ± 3
Sodium (mmol/l) 137 ± 4.0 139 ± 2 138 ± 3 140 ± 5 138 ± 1 141 ± 3
Potassium (mmol/l) 5.4 ± 1.0 4.9 ± 0.2 4.8 ± 0.6 5.1 ± 0.2 4.2 ± 0.2 5.9 ± 0.5
Chloride (mmol/l) 105 ± 4.4 104 ± 1 97 ± 2 108 ± 3 105 ± 2 106 ± 2
Osmolarity (mOsm/l) 285 ± 19.4 281 ± 20 279 ± 18 284 ± 20 280 ± 12 285 ± 28
 
 
Data are expressed as mean ± standard error of mean (SEM) Symbols represent;- *p<0.05, **p<0.01 and ***p<0.001 compared to 
sham-operated control rats; $p<0.05, $$p<0.01 and $$$p<0.001 compared to respective saline treated control rat. Abbreviations: sham, 
sham-operated; BDL, bile duct ligation; LPS, lipopolysaccharide and aTNF, Infliximab.  
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Table 2 
Cytokine levels (pmol/L) Sham BDL BDL + LPS BDL + LPS + OP BDL + LPS + aTNF BDL + LPS + OP + aTNF
Plasma TNF-α 90 ± 25 1859 ± 417* 4143 ± 528***/## 1919 ± 741$$ 1371 ± 717$$$ 179 ± 24$$$
Plasma  IL-6 153 ± 52 1470 ± 422 4135 ± 560***/## 3730 ± 832 1462 ± 481$$ 621 ± 267$$
Brain TNF-α 45 ± 13 179 ± 62 302 ± 68* 213 ± 38 188 ± 26 185 ± 38
Brain IL-6 26 ± 5 144 ± 99 226 ± 75 126 ± 83 156 ± 31 43 ± 19$
 
 
Data are expressed as mean ± standard error of mean (SEM) Symbols represent;- *p<0.05, **p<0.01 and ***p<0.001 compared to 
sham-operated control rats; $p<0.05, $$p<0.01 and $$$p<0.001 compared to BDL + LPS rats and #p<0.05, ##p<0.01 and ###p<0.001 
compared to BDL rats. Abbreviations: sham, sham-operated. BDL, bile duct-ligation. LPS, lipopolysaccharide. aTNF, Infliximab. 
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Research answers 
 
1. Can a reduction in ammonia in cirrhotic rats prevent LPS induced worsening of 
brain oedema and progression to pre-coma and coma stages? 
 
A reduction in arterial ammonia concentration with OP, prevent LPS induced 
worsening of HE and brain oedema, thereby priming the brain to the deleterious 
effect of LPS; though the mechanism of how ammonia primes the brain remains 
uncertain. 
 
2. Does targeting hyperammonaemia and inflammation together provide 
therapeutic synergy in the treatment HE?  
 
Although there was an observed advantage to combining ammonia-lowering and 
anti-inflammatory agents, there was no clear synergy, which may reflect the 
limitations of the specific inflammatory pathway used. 
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Abstract 
Liver failure is associated with progressive astrocyte swelling resulting in cytotoxic 
brain oedema, which is thought to underlie the pathogenesis of hepatic 
encephalopathy (HE). Although ammonia is considered to be central to the 
pathogenesis of HE, superimposed inflammation appears to play an important 
synergistic role in its pathogenesis. However, the mechanism underlying brain 
oedema in liver failure is unknown. The aim of this study was to determine whether 
aquaporin-4 (AQP4), an astrocyte bi-directional water channel, is involved in the 
brain oedema observed in liver failure. Method: (n=60) rats, received either sham-
operation (sham), 5 days hyperammonaemia-inducing diet (HD), galactosamine 
(GALN) induced acute liver failure (ALF), 4 weeks’ bile-duct ligation (BDL) induced 
cirrhosis, or caecal ligation and puncture (CLP), a 24 hour model of bacterial 
peritonitis. Rats in each of the groups (except CLP) were randomised to 
intraperitoneal (IP) injections of lipopolysaccharide (LPS; 1mg/kg) or saline, prior to 
termination 3 hours later. Brain water, AQP4 protein expression (western blot) and 
AQP4 localisation by Immunogold electron microscopy were investigated. Results: 
Significant hyperammonaemia was observed in BDL (p<0.05), GALN (p<0.01) and 
HD (p<0.01), compared to sham rats. LPS did not affect arterial ammonia and 
plasma biochemistry. Increased brain water was observed in GALN (p<0.05), CLP 
(p<0.01) and HD rats (p<0.01). Brain water was moderately increased in BDL rats, 
but this failed to reach significance (p=0.09). LPS treatment further increased 
oedema significantly in all groups (p<0.05, respectively). AQP4 expression was 
significantly increased in BDL (p<0.05), but not other rats, with maintained 
membrane polarisation in BDL rats. Conclusion: Our results suggest that AQP4 is 
not directly associated with the development of brain oedema in liver failure, 
hyperammonaemia or sepsis. In cirrhosis, there is increased AQP4 protein 
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expression with retained cellular polarisation possibly indicating a compensatory 
role to limit severe brain oedema.  
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Background 
In patients with acute liver failure (ALF), about 30-50% progress to intracranial 
hypertension and cerebral edema.(267) On a background of hyperammonaemia and 
in the presence of retained blood brain barrier integrity, advanced HE is 
characterised by cytotoxic brain injury with astrocyte swelling; with severity of 
intracranial hypertension and mortality correlated to arterial ammonia levels, brain 
ammonia delivery and uptake.(116, 146) With cirrhosis, despite the presence of 
hyperammonaemia and a proinflammatory state,(331, 360) there is often only ‘type 
2’ astrocytosis and occasional minimal brain swelling.(2, 150, 361, 362) However, 
following an episode of profound acute infection or aseptic inflammation, cirrhosis 
may decompensate to acute-on-chronic liver failure (ACLF),(7) with rapidly 
worsening cerebral oedema, similar to that observed with ALF. This may indicate 
that on a background of hyperammonaemia, type 2 astrocytosis predisposes the 
astrocyte to profound changes in cellular hydration following inflammation and/or 
osmotic stress. The mechanism of astrocyte oedema in the context of liver 
dysfunction and consequent hyperammonaemia has been hypothesised to be 
associated with an alteration in brain osmolytes, manifested by an accumulation of 
glutamine.(1, 177, 363, 364) The results of several lines of investigation support 
this hypothesis,(3, 107, 121, 149, 150, 307, 338, 361, 365) but the mechanism of 
worsening astrocyte oedema in the presence of an inflammatory insult in liver 
disease and hyperammonaemia is unclear. In a previous study, an inflammatory 
insult superimposed on a background of cirrhosis, was found to be associated with 
increased brain oedema and rapid progression to coma, but the blood-brain barrier 
and brain osmolytes remained apparently unaffected, suggesting that alternative 
mechanisms were likely to be important in the development of pathological brain 
oedema.(331)  
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In the brain, the bi-directional transmembrane water channel proteins - Aquaporin 
(AQP) 1, 4 and 9 assist in the regulation of cellular water homeostasis along 
osmotic gradients. AQP4 in particular is overwhelmingly expressed at astrocyte 
endfeet,(366) making it integral to blood-brain barrier integrity(367) and a 
potential factor in both vasogenic or cytotoxic oedema. The current literature 
supports a role for AQP4 in brain oedema associated with multiple forms of brain 
injury,(366, 368-371) although it remains unclear whether this is related to 
temporal and/or spatial changes in AQP4 expression,(372) especially in liver failure, 
about which data is limited to studies in isolated cultured astrocytes exposed to 
high concentrations of ammonia.(373-375) AQP4 has recently been implicated in 
the anti-oedema effect of hyperosmotic agents such as hypertonic saline in focal 
cerebral ischemia(376)  but whether altered AQP4 is important in the pathogenesis 
of brain edema in liver failure is unknown. Furthermore, the role of AQP4 in cellular 
hydration may involve the activation (phosphorylation) of p38 Mitogen-activated 
protein kinase (p38MAPK).(372) 
 
Research hypothesis  
The above observations have led to the hypothesis that AQP4 is an integral 
component in the development of pathogenic brain oedema in liver failure, 
especially following an inflammatory insult, via MAPK-dependent pathways and 
changes in cellular localisation.  
Research questions  
4. Are spatial and/or temporal changes in AQP4 involved in the development of   
pathogenic brain oedema in liver failure?  
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5. LPS augments cerebral oedema in HE; does this involve alteration in AQP4 
expression as suggested in other disease states?  
6. Does any effect of AQP4 expression on such brain oedema involve changes in 
MAPK expression? 
 
Aim of Study 
The aim of this study was to determine whether the development of brain oedema 
in models of liver failure is associated with altered AQP4 protein expression and 
cellular localisation, and whether this is influenced by the duration of liver injury, 
extent of hyperammonaemia, sepsis or aseptic inflammation. Levels of p38MAPK were 
also investigated in order to determine whether any alteration in AQP4 expression is 
associated with increased phosphorylation of p38MAPK.  
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Methods 
All animal experiments were conducted according to Home Office guidelines under 
the UK Animals and Scientific Procedures Act 1986. Male Sprague-Dawley rats 
(Charles-Rivers, UK), weighing 230–280g, were obtained from the Comparative 
Biology Unit at University College London. For the induction of the septic 
encephalopathy (caecal ligation & puncture; CLP), male Wister rats (Harlan Teklab, 
UK) weighing between 180–240g, were obtained from the Biological Research 
Facility at St Georges University of London. All rats were housed in the respective 
unit and given free access to standard rodent chow and water, serially weighed, 
with a light/dark cycle of 12 hours (the dark phase extended from 1900–0700 
hours), at a temperature of 22–23°C and approximately 50% relative humidity. 
Animal models 
Bile-duct Ligation (BDL): (n=12) rats underwent BDL to induce biliary cirrhosis, or 
sham-operation (sham) (n=12) under anaesthesia - intravenous (IV) diazepam 
(1mg/kg), followed by a 150µl/kg of intramuscular Hypnorm® (Janssen 
Pharmaceutica, Belgium), as described previously.(306)  
Galactosamine (GALN) induction of ALF rats: (n=12) rats received a single 
intraperitoneal (IP) injection of GALN (1mg/kg), 24 hours before sacrifice.  
High protein (Ammoniagenic) diet (HD): (n=12) rats were administered an 
ammoniagenic high protein diet for 5 days prior to termination (as outlined above). 
The diet consisted of a liquid rodent feed (Bioserve, Frenchtown, NJ 08825, USA) 
and a tailor-made mixture mimicking the amino-acid composition of the 
haemoglobin molecule (4g/Kg/day Nutricia, Cuijk, The Netherlands) as described 
previously,(115, 307) and mixed with commercially available gelatin to prevent 
sedimentation. This regimen produces chronic hyperammonaemia.(331) 
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Caecal ligation & puncture (CLP): CLP is 24 hours rat model of bacterial peritonitis 
with sepsis, known to exhibit severe perimicrovessel oedema, swollen cortical 
astrocyte endfeet, due to both cytotoxic and vasogenic injury.(184) Six (n=6) rats 
underwent CLP under general anaesthesia to induce septic encephalopathy, and 
(n=6) underwent sham, as previously described.(184) General anaesthesia was 
induced by inhalation of a mixture of 0.6 l/min O2 + 0.4 l/min N2O and 4–5% 
Halothane (Zeneca Pharmaceuticals, UK). Anaesthetic agents are known to interact 
with a number of molecular sites, including glutamatergic and GABAergic receptors 
and uptake transporters for glutamate, GABA, and dopamine, among others; 
affecting the release of dopamine, acetylcholine, and L-glutamate and also mask 
drug-related effects on neurotransmitter release. CLP-shams were therefore used to 
rule-out a possible confounding effect of anaesthesia on these CLP rats compared to 
those used in the other study groups.  
The rats were kept warm during surgery to prevent anaesthetic-induced 
hypothermia. The lower right quadrant of the abdomen was shaved and disinfected 
with 100% alcohol and the caecum mobilised through an approximately 2 cm long, 
right lower paramedian incision. For CLP rats, the caecum was filled by gently 
‘milking back’ colon contents and then ligated below the ileo-ceacal valve without 
obstructing the continuity between the ileum and colon. The caecum was then 
subjected to a single ‘through and through’ perforation with a sterile 23-gauge 
needle and gently squeezed until its contents began to exude, to ensure patency of 
the perforation sites. For sham-CLP rats, the caecum was minimally handled 
without ligation and puncture. The bowel was then repositioned and the abdominal 
incision closed in layers with silk surgical sutures. 
Study Design 
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In order to determine the effect of superimposed inflammation on the background 
of hyperammonaemia and/or liver dysfunction the treatment groups were given 
either saline or LPS. Four weeks after bile duct-ligation (or sham) rats were 
randomised, as were GALN and HD rats, to receive either an intraperitoneal (IP) 
injection of lipopolysaccharide (LPS; 1mg/Kg), or saline three hours before 
termination. A separate study was undertaken on the CLP rats approximately 24 
hours after CLP, or sham-CLP. The final study groups were: 1) sham + saline 
(n=6), 2) sham + LPS (n=6), 3) GALN + saline (n=6), 4) GALN + LPS (n=6), 5) 
BDL + saline (n=6), 6) BDL + LPS (n=6), 7) HD + saline (n=6) 7) HD + LPS (n=6), 
8) CLP (n=6) and 9) sham-CLP (n=6).  Treatment groups 1) – 7) were given free 
access to food and water for 3 hours post-intervention in a temperature controlled 
environment and were then sacrificed by exsanguination under lethal anaesthesia 
IM Hypnorm (200µL/kg), 20 minutes after IP diazepam (1mg/kg). CLP and sham 
CLP rats (groups 8 and 9) were given free access to food and at water in a 
temperature controlled environment and approximately 24 h post-intervention were 
given a lethal dose of anaesthetic (Pentobarbital 35 mg/kg IP (Animalcare Ltd, York, 
U.K). Blood was withdrawn from the descending aorta of all lethally anaesthetised 
rats and immediately put into ice cold heparin/EDTA containing tubes, centrifuged 
at 3120 x g and 4oC, and the plasma collected and stored at -80°C until assayed. 
Brain tissue was immediately harvested and collected and stored at -80°C until 
analysed. 
Assessment of level of consciousness 
The level of consciousness of all rats used in this study was rated prior to sacrifice 
using an established neurological scale.(308) It was rated as either normal, with 
loss of the scatter reflex (c.f. Grade 1 encephalopathy) and ataxia (c.f. Grade 2 
encephalopathy), together representing pre-coma stages, or loss of the righting 
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reflex (c.f. Grade 3-4 encephalopathy) representing the coma stage. For CLP rats, 
behaviour and consciousness was measured as previously described.(184) In CLP 
rats, lethality is reported to be high, a humane endpoint was pre-set before the 
onset of lethality using behavioural and physiological parameters(377, 378) and 
measured as previously described.  
Brain water  
Immediately after death, the whole brain was rapidly removed and 50mm2 samples 
of frontal cortex were taken. Cerebral cortex water content was determined using a 
previously described wet-to-dry weight ratio technique.(322, 334)  Briefly, oven 
dried eppendorf’s were weighed, then 50mm2 wet frontal cortex samples placed into 
individual eppendorf’s and reweighed; all samples weighed within 0.1 mg of each 
other. The dry weight of each sample of frontal cortex was determined after the 
brain-loaded eppendorf’s were spun in a vacuumed eppendorf centrifuge at 10,000 
x g and 40°C for 2 days. Tissue water content was then calculated as % H2O = (1-
dry wt/wet wt) x 100%. 
Measurement of plasma biochemistry 
Plasma samples (200µl) were analysed for: ammonia, alanine aminotransferase 
(ALT), albumin, total protein, bilirubin, urea and electrolytes using a Cobas integra 
400 multianalyser with the appropriate diagnostic kits (Roche-diagnostics, Burgess 
Hill, West Sussex UK). 
Western blot analysis 
Snap frozen (-80°C) and stored 100µg cortical brain samples were homogenised 
and deproteinised (using a glass tube Teflon pestle homogeniser) in 300µl of ice-
cold cell lysis buffer solution. After centrifugation at 12,000g for 10 minutes at 4°C, 
the supernatants were collected for processing. Following protein concentration 
quantification of equilibrated 50µl brain protein samples were analysed with protein 
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separation and transfer were performed using a NuPAGE® pre-cast gel system 
(Invitrogen Ltd, UK). Specific protein bands were detected using rat polyclonal IgG’s 
for phosphorylated p38MAPK and total p38MAPK (Santa Cruz Biotechnology, Inc. USA) 
rabbit, anti-rat affinity purified polyclonal aquaporin-4 antibody (Chemicon 
International, U.K.) with a secondary goat polyclonal antibody to rabbit IgG, HRP 
conjugated (Hycult biotechnology, Netherlands). Alpha-tubulin (α-tubulin) was used 
as the housekeeping protein (Santa Cruz Biotechnology, Inc. USA), with a 
secondary goat polyclonal antibody to mouse IgG, HRP conjugated (Hycult 
biotechnology, Netherlands). All antibodies were used at a dilution of 1:1000. 
Protein bands were visualised using Amersham ECL™ advance western blotting 
detection reagents and Hyperfilm™ (GE Healthcare, UK). Densitometry 
measurements where made using Image-J software (freeware; rsbweb.nih.gov/ij).                                                                                    
To allow for accurate measurements of protein expression, it was necessary to take 
into account differences in total protein expression between sample tissues by 
corrected for the ubiquitous cellular cytoskeletal protein, α-tubulin.  
Total P38MAPK and phosphorylated P38MAPK’ ratio: To reflect the relative activation of 
the P38MAPK pathway (indicated by phosphorylated P38MAPK), the ‘P38MAPK/P38MAPK’ 
ratio was calculated. 
Aquaporin-4 Immunogold labelling 
AQP4 localisation was assessed by Immunogold electron microscopy using a 
previously validated technique (performed by Dr G Wright and Dr Heather Brooks at 
the Institute of Hepatology, UCL and The Department of Anatomy, St Georges 
University, London). Sham and BDL rats under anaesthesia were perfused with 100 
ml of phosphate buffer (0.1 M, pH 7.4) followed by 200 ml of 4% paraformaldehyde 
(in phosphate buffer), containing 0.2% glutaraldehyde and 4% sucrose. Brains were 
dissected out and 3 mm3 pieces of frontal cortex were rinsed twice in phosphate 
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buffer for 15 minutes each time. Samples were then dehydrated in ascending 
alcohol (50%, 70%, 90%, 95%, 100%) for 30 minutes each before being left in a 
2:1 ratio of ethanol:methacrolate overnight. The following morning samples were 
put into a 1:1 ratio of ethanol:methacrolate overnight. The following morning 
samples were put in a 1:1 ratio of ethanol:methacrolate for one hour before placing 
in pure methacrolate for 72 hours under UV light. Thin sections with a silver/gold 
interface colour (approximately 80-100 nm) were cut from the methacrolate 
embedded tissue blocks and collected on 200 mesh 3 mm nickel grids (Agar 
Scientific, U.K.). Sections were then rinsed in phosphate buffer (0.1M, pH 7.4) for 
10 minutes before being placed in 10% goat serum (Invitrogen, Scotland, U.K.) for 
30 minutes. Sections were then rinsed twice in phosphate buffer for 5 minutes each 
before being incubated overnight (4°C) in rabbit, anti-rat aquaporin-4 affinity 
purified polyclonal antibody (Chemicon International, U.K.), at a concentration of 
1:250. Samples were again rinsed twice in phosphate buffer for 5 minutes each 
before being incubated for 1.5 hours (room temperature) in goat, anti-rabbit lgG 
(H&L) with 30 nm gold particles (British-biocell International, Cardiff, U.K.). Finally 
samples were rinsed twice with phosphate buffer (5 minutes each), rinsed once with 
distilled water (5 minutes) and stained with uranyl acetate. Grids were later viewed 
using a Hitachi 7100 transmission electron microscope at 75 kV. Digital images 
were captured with a Gatan column-mounted CCD camera at a resolution of 
1024x1024 pixels and archived on a personal computer. 
Statistics 
Data are expressed as mean ± SEM. Treatment effects were investigated using 
Newman-Keuls multiple comparison test; p<0.05 was taken to be statistically 
significant. Software used included Microsoft Excel 2003 (Microsoft Corp., Redmond, 
WA) and GraphPad Prism 4.0 (GraphPad Software, Inc., San Diego, CA).  
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Results  
There was no significant difference in the weight immediately prior to termination of 
GALN and CLP compared to sham-operated rats. There was no significant difference 
in the final weight of BDL and sham rats, and both groups continued to gain weight 
following surgery (mean BDL ± SEM = 320g ± 14 and mean sham ± SEM = 301g ± 
19). The systemic haemodynamics in the BDL animals were well maintained as 
previously shown.(320, 331)  
Neurobehavioral changes 
All rats were alive 3 hours after injection of saline or LPS. Rats administered LPS 
showed a demonstrable effect with all displaying pilo-erection or hunched posture. 
The level of consciousness of BDL rats given LPS showed a marked, progressive 
deterioration, starting within 30 - 60 minutes and reaching pre-coma stages at the 
3-hour killing time. Sham, GALN and HD rats administered saline and the sham and 
HD rats administered LPS remained fully alert. CLP lead to a reduction in activity 
indicative of lethargy (a diagnostic feature of systemic sepsis) without any evidence 
of grade 3 or 4 encephalopathy.(184) 
Brain water measurements 
There was a significant rise in frontal cortex water content in HD (p<0.01), GALN 
and CLP rats (p<0.05, respectively), compared to sham saline-treated controls. 
There was a numerical increase in cortical water content in BDL rats, but this just 
failed to reach statistical significance (p=0.09); Figure 1 and Table 1), consistent 
with previous findings with this model.(331) There was also a significant increase 
(p<0.05 for all comparisons) in the frontal cortex water content of LPS treated 
compared to the corresponding saline-treated (sham, GALN, HD and BDL) rats, 
Figure 1.   
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Arterial ammonia 
When compared to sham controls there was a significant increase in plasma 
ammonia in BDL (p<0.01), GALN and HD rats (p<0.01) respectively; Figure 2 & 
Table 1). Induction of peritoneal sepsis by CLP had no significant impact on 
ammonia levels, nor did the administration of LPS in either sham, GALN, HD or BDL 
rats, compared to their saline treated counterparts. (Table 1) 
Plasma biochemistry  
Following BDL, there was a significant increase in bilirubin and a reduction in 
albumin consistent with cirrhosis, and an increase in ALT in the GALN animals 
(p>0.001), compared to sham rats, Table 2. Administration of LPS to sham, GALN, 
HD or BDL rats had no significant effect on plasma biochemistry except for a 
previously well-described increase in ALT and urea seen in LPS challenged BDL rats. 
Otherwise, renal function, sodium, potassium and plasma osmolarity were not 
statistically different between study groups.  
Protein expression 
AQP4 expression: There was a statistically significant increase in the expression of 
AQP4 following BDL (p<0.05; Figure 3) compared to sham rats, which was not 
observed following GALN-induced ALF or CLP. There was no significant effect of 5 
days induced hyperammonaemia on AQP4 expression, when compared to sham 
controls. Administration of LPS to sham, GALN, BDL and HD rats also had no 
significant effect on AQP4 expression.  
Phosphorylated-P38MAPK/P38MAPK expression: There was a statistically significant 
increase in the expression of activated p38MAPK in BDL (p<0.05; Figure 4) compared 
to sham rats, which was not observed in GALN rats. In contrast, there was no 
significant increase in activated p38MAPK by induction of hyperammonaemia over 5 
days in HD rats, with peritoneal sepsis in CLP rats, or any significant change in 
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activated P38MAPK levels with administration of LPS to sham, GALN, BDL or HD rats, 
compared to their saline treated counterparts. 
Cellular localisation of AQP4 with Bile duct ligation and LPS administration 
In view of the fact that increased AQP4 expression was observed in BDL rats, the 
ultra-structural localisation of this increased expression was investigated compared 
to sham rats. As previously reported,(331) the frontal cortex microvessels of BDL 
rats were partially collapsed (crescent shaped) with perivascular, compared with 
sham rats (Figure 5a, 5b). Immunogold labelling further demonstrated retained 
perivascular localisation of AQP4 in BDL rats with a demonstrable increase in levels. 
Although administration of LPS to BDL rats produced an increase in perivascular 
there did not appear to be any qualitative effect on AQP4 localisation (Figure 5c).   
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Discussion 
The most important observations of this study were firstly to demonstrate that 
hyperammonaemia and/or inflammation, whether associated with liver dysfunction 
or not, causes an increase in brain water. Secondly, that the severity of brain 
swelling in these different models variably combining hyperammonaemia, liver 
dysfunction and inflammation are not associated with any increase in the expression 
of AQP4 in the brain. However, increased AQP4 protein expression was observed in 
BDL rats, but no further increase in AQP4 expression occurred in BDL rats treated 
with LPS (a model of ACLF), even though this resulted in a marked increase in brain 
water. These novel observations throw doubt on a causal role for AQP4 mediated 
brain oedema in not only liver failure, but also septic models. 
The extent of brain water accumulation was profound in CLP, GALN, HD rats and 
LPS challenged BDL rats, with no correlation between AQP4 levels and extent of 
cerebral oedema. The only intervention that showed an increase in AQP4 protein 
expression was BDL, which manifests low grade brain oedema(150, 361) (with LPS 
not having any additional effect).  
Immunogold labelling of thin electron microscopic sections,(379, 380) involves 
conjugation of gold particles to either primary of secondary antibodies for specific 
(especially surface) antigen detection. This is a well-established method for the 
cellular localization of AQP4,(381) with studies confirming that over 95% of brain 
AQP4 is concentrated in the membrane of astrocyte endfeet.(382) Importantly, 
Immunogold labelling confirmed the increased AQP4 expression found on western 
blotting, but also demonstrated that BDL has no effect on the ultra-structural 
localisation of AQP4. The literature on AQP4 expression following brain insult is 
confusing and is principally derived from models of focal brain ischaemic (FBI). 
Some studies have shown AQP4 to be down-regulated within 24 hours of FBI, when 
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brain water accumulation has occurred,(369, 383) although in another study(384) 
AQP4 mRNA was reported to be elevated, during resolution of the cerebral oedema 
(but only by day 3). A temporal and spatial alteration in AQP4 expression and any 
relationship to the site of water accumulation has also been shown to be highly 
variable in longitudinal studies.(385) In a key longitudinal study of AQP4 expression 
following FBI over days, AQP4 expression was shown to be increased at 1 and 48 
hours post ischaemia, correlating with the peaks of brain water accumulation.(385) 
In a similar model, AQP4 down-regulation was reported to have occurred at the 
centre of ischaemic injury as early as 90 min post insult, peaking at 24 hours during 
the reperfusion phase, with partial recovery by 72 hours; though interestingly AQP4 
expression was up-regulated at the border of injury.(386) Water intoxication (IP 
water and 8-deaminoarginine vasopressin), significantly increases AQP4 levels in 
wild-type mice after just 15 min, but this increase does not occur in similarly 
challenged AQP4 knockout mice that appear to be protected from brain 
oedema.(368, 387)  Furthermore, the vasogenic brain oedema that occurs in wild-
type mice following tumour cell implantation is not apparent in AQP4 knockout 
mice. Yet it seems improbable that demonstrable AQP4 protein turnover occurs 
within a matter of minutes or hours to induce pathogenic oedema, unless there was 
a sizable alteration to an existing cellular pool or functional modulation. Unless 
there is an increase in AQP4 levels and transmembrane polarisation before brain 
water accumulation, it is difficult to conclude a causal role for AQP4. A recent study 
showed that increasing AQP4 protein expression by 2-fold in astrocytes of AQP4-
overexpressing transgenic (Glial fibrillary acid protein (GFAP)-AQP4 positive) mice, 
had no affect on survival, behaviour, or anatomy and did not induce brain oedema 
and intracranial hypertension, unless accompanied by a water-intoxification.(388) 
These findings imply that AQP4 upregulation may simply provide the environment 
  
 
223
for further insult (e.g. osmotic). This is particularly pertinent to any possible 
association with liver disease with the importance of shifts in intracellular osmolytes 
in astrocytes as part of the ‘ammonia-glutamine-brain swelling hypothesis’. The 
only prior study of AQP4 expression in relation to liver failure has been in astrocyte 
cell cultures incubated with very high concentrations of ammonia (5 mmol, 
ammonium chloride) where increased AQP4 expression was observed 2 hours 
before astrocyte swelling (10 hours post exposure) and persisted for 48 hours.(374) 
This swelling is thought to be due to oxidative stress induced changes in MAPK-
pathways.(375) However, incubating astrocytes with ammonium chloride does not 
fully model the effects of liver failure on the brain, because it involves an 
unphysiological osmotic stress and therefore, does not allow extrapolation of a 
causal role for AQP4 in the brain oedema of liver failure.    
It is likely that the increased AQP4 expression in BDL rats in the current study is a 
compensatory mechanism to minimise pathogenic oedema as hypothesised in 
earlier reports of the role of AQP4 in cerebral oedema (e.g. vasogenic cerebral 
oedema associated with brain tumour and contusion injury(389) and bacterial 
abscess (390)). 
The results of the current study also provide further evidence to indicate that brain 
swelling is not a surrogate for HE. Indeed, marked increases in brain water in 
several groups of animals was not associated with changes in mental state and our 
results also confirmed that superimposed inflammatory stress induced by LPS on 
the background of liver disease (both BDL and GALN) was associated with 
progression to pre-coma stages. The results of this study argue against a role for 
AQP4 as the key causal factor in pathogenic brain swelling. However, much of the 
evidence in support of this view is based on studies utilising AQP4 knockout mice 
(e.g. deletion of the anchoring protein α-Syn(-/-) which decreases the AQP4 
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perivascular pool by >90%) and AQP4-overexpressing transgenic mice.(366, 369-
371, 376, 385, 387, 388, 390-392) However, data derived from such physiologically 
unrepresentative models should be treated with caution, because they may also 
exhibit possible confounding effects (e.g. changes in blood brain barrier 
integrity(367, 376)). Indeed, α-Syn-/- mice have less brain water than wild type 
mice (α-Syn+/+)(376) and with such differing baseline control animals; it is difficult 
to assess changes in brain water following interventions (e.g. administration of 
hypertonic saline). Furthermore, the fact that that AQP4 over-expression only 
causes oedema with hyperosmolar insult(388) appears counterintuitive if  AQP4 
plays a pivotal causal role in brain oedema. Further doubt is cast upon a role for 
increased AQP4 expression causing cerebral oedema, by the results of a pathology 
study of AQP4-/- knockout mice, which demonstrate that the absence of perivascular 
AQP4 expression is associated with open inter-endothelial cell tight junctions and 
swelling of perivascular astrocyte endfeet, reducing blood-brain barrier 
integrity.(367)  
It is important to point out that in the current study there was no confounding 
effect of plasma electrolytes between the treatment groups. This observation is 
important, because it could be argued that shifts in plasma K+ levels may be 
integral to AQP4-dependent cellular hydration, via its close association with the K+ 
inward rectifying (Kir-4.1) transporter, although the impact of this transporter has 
recently been questioned.(393) Another finding of the current study was that only 
bile duct-ligation lead to an increase in activated p38MAPK. Given that increased 
AQP4 expression was also only caused by BDL, there appears to be an association 
between p38MAPK activation and AQP4 expression. A similar association has been 
reported to occur in cultured astrocytes under conditions of hyperosmolar 
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stress(372) and suggests a role for MAP Kinase intracellular signaling (with 
resultant downstream nuclear factor kappa beta(394)) in AQP4 regulation.  
 
In conclusion, AQP4 does not appear to play a significant role in the development 
of brain oedema associated with hyperammonaemia or inflammation, either with or 
without acute liver dysfunction. However, the brain oedema in cirrhosis is 
associated with upregulation of AQP4 with contemporaneous p38MAPK activation and 
retained cellular polarisation, possibly as a compensatory response to inhibit 
oedema formation. 
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Table 1 
Sham Sham + LPS GALN GALN + LPS BDL BDL + LPS HD HD + LPS sham CLP CLP
Frontal brain water (%) 78.3 ± 0.3 79.8 ± 0.3$ 79.9 ± 0.4* 80.2 ± 0.2*$ 79.5 ± 0.3 80.8 ± 0.2$ 81.1 ± 0.1** 81.8 ± 0.2** 79.6 ± 0.2 81.2 ± 0.2*
Arterial ammonia (µmol/l) 63 ± 7 67 ± 6 201 ± 20** 182 ± 21* 188 ± 16* 172 ± 36* 209 ± 17** 220 ± 32** 67 ± 4 71 ± 6
 
 
Data are expressed as mean ± standard error of mean (SEM).   * = p<0.05, ** = p<0.01 and *** = p<0.001 compared to sham-operated control rats; $ = p<0.05, $$ 
= p<0.001 and $$$ = p<0.001 compared to their respective saline-treated controls. Abbreviations: sham, sham-operated; GALN, galactosamine; BDL, bile duct 
ligation; HD, high-ammonia diet; LPS, lipopolysaccharide and CLP, caecal ligation & puncture. 
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Table 2 
 
Sham Sham + LPS GALN GALN + LPS BDL BDL + LPS HD HD + LPS CLP sham CLP
Plasma ALT (U/l) 70 ± 6 90 ± 12 1505 ± 500** 1828 ± 294** 98 ± 15 168 ± 54 31 ± 2 37 ± 4 60 ± 12 132 ± 40
Plasma bilirubin (mol/l) 10 ± 3 24 ± 6 19 ± 9 17 ± 9 180 ± 18** 181 ± 14** 28 ± 3 32 ± 3 11 ± 3 12 ± 4
Plasma creatinine (mol/l) 22 ± 1 24 ± 3 39 ± 2 49 ± 2 18 ± 0.0 27 ± 5 39 ± 2 32 ± 2 18 ± 0 18 ± 0
Plasma urea (mmol/l) 5 ± 0.2 5 ± 0.6 6 ± 0.6 6 ± 0.3 5 ± 0.6 9 ± 0.4 7 ± 0.6 6 ± 0.9 6 ± 1 8.9 ± 1.2
Plasma albumin (g/l) 35 ± 2 38 ± 1 35 ± 0.6 38 ± 1 26 ± 1 24 ± 2 39 ± 0.7 40 ± 0.7 39 ± 0.7 40 ± 0.3
Plasma total protein (g/l) 46 ± 3 48 ± 2 45 ± 2 45 ± 2 54 ± 3 48 ± 3 51 ± 0.9 51 ± 1 43 ± 5 40 ± 3
Plasma sodium (mmol/l) 139 ± 2 138 ± 3 140 ± 5 138 ± 1 141 ± 3 141 ± 3 136 ± 5 139 ± 5 139 ± 5 137 ± 4
Plasma potassium (mmol/l) 4.9 ± 0.2 4.8 ± 0.6 5.1 ± 0.2 4.2 ± 0.2 5.9 ± 0.5 6.0 ± 0.3 5.2 ± 0.4 5.1 ± 0.1 5.0 ± 0.2 5.9 ± 0.5
Plasma chloride (mmol/l) 104 ± 1 97 ± 2 108 ± 3 105 ± 2 106 ± 2 105 ± 3 97 ± 0.9 99 ± 0.9 102 ± 1 102 ± 1
Plasma osmolarity (mOsm/l) 281 ± 20 279 ± 18 284 ± 20 280 ± 12 285 ± 28 288 ± 23 278 ± 23 284 ± 36 283 ± 20 280 ± 19
 
 
Data are expressed as mean ± standard error of mean (SEM).  * = p<0.05, ** = p<0.01 and *** = p<0.001 compared to sham-operated control rats; $ = p<0.05, $$ 
= p<0.01 and $$$ = p<0.001 compared to their respective saline-treated controls. Abbreviations: sham, sham-operated; GALN, galactosamine; BDL, bile duct 
ligation; HD, high-ammonia diet; LPS, lipopolysaccharide and CLP, caecal ligation & puncture. 
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Figure 1: Frontal cortex brain water content 
 
 
There was significant brain swelling in galactosamine (GALN), cecal ligation and puncture (CLP) and high-
ammonia diet (HD) rats, but bile duct-ligation (BDL) rats administered saline, were not significantly 
different from sham-operated (sham) rats. Lipopolysaccharide (LPS) significantly augmented brain 
swelling in all treatment groups (p<0.05, for all comparisons). * = p<0.05, compared to sham rats; $ = 
p<0.05, compared to respective saline-treated controls  
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Figure 2: Plasma ammonia levels 
 
 
There was a significant rise in plasma ammonia in bile duct ligation (BDL), galactosamine (GALN) and 
high-ammonia diet (HD) rats. Administration of lipopolysaccharide (LPS) or induction of sepsis by cecal 
ligation and puncture (CLP) had no demonstrable additional effect on ammonia levels.  * = p<0.05 and ** 
= p<0.01 compared to sham-operated (sham) control rats.  
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Figure 3: AQP4 levels in the frontal cortex    
    
 
There was a significant increase in AQP4 protein expression in bile duct ligation (BDL) rats that was not 
observed with galactosamine (GALN), high ammonia diet (HD) or cecal ligation and puncture (CLP) rats. 
Administration of lipopolysaccharide (LPS) had no effect on AQP4 expression.  * = p<0.05, ** = p<0.01 and 
*** = p<0.001 compared to sham-operated (sham) control rats; $ = p<0.05, $$ = p<0.001 and $$$ = p<0.001 
compared to respective saline-treated controls. 
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Figure 4: Changes in p38MAPK activation  
 
 
There was a significant increase in p38MAPK activation in bile duct ligation (BDL) rats that was not 
observed with galactosamine (GALN), high-ammonia diet (HD) or cecal ligation and puncture CLP. 
Administration of lipopolysaccharide (LPS) had no effect on p38MAPK activation. * = *p<0.01 and *** = 
p<0.001 compared to sham-operated (sham) control rats.  
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Figure 5a: Representative Immunogold labelled transmission electron 
micrograph of a brain microvessel from the frontal cortex of a sham-
operated rat      
 
                  
        
This shows an intact and well-perfused microvessel with no surrounding astrocyte, perivascular changes. 
AQP4 immunogold (Au) labelling, detected as black dots (see arrows), can be seen to decorate astrocyte 
endfoot membranes in contact with the abluminal surface of the microvessel. Abbreviations: Ecn, 
Endothelial cell nucleus, Au, gold particle, Oed, oedema.  
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Figure 5b: Representative Immunogold labelled transmission electron 
micrograph of a brain microvessel from the frontal cortex of a bile duct 
ligation rat  
 
                  
 
This shows a collapsed (crescent-shaped) microvessel with an intact endothelial barrier with minimal 
perivascular oedema. AQP4 immunogold (Au) labelling, detected as black dots (see arrows), shows 
retained perivascular polarization of AQP4 in astrocyte endfeet processes, in greater abundance than in 
sham-operated rats. Abbreviations: Ecn, Endothelial cell nucleus, Au, gold particle, Oed, oedema.  
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Figure 5c: Representative Immunogold labelled transmission electron 
micrograph of a brain microvessel from the frontal cortex of a LPS 
challenged BDL rat  
 
                   
 
This shows a partially collapsed microvessel with profound perivascular oedema (Oed). AQP4 
immunogold (Au) labelling, detected as black dots (see arrows), shows retained perivascular polarization 
of AQP4, similar to that in BDL saline treated controls. Abbreviations: Ecn, Endothelial cell nucleus, Au, 
gold particle, Oed, oedema. 
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Research answers 
 
1. Are spatial and/or temporal changes in AQP4 involved in the development of   
pathogenic brain oedema in liver failure?  
AQP4 is not involved in the development in pathogenic brain oedema in liver failure, 
sepsis and hyperammonaemic rat models. 
2. LPS augments cerebral oedema in HE; does this involve alteration in AQP4 
expression as suggested in other disease states?  
AQP4 is not involved in the development in LPS triggered pathogenic brain oedema. 
3. Does any effect of AQP4 expression on such brain oedema involve changes in 
MAPK expression? 
MAPK expression has a contemporaneous association with AQP4 expression. 
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Chapter 6 
 
Hepatic encephalopathy: The role of 
Inflammation, Ammonia and 
Aquaporin Expression in the 
Pathogenesis of Cerebral Oedema 
 
PhD Thesis Summary 
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Introduction 
This thesis was undertaken to expand our current understanding of interorgan 
ammonia and amino acid metabolism in the pathogenesis of hepatic encephalopathy 
(HE); discussed in chapter one. A review of HE literature highlighted a number of 
key unanswered questions, chiefly focused on the mechanisms underlying the 
possible synergy between ammonia and inflammation. Utilising animal and 
laboratory experiments, this thesis comprehensively explored a number of concise 
hypotheses (chapter 2-5). The findings from these key studies are summarised as 
follows:  
 
STUDY 1 (Chapter 2) 
Current evidence indicates synergy between hyperammonaemia and inflammation 
in the development of Hepatic encephalopathy (HE). However, it is not clear 
whether it is the background cirrhotic state or the associated hyperammonaemia 
that predisposes to the effects of superimposed inflammation. 
 
Question 1: In bile duct-ligated (BDL) rats, does lipopolysaccharide (LPS) induced 
systemic inflammation worsen the brain oedema of cirrhosis? If so, is this 
associated with blood-brain barrier disruption? Altered brain ammonia metabolism? 
or modulation of inflammatory brain responses? 
 
Answer 1: LPS derived systemic inflammation triggered brain oedema in sham-
operated control rats worsened the marked oedema observed in ammonia fed naïve 
rats and the pre-existing low-grade oedema (consistent with minimal HE) observed 
in cirrhotic rats. However, despite the extent of oedema induced by ammoniagenic 
feed (and in rats given LPS), only cirrhotic rats challenged with LPS progressed to 
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pre-coma/coma. Furthermore these changes occurred in the context of retained 
barrier integrity, indicative of cytotoxic oedema. However, plasma and brain 
ammonia levels were high in both ammonia fed naïve and cirrhotic rats and both 
observed worsening brain oedema with the acute inflammatory insult of high dose 
LPS, though LPS did not independently alter plasma or brain ammonia levels. An 
explanation for the difference in coma levels between these 2 groups, which both 
display the phenotype of background high circulating ammonia and acute 
inflammation, may be related to the chronicity (‘time to development’) of significant 
hyperammonaemia - chronic (BDL) or acute (ammonia fed) rats. The slower rise in 
ammonia with the secondary cirrhosis of BDL, may allow for a relative protection 
against intracellular osmolyte shifts consistent with the ‘ammonia-glutamine-brain 
water’ hypotheses. This hypothesis describes the brain edema of 
hyperammonaemia in terms of alterations in brain osmolytes, characterised by 
increases in the brain glutamine/myo-inositol ratio. In ammonia fed naïve rats (that 
had markedly more oedema than cirrhotic BDL rats), there was a more significant 
increase in the brain glutamine/myo-inositol ratio than that observed with BDL rats. 
The acute systemic proinflammatory (cytokine and nitric oxide) stimulus induced by 
LPS, augmented a background proinflammatory cytokine response (e.g. Tumour 
necrosis factor-alpha (TNF-α) and Interleukin-6 (IL-6)) in cirrhotic BDL rat brain, 
not evident in other groups. Interestingly, only comatose LPS challenged BDL rats 
showed high levels of brain nitrotyrosine, possibly suggesting that 
hyperammonaemia and inflammation on a background of cirrhosis provide an 
environment for nitrosation of brain proteins. The LPS challenged BDL rat is 
therefore the first small animal model which mimics the clinical presentation of 
‘acute-on-chronic liver failure’ (ACLF) and also provides support for the concept of 
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synergy between ammonia and inflammation in the development of brain oedema 
and progression to coma in cirrhotic rats. 
 
In conclusion, injection of LPS into cirrhotic BDL rats induces pre-coma/coma, and 
exacerbates cytotoxic oedema due to the synergistic effect of hyperammonaemia 
and induced inflammatory responses. Although the exact mechanism of how 
hyperammonaemia and LPS facilitate cytotoxic oedema and pre-coma/coma in 
cirrhosis is not clear, this data supports an important role for the nitrosation of 
brain proteins. 
 
 
STUDY 2 (Chapter 3) 
In patients with cirrhosis, new therapies targeting hyperammonaemia and HE are 
necessary. A novel new drug, L-ornithine Phenylacetate (OP), which combines two 
known ammonia-lowering agents, is hypothesised to improve ammonia reduction, 
but the exact mechanisms of its beneficial action have yet to be fully explored. 
 
Hypothesis 
In hyperammonaemic BDL rats, the combination of L-ornithine and phenylacetate 
as OP: 
1) Traps ammonia as glutamine within muscle by provision of L-ornithine to 
muscle glutamine synthetase  
2) L-ornithine derived glutamine is excreted by conjugation with phenylbutyrate 
(converted to phenylacetate) to phenylacetylglutamine 
This means that ammonia will not be available for later return to the circulation, 
resulting in net removal and reduction in ammonia concentration. 
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Question 2: Does L-ornithine and phenylacetate (when combine as OP), act 
synergistically to provide an improved and more sustained reduction in ammonia? 
Is this achieved by L-ornithine acting as a substrate for glutamine synthesis thereby 
detoxifying ammonia? and/or the phenylacetate excreting the ornithine derived 
glutamine as phenylacetylglutamine in the urine?  
 
Answer 2: BDL produces high arterial ammonia, brain oedema and lower brain 
myo-inositol consistent with secondary cirrhosis. When compared to lone therapy 
with either L-ornithine or phenylacetate, the administration of OP was associated 
with a more significant and sustained reduction in arterial ammonia. The reduction 
in ammonia with administration of OP occurs within hours and is associated with an 
initial increase in circulating ornithine at 1 hour, and corresponding rise in 
circulating glutamine at 3 hours as ornithine falls. These findings are in accordance 
with the first part of the hypothesis, with such changes in glutamine levels 
consistent with previous observations of increased skeletal muscle glutamine 
synthetase activity. The reduction in ammonia with OP was associated with a 
significant reduction in the brain glutamine/myo-inositol ratio and prevention of 
brain oedema, principally by maintaining higher brain myo-inositol levels. This 
implies an increase in the brain buffering capacity to the effects of other 
precipitants such as further hyperammonaemia or hyponatraemia that are known to 
increase brain swelling. The beneficial effects of OP were sustained during a 10 day 
period of administration with respect to limiting hyperammonemia and also brain 
oedema, without any evidence of a rebound increase in ammonia over this period. 
In accordance with the proposed hypothesis, glutamine generated by the 
administration of L-ornithine was conjugated and excreted as phenylacetylglutamine 
by co-administration of phenylbutyrate. 
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In conclusion: The results of this study provide proof of concept that L-ornithine 
and phenylbutyrate act synergistically to produce sustained improvement in arterial 
ammonia, its brain metabolism and brain water. As L-ornithine and phenylbutyrate 
are already in use in man, it is likely that these findings can be translated relatively 
quickly into appropriate clinical studies to determine exact dosing, 
pharmacokinetics, safety and efficacy. 
 
 
 
STUDY 3 (Chapter 4) 
In liver failure, inflammation synergistically modulates the cerebral effects of 
ammonia, with interventions targeting either hyperammonemia or inflammation 
limiting progression of HE. 
 
Question 3: Can a reduction in ammonia in cirrhotic rats prevent LPS induced 
worsening of brain oedema and progression to pre-coma and coma stages? Does 
targeting hyperammonaemia and inflammation together provide therapeutic 
synergy in the treatment HE? 
 
Answer 3: The results of this study show for the first time that reduction in arterial 
ammonia concentration using OP in BDL rats is associated with a reduction in LPS 
induced progression to pre-coma/coma which is associated with a marked 
attenuation in brain swelling. These data provide a strong argument in support of 
the hypothesis that, on the background of chronic liver disease (BDL), ammonia 
may prime the brain to the deleterious effect of LPS. As predicted, administration of 
Infliximab was associated with marked attenuation of the pro-inflammatory drive 
manifested by a reduction in arterial TNF-α and IL-6 concentrations without an 
effect on ammonia levels, but this was not associated with any significant reduction 
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in brain oedema. Co-administration of OP and Infliximab had similar effects to that 
observed in the OP treated group, thus failing to demonstrate any significant 
therapeutic synergy between OP and Infliximab. These observations provide proof 
for the concept that ammonia may in some way ‘prime’ the brain to the effects of 
LPS. These findings, along with recent data from our group showing differential TLR 
expression (and thus innate immunity) in the brain of BDL rats, suggesting that 
ammonia might prime the brain to the effects of microbial challenge via effects on 
TLR expression. 
 
In conclusion: the findings of this study substantiate the predominant role of 
ammonia in priming the brain to the deleterious effect of LPS and suggest that a 
reduction in arterial ammonia concentration with OP may prevent LPS induced 
worsening of HE and brain edema. The mechanism of how ammonia primes the 
brain remains uncertain but our results supports the role for TLR.   
 
STUDY 4 (Chapter 5) 
Progressive astrocyte swelling as the underlying pathogenic process of cytotoxic 
brain oedema is considered critical to advanced HE. Though ammonia is thought 
central to its pathogenesis, superimposed inflammation plays an important 
synergistic role, often provoking brain oedema. Yet the mechanism of brain oedema 
in liver failure is unknown. Current literature, suggests a possible role for 
aquaporin-4 (AQP4), a bi-directional water channel predominant in astrocytes, in 
the development of brain oedema in a number of neuropathic disorders. 
 
Question 4: Is AQP4 causal in the brain oedema associated with various models of 
liver failure?  
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The study incorporated the following models: 
• BDL (cirrhotic) rats  
• BDL + LPS challenged (ACLF) rats 
• Galactosamine (Acute liver failure (ALF)) rats 
• Ammonia fed naïve (hyperammonaemic) rats 
• Caecal ligation and puncture (CLP) rats; a 24 hour model of sepsis 
 
Answer 4: This study firstly confirms that hyperammonaemia and/or inflammation, 
whether associated with liver dysfunction or not, causes an increase in brain 
oedema. Secondly, that the severity of brain swelling in these different models, 
which variably combine hyperammonaemia, liver dysfunction and inflammation, are 
not associated with any increase in the expression of brain AQP4, except for in 
cirrhotic rats. In cirrhotic rats (which manifest low grade brain oedema), increased 
AQP4 protein expression was observed, with a clear contemporaneous association 
to p38MAPK activation. With progression to cirrhosis, there was an apparent temporal, 
but not spatial change in the distribution of AQP4 along perivascular astrocytes 
(using Immunogold labelling). The addition of LPS to cirrhotic rats (a model of 
ACLF) had no effect on AQP4 protein expression, seriously questioning the role of 
AQP4 in the pathogenesis of brain oedema in these models. The results of this study 
also provide further evidence to indicate that brain swelling is not a surrogate for 
HE. Indeed, marked increases in brain water in several groups of animals was not 
associated with changes in mental state and our results also confirmed that 
superimposed inflammatory stress induced by LPS on the background of liver 
disease (both BDL and GALN) was associated with progression to pre-coma stages. 
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In conclusion, AQP4 does not appear to play a significant role in the development 
of brain edema associated with hyperammonemia or inflammation, either with or 
without acute liver dysfunction. However, the brain edema in cirrhosis is associated 
with upregulation of AQP4 with contemporaneous p38MAPK activation and retained 
cellular polarisation, possibly as a compensatory response to inhibit edema 
formation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 245 
 
Conclusion 
The body of work within this thesis demonstrates the critical nature of interorgan 
ammonia and amino acid metabolism and the relationship that exists between 
ammonia and inflammation in the pathogenesis of HE. This research has also shown 
that systemic inflammatory mediators modulate cerebral inflammatory processes, 
which are likely primed by the effects of ammonia on the brain. Also this thesis 
helps dispel any belief of a causal role for AQP4 expression in the development of 
brain oedema in HE (and likely other neuropathic conditions). Understanding the 
importance of interorgan ammonia and amino acid metabolism has lead to the 
development of a novel drug - L-ornithine, phenylacetate (OP), which may provide 
us with the first clinically useful intervention for this life-threatening condition. As L-
ornithine and phenylbutyrate are already in use in man, it is likely that these 
findings can be translated relatively quickly into appropriate clinical studies to 
determine exact dosing, pharmacokinetics, safety and efficacy. Furthermore, to test 
the hypothesis of synergy this thesis has for the first time studied the application of 
combining therapies targeting both ammonia and inflammation. This thesis 
concludes that while hyperammonaemia remains the chief culprit and main 
therapeutic target in the treatment of HE, as it also appears to prime cells to the 
effect of inflammation, a better understanding of its potentially synergistic 
interaction with inflammatory processes may yet prove a worthwhile therapeutic 
goal in the foreseeable future.  
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